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Nicole L. Daly
RNA polymerases I and III are responsible for approximately 80% of all nuclear 
transcription. The activity of these enzymes is a major determinant of the biosynthetic 
capacity of cells, since they synthesise important products required for protein 
synthesis, such as tRNAs and rRNAs. Regulation of these polymerases is likely to be 
of fundamental importance, since their activity is controlled directly by two cardinal 
tumour suppressors, RB and p53.
Cervical, breast and colorectal malignancies were investigated to assess if activity of 
RNA polymerases I and III is deregulated in these cancers. Expression studies of 
genes transcribed by these polymerases demonstrated that most of the tumour biopsies 
examined displayed deregulated transcriptional activity in comparison with matched 
normal tissue.
In the cervical biopsy samples examined, the presence of human papillomavirus 16 
coiTelated with dramatic and specific overexpression of genes transcribed by these 
polymerases. This may be explained by the fact that, upon integration into the host 
genome, this virus upregulates the levels of the oncoproteins E6 and E7, which are 
able to neutralise p53 and RB, respectively. Furthermore, Brfl, a subunit of TFIIIB, 
was also found to be overexpressed, and this coiTelated with the increased levels of 
RNA polymerase III transcripts in the human papillomavirus 16 infected samples. 
This subunit was also found to be elevated in some cases of the other tumour types 
tested.
When other factors were investigated that may contribute to upregulated rates of 
transcription, it was found that in the breast tumour biopsies, upregulation of c-Myc 
closely correlated with increased levels of RNA polymerase I transcripts as well as 
MRP and 7SK transcripts. In the colon tumour biopsies, a correlation was observed 
between the c-Myc target, cyclin D2, and increased levels of RNA polymerase III 
transcripts. It was also found thiough comparison of a transformed and untransfoimed 
cell line that RNA polymerase III transcription may be regulated through acétylation 
and deacetylation.
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Chapter 1 
Introduction
Chapter 1______________________________________________________ Introduction
1.1 Transcriptional Control of Cellular Activity.
The actions and properties of a cell are largely detennined by the genes it expresses. 
The first step of this process, transcription, is subject to a wide variety of regulatory 
controls. This allows the cell to constantly adapt in response to environmental changes 
and metabolic requirements. Defects in transcription are responsible for a wide range 
of human diseases and play a crucial part in the development of cancer.
1.2 Eukaryotic RNA Polymerases.
Transcription of eukaiyotic nuclear genes requires thi’ee different RNA polymerases, 
designated I, II, and III. Structurally, these multisubunit enzymes are quite similar to 
each other, the two largest subunits being closely related and some of the smaller ones 
being shared by more than one polymerase. Functionally, however, they are quite 
distinct, transcribing different sets of genes (White, 1998). RNA polymerase I (pol I) 
synthesises the precursor rRNA (pre-rRNA) which is processed into 5.8S, 18S, and 
28S ribosomal RNAs (rRNAs), RNA polymerase II (pol II) synthesises messenger 
RNA (mRNA) and most small nuclear RNAs (snRNA), and RNA polymerase III (pol 
III) synthesises transfer RNA (tRNA), 5S rRNA, and an aiTay of small cellular and 
viral RNAs (Chambon, 1975; Roeder & Rutter, 1969; Zieve, 1981).
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1.3 RNA Polymerases I and III and Cancer.
The activities of pol I and pol III dominate cellular transcription, combining to exceed 
80% of total RNA synthesis in growing cells. Therefore, tight regulation is of 
considerable importance to the balance of cellular metabolism, and ensures that the 
output of pols I and III is matched to a cell’s biosynthetic requirement. The rapid 
growth of tumours requires elevated rates of biosynthesis. This would not be possible 
if rRNA or tRNA were limiting. Abnonnally high rates of transcription by pols I and 
III are a general feature of transfomied and tumour cells. Schwartz et a l (1974) 
demonstrated that the activities of pols I and III increase in mice myelomas, whereas 
the activity of pol II remains normal. Many different types of transformed cells have 
been found to overexpress the products of pols I and III, including cells transformed 
by DNA tumour* viruses (e.g. SV40, hepatitis B virus), RNA tumour viruses (e.g. 
human T-cell leukaemia virus 1) and chemical carcinogens (e.g. 12-0-
tetradecanoylphorbol-13-acetate) (Gottesfeld et a i, 1996; Larminie et ah, 1999; Scott 
et aL, 1983; Wang et al.^ 1995, 1997; White et aL  ^ 1990; Ying et aL, 1996; Zhai & 
Comai, 1999). Although many studies have examined transcriptional outputs by pols I 
and III in cultured cells, this has yet to be thoroughly addressed in human tumours. So 
far only two groups have carried out such experiments. Chen et a l  (1997a) reported 
that a pol III transcript is abnormally abundant in 19 different types of tumour tissues 
relative to normal tissue from the same patient. Furthermore, Winter et a l (2000) 
showed that pol III transcripts important in protein synthesis are overexpressed in 
ovarian carcinomas.
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1.4 Genes Transcribed by RNA polymerase III.
Pol III is responsible for approximately 10% of all nuclear transcription, producing a 
variety of transcripts, many of which have essential functions in cellular metabolism 
(White, 1998; Willis, 1993). These include tRNA and 5S rRNA, which are required 
for protein synthesis, 7SL RNA, which is involved in protein translocation, 7SK, 
which regulates a pol II elongation factor, and the U6, HI and MRP RNAs, which aie 
involved in post-transcriptional processing. Pol III also synthesises the VA RNAs 
encoded by adenovirus, which function in the selective translation of viral mRNA. 
Other class III genes encode transcripts with no known roles; these include the short 
interspersed repeat (SINE) gene families, such as Alu, which constitute the majority 
of pol III templates in mammals (reviewed in White, 1998). Generally, class III gene 
products are untranslated, short transcripts (usually less than 200bp), which are made 
and exported rapidly from the nucleoplasm. In a HeLa cell ~10 000 transcripts are 
made by pol III at any moment. These are concentrated in —2000 sites which contain 
approximately five active polymerases (Pombo et al.  ^ 1999).
1.4.1 5S rRNA Genes.
5S rRNA is approximately 120 nucleotides in length. It is found associated with the 
large ribosomal subunit providing binding sites for accessory molecules that are 
necessary for protein synthesis. Genes coding for the 5S rRNA are present in all 
eukaryotic organisms and are organised in clusters of tandem repeats, although there 
is evidence that some 5S genes are probably dispersed as single copies (Sorensen & 
Frederiksen, 1991). The total number of 58 related sequences in the haploid genome
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is classically cited as 1700-2000, the majority of which were thought to be 
pseudogenes and gene variants, with 300-400 true 5S rRNA genes (Sorensen & 
Frederiksen, 1991). However, only four individual copies of 5S rDNA were identified 
in the draft human genome sequence, with 520 more distantly related sequences 
(International Human Genome Consortium, 2001).
1.4.2 tRNA Genes.
Eukaryotic cells contain 50-100 chromatographically distinct tRNA species (Sharp et 
a l,  1985). Each is designed to carry one of the 20 amino acids used for protein 
synthesis; a tRNA that cames tyrosine is designated tRNA^ "^^  and so on. The initial 
transcripts produced from tRNA genes are precursor molecules, which are processed 
into mature tRNAs, vaiying in length between 70-90 nucleotides. They have a 
cloverleaf secondary structure and an L-shaped tertiary structure. Their main role is 
translating inRNA into protein on the ribosome and their intracellular levels 
correspond strongly with the codon requirements of mRNA (Garel, 1976). They 
function in the initiation of peptide synthesis, the elongation of peptide chains, and the 
attachment of the growing polypeptide chain to the ribosome. tRNA^^^ also functions 
as a carrier molecule upon which selenocysteine is synthesised (Low & Berry, 1996); 
it also differs from the other tRNAs in the fact that it is encoded by a single copy gene 
(O’Neill et al. 1985). The human haploid genome contains 821 tRNA related loci, 497 
of which are tRNA genes, the other 324 are tRNA-derived putative pseudogenes 
(International Human Genome Consortium, 2001). These are scattered throughout the 
genome, often in clusters (International Human Genome Consortium, 2001). 28% of 
the tRNA genes are found in a 4 MB region on chromosome 6. Clustering also occurs
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on chromosomes 1 and 7, whereas, chromosomes 22 and Y have no copies of tRNA 
genes (International Human Genome Consortium, 2001).
1.4.3 Virus Class III Genes.
Several viruses contain short class III transcriptional units within their genomes. The 
best-characterised example is that of adenovirus, which encodes two small pol III 
transcripts, called VAI and VAII, that are synthesised at high levels during the late 
stages of viral infection (Soderlund et a l 1976). These genes are approximately 160bp 
long and are separated from one another by 98bp. VAI is required for efficient 
expression of the adenovirus genome, whereas deletion of the YAH gene does not 
have a major effect upon the viral life-cycle (Thlmmappaya et a l 1982). The VA 
RNAs act by subverting the host cells translational apparatus, in order to ensure the 
synthesis of viral proteins (Thimmappaya et a l 1982). The genome of Epstein-Ban- 
virus (EBV) also contains two small adjacent genes that are transcribed by pol 111.
1.4.4 7SL Genes.
7SL RNA is about 300 nucleotides long, and is a constitutive and indispensable part 
of the signal recognition particle. This aids in the secretion of newly formed 
polypeptides thiough the membranes of the endoplasmic reticulum (Walter & Blohel, 
1982). 7SL is flanked on hoth ends by regions homologous to the highly repeated Alu 
family, and contains a central S-sequence region of 140 nucleotides of non-Alu DNA. 
In the human genome, there are over 770 sequences related to this S-sequence, the
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majority of which are pseudogenes that are truncated at one or both ends. Only three 
or four represent functional 7SL genes (International Human Genome Consortium, 
2001).
1.4.5 SlNEs.
A variety of short interspersed elements (SINEs) constitute quantitatively important 
classes of pol III template in higher organisms (Jelinek & Schid, 1982; Singer, 1982). 
The functional role of these templates has not been unequivocally demonstrated, 
despite a broad range of speculations (reviewed by Howard & Sakamoto, 1990). 
These genes are commonly found in clusters, often in tandem arrays, and are spread 
out on all of the chromosomes (Bennett et ai, 1984). The major SINE in primates is 
the Alu family. Alu genes consist of two imperfect repeats separated by an 18bp 
spacer (Rubin et a i, 1980; Delninger et a i,  1981). The Alu consensus sequence is 282 
nucleotides long, but transcription continues into a downstream A-rich region to 
produce poly(A)+ RNAs with an average length of ~400bp (Weiner et al., 1986). 
There are over one million copies of the Alu gene in the haploid human genome 
(International Human Genome Consortium, 2001). In rodent species the most 
abundant SINEs are the BI and B2 genes (Bennett et al., 1984); the latter gene is 
specific to these mammals (Bennett et al., 1984; Rogers, 1985). Bl genes are 
approximately 80% homologous to human Alu genes, but with only one of the two 
repeats. They are ~130bp long and are present in about 100,000 copies per haploid 
mouse genome (Bennett et al., 1984; Krayev et al., 1980). B2 genes are ~180bp long, 
with -80,000 copies per haploid mouse genome (Bennett et al., 1984; Rogers, 1985). 
Several SINE families, such as B2, appear to have evolved from tRNA genes, and so
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can be regarded as amplified tRNA pseudogenes (Daniels & Deininger, 1985). It is 
thought that Bl and Alu families have evolved from the 7SL gene (Mighell et al., 
1997; Ullu & Tschudi, 1984).
1.4.6 RNase MRP Genes.
The site-specific endonuclease RNase MRP contains a 265 nucleotide RNA (Topper 
& Clayton, 1990). It has a major nuclear function in the late stage processing of rRNA 
(Clayton, 1994; Lygerou et al. 1996) and it also functions in mitochondria to process 
RNA primers for DNA synthesis. In humans, a single copy gene has been identified 
that encodes MRP RNA, which is located on chromosome 9 (Hsieh et al. 1990). 
However, several pseudogenes also exist.
1.4.7 U6 snRNA Genes.
U6 is an abundant, small nuclear RNA (snRNA) species, which is capped at its 5’ end 
(Epstein et al. 1980). It forms a series of complexes with four other uridylic acid-rich 
RNAs and protein factors, which carry out splicing of pre-mRNA. These are present 
at approximately ten million copies per mammalian cell, and are involved in the 
splicing of pre-mRNA (Mattaj et al. 1993). It is the smallest of these snRNAs, 106 
nucleotides in length (Epstein et al. 1980), and is the only one to be transcribed by pol 
III (Reddy et al. 1987); the others are pol II transcripts. There were 44 copies of the 
U6 sequence identified within the draft haploid human genome, and over 1100 related
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pseudogenes (International Human Genome Consortium, 2001). These exist as 
dispersed middle repetitive DNA (Hayashi, 1981).
1.4.8 7SK Genes.
The 7SK gene encodes a snRNA transcript of 330 nucleotides in length. It functions 
as a negative regulator of the pol II elongation factor P-TEFb (Nguyen et al., 2001; 
Yang et al, 2001). Mammalian 7SK RNA has an abundance of approximately 
200,000 copies per cell, and is evolutionarily conserved (Zieve et al, 1977). The 50bp 
immediately flanking the start of transcription is homologous to 7SL and U6 RNA 
(Murphy et al., 1986). The human genome contains a large family of truncated 7SK 
pseudogenes, but only one full-length 7SK gene (International Human Genome 
Consortium, 2001; Kruger, 1987; Murphy, 1984).
1.5 Class III Gene Promoters.
An unusual feature of promoters of most genes transcribed by pol III is that they 
include internal control regions (ICRs) downstream of the transcriptional start site, 
within the transcribed region. These structures are generally discontinuous, composed 
of essential blocks separated by non-essential regions. There are tliree general types 
of pol III promoters.
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1.5.1 Type I Promoters.
Type I promoters, found in 5S rRNA genes, consist of tliree sequence elements; a 5’ 
A-block which is well conserved, an intermediate element, and a 3’ C-block (Pieler et 
a i, 1987). These elements span a region of approximately 50bp beginning at position 
+45.
1.5.2 Type II Promoters.
Type II promoters are the most common arrangement; examples include tRNA and 
the VA RNA genes. These promoters are identified by highly conserved A and B 
block elements. The A block is positioned close to the transcription start site (usually 
about 10-20bp) (Galli et al, 1981). This reflects its role in start-site selection. The 
distance of the B block downstream of the A block is extremely variable, with an 
optimal spacing for transcription being 30-60bp (Baker et ah, 1987; Fabrizio et ah, 
1987).
1.5.3 Type III Promoters.
Type III promoters, like the human U6, 7SK and RNase MRP genes, reside 
exclusively upstream of the coding sequence (Das et ah, 1988; Kunkel & Pederson, 
1989; Lobo & Hernandez, 1989). These contain a TATA box located near position 
-30, and a proximal sequence element (PSE) at around position -60. These elements 
constitute a basal promoter, which is subject to activation by a variety of factors that 
bind to distal sequence elements (DSE).
10
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1.5.4 Other Promoters.
Several genes have promoters that do not conform to the aforementioned groups. 
Among these is the 7SL gene. Transcription of this gene is dependent on a novel 
intragenic element, a DSE element and an ATF-binding site at position -50. The 
intragenic element is located proximal to the start site and overlaps, but is distinct 
from, a sequence that resembles the A block (Bredow et a l 1990).
1.6 The Transcription Machinery of Pol III.
Pol III alone has little specificity for paiticular DNA sequences. Its recruitment to 
specific genes requires the presence of transcription factors. The combination of these 
factors utilized during transcription initiation is dependent on promoter structure.
1.6.1 Transcription Complex Assembly at Type II Promoters.
It is transcription factor IIIC (TFIIIC) that initially recognises the promoter of type II 
genes. This is a large multisubunit and multifunctional complex, that in humans can 
be resolved into two components, called TFIIIC 1 and TFIIIC2. TFIIIC 1, which is not 
yet well characterised, contains at least four subunits with molecular masses of 70, 50, 
45, and 40 kDa (Wang & Roeder, 1998). Purified TFIIIC2 has been shown to consist
11
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of five polypeptides of 220, 110, 102, 90 and 63 kDa. These subunits form a stable 
complex.
During transcription complex assembly, TFIIIC2 binds preferentially to the B block 
region with high affinity (Yoshinaga et al 1987, 1989). This occurs through the largest 
subunit, TFIIIC220 (L’Etoile et al., 1994; Lagna et al., 1994). Weak interactions also 
occur with the A block thi'ough the smallest subunit, TFIIIC63 (Carrey et al, 1986; 
Hseih et al., 1999a). The TFIIÎC90 subunit provides key interactions that hold the 
transcription factor together (Hseih et al., 1999a). This initial DNA-TFIIIC2 
interaction then allows the recruitment of TFIIIC 1 (Dean & Berk, 1988), which 
enhances and extends the footprint produced by TFIIIC2 (Yoshinaga et al, 1987; 
Wang & Roeder, 1996; Oettel et al, 1997).
TFIIIC2 can be isolated in both active (TFIIIC2a) and inactive (TFIIIC2b) foims. 
These promoter complexes were shown to be clu'omatographically distinct by 
Hoeffler et al (1988). Silver staining revealed that the 110 kDa subunit was absent in 
TFIIIC2b, rendering it transcriptionally inactive; instead an additional band of 77 kDa 
was present (Kovelman & Roeder, 1992; Sinn et al 1995). It has been shown that 
antibodies against TFIIICl 10 do not recognise the 77 kDa component of TFIIIC2b. 
This suggests that the 77 kDa polypeptide is not a proteolytie produet of TFIIICl 10, 
although it is possible that the epitopes recognized by the antibody have heen 
degraded.
The primary function of TFIIIC is to recruit a second transcription factor TFIIIB, 
which is regarded as the pivotal initiation factor of the pol III system. TFIIIB is
12
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Figure 1.1
A model for transcription initiation at a type II promoter.
Diagram indicating the order of interaction of transcription factors and pol III with a 
typical type II promoter such as that of a tRNA gene. The site of transcription 
initiation is depicted by +1 and the site of termination is indicated by Tn.
13
Type II Promoter
+ 1
A -B lock B -B lock
Trl tD N A
TFIIIC
ÏTFIIIC90m
TFIIICl
TFIIIB
TFIIIC90
TFIIICl
pol III
m clio
TFIIICl
Chapter 1_______________________________________________________Introduction
composed of thiee polypeptides (Kassavetis et al., 1990), one of which is the TATA- 
box binding protein (TBP). The largest of the TBP-associated factors is the B double 
prime 1 (Bdpl) protein, which displays little homology to other proteins. The other 
component, because of its homology to TFIIB in its N-terminal half, is referred to as 
TFIIB-related factor 1 (Brfl), It has been shown that Brfl is tightly associated with 
TBP, whereas Bdpl is weakly associated with the TBP-Brfl complex (Kassavetis et 
al, 1991; Wang & Roeder, 1995).
There is a network of protein-protein interactions between TFIIIC and TFIIIB. Three 
such TFIIIC2 associations have been identified; TFIIIC 102 interacts with Brfl and 
TBP (Hseieh et al., 1999b), TFIIIC90 interacts with Brfl (Hsieh et a l,  1999a), and 
TFIIIC63 interacts with both Brfl and TBP (Hsieh et al., 1999b). Binding of TFIIIB 
just upstream of the transcription start site in turn allows the recruitment of pol III to 
the promoter, where it is positioned over the initiation region so that transcription can 
commence (Kassavetis et al, 2001). This occurs mainly thiough protein-protein 
interactions with the Brfl and TBP subunits of TFIIIB (Khoo et a l, 1994; Wang & 
Roeder, 1997; Werner gr a/., 1993) (Figure 1.1).
1.6,2 Transcription Complex Assembly at Type I Promoters,
Although TFIIIC binds directly to the promoter sequences that are present within the 
coding regions of most pol III templates (Lassar et al., 1983), an additional gene- 
specific factor TFIIIA is required by 5S rRNA genes to provide a platform for TFIIIC 
(Lassar et al, 1983). TFIIIA is the founding member of the C2H2 zinc finger family 
of DNA-binding proteins, since most of its 344 residues are taken up by nine tandem,
14
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Figure 1.2
A model for transcription initiation at a type I promoter.
Diagram indicating the order of interaction of transcription factors and pol III with the 
promoter of a 5S rRNA gene. The site of transcription initiation is depicted by +1 and 
the site of termination is indicated by Tn.
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zinc-dependent DNA-binding domains (Miller e/ at., 1985). These bind extensively to 
>50bp of 5S rDNA. The C block is recognised by the N-terminal thiee fingers 
(fingers 1-3), which contribute -95%  of the total binding energy of full-length 
TFIIIA; these fingers wrap smoothly around the major groove in a manner that is 
typical for this class of DNA-binding domain (Clemens et al., 1992; Foster et al., 
1997; Nolte et al., 1998). Fingers 7-9 aie thought to contact the A block in a similar 
fashion, but with lower affinity (Clemens et al., 1992). The middle three fingers adopt 
a completely different configuration in order to span the interblock DNA, which is 
twice as long as the regions bound by fingers 1-3 or 7-9 (Nolte et al., 1998).
Surprisingly little is known about how TFIIIA recruits TFIIIC to the DNA. Only once 
TFIIIA and TFIIIC are both bound can TFIIIB be recruited onto the 5S rRNA gene 
(Bieker et a l, 1985; Carey et al., 1986a; Setzer & Brown, 1985). It has been observed 
that TFIIIB recruitment to the promoter is the rate-limiting step (Bieker et al., 1985). 
Pol III is then assembled onto the preformed TFIIIB/TFIIIC/TFIIIA/5S gene complex 
(Bieker et al., 1985; Carey et al., 1986a; Setzer & Brown, 1985) (Figure 1.2).
1.6.3 Transcription Complex Assembly at Type III Promoters.
The type III promoters associated with vertebrate 7SK and some U6 snRNA genes 
have distinct factor requirements fiom genes with type I or II promoters (Mital et al, 
1996; Yoon et al., 1995). The lack of an ICR obviates the need for TFIIIA or TFIIIC2 
(Lagna et al., 1994; Oettel et al., 1997). Instead, other factors are recruited to the 
external upstream sequence elements in order to initiate transcription.
16
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The DSE of these promoters is recognised by Oct-1. This factor can activate 
transcription of the 7SK gene both in vitro and in vivo (Murphy, 1997; Murphy et al., 
1989). Downstream from this, the PSE is bound by the five subunit PSE-binding 
transcription factor (PTF) (Murphy et al., 1992; Sadowski et al., 1993). Binding of 
PTF and Oct-1 occurs cooperatively (Mittal et al., 1996; Murphy et al., 1992). The 
relatively weak binding of Oct-1 is stabilized by interaction with DNA-bound PTF. In 
turn, PTF binding is strongly dependent on DNA-bound Oct-1 (Murphy, 1997). The 
poor DNA binding of PTF on its own is due to self-repression, as the PSE-binding 
domain is substantially occluded in the complete complex (Mittal et ah, 1996). 
However, through interaction with Oct-1 the occluding flap is removed enabling the 
partial complex to bind to the DNA more effectively (Ford et al., 1998; Mittal et al.,
1996). Efficient binding of PTF, through interaction with Oct-1 and activation of 
transcription in vitro, occurs only when Oct-1 binding sites are close to the PSE 
(Murphy et al., 1992; Stunkel et al., 1997). DNase I digestion patterns have suggested 
that a nucleosome is positioned between the DSE and the PSE of class III genes in 
vivo, bringing these elements into juxtaposition, thereby enhancing physical 
interaction between factors binding to them (Boyd et al., 2000).
In addition to these interactions, TBP binds to the TATA box (Mittal & Hernandez,
1997). The N-terminal domain of TBP also potentiates binding of PTF to the PSE 
(Mittal & Hernandez, 1997). This binding occurs cooperatively with PTF, as TBP 
binds poorly to DNA on its own (Mittal & Hernandez, 1997). TBP also interacts with 
another factor, Brf2, which is related to both Brfl and TFIIB in its N-terminal region 
(Schramm et al., 2000; Teichmann et al., 2000). Recruitment of Brf2 to the TATA 
box is TBP-dependent. Brf2 in turn stabilises TBP on TATA-containing templates.
17
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Figure 1.3
A model for transcription initiation at a type III promoter.
Diagram indicating the order of interaction of transcription factors and pol III with a 
type III promoter such as that of a 7SK gene. The site of transcription initiation is 
depicted by +1.
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and extends the TBP footprint both upstream and downstream of the TATA box 
(Cabart & Murphy, 2001). Once the Brf2-TBP-DNA subcomplex has assembled, the 
transcription factor Bdpl is recruited (Cabart & Muiphy, 2002). The N-terminal 
region of Brf2, containing a zinc ribbon, inhibits the direct association of Brf2 with 
Bdpl. This negative mechanism is deactivated by TBP thiough protein-protein 
contacts with both Bdpl and Brf2 (Cabart & Murphy, 2002). In addition to the TATA 
box, a GC-rich sequence (the BURE) has been identified downstream from this 
promoter structure. This sequence, depending on the strength of the TATA box, can 
either enhance BrfZ binding to the TBP-DNA complex, or Bdpl association with the 
Brf2-TBP-DNA complex, and substantially stimulate pol III transcription (Cabart & 
Murphy, 2002).
Although transcription at type I and II promoters requires both TFIIICl and TFIIIC2, 
TFIIICl alone is required at type III promoters (Yoon et al, 1995). It remains to be 
determined how TFIIICl is recruited, but this may be a late step in complex assembly 
on type III promoters (Paule & White, 2000). The combination of binding by these 
transcription factors ultimately leads to the recruitment of pol III (Figure 1.3).
1.7 Genes Transcribed by RNA polymerase I.
Pol I transcribes a single RNA species, the large ribosomal RNA precursor molecule 
(pre-rRNA). Although it synthesises only one essential product, pol I may be 
responsible for as much as 70% of all nuclear transcription, and in an actively 
growing cell rRNA may constitute 80% of the total steady-state RNA (White, 2001). 
This high level of production from class I genes is necessaiy in order to make the
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several million new ribosomes that are needed per generation to maintain protein 
biosynthetic capacity.
1.7.1 Pre-rRNA Genes.
During ribosome biogenesis, the large polycistronic transcript pre-rRNA is processed 
into 5.8S, 18S and 28S rRNAs by a series of specific endonucleolytic reactions that 
are mediated by U3 RNA, a small nucleolar RNA speeies (Sharma & Tollervey,
1999). 18S rRNA is approximately 2000 nucleotides long and is a component of the 
small ribosomal subunit, whereas 5.8S (-160 nucleotides) and 28S rRNA (-4000 
nucleotides) are components of the large ribosomal subunit. During this processing, 
the mature rRNA sequences undergo extensive covalent nucleotide modification. In 
addition, the rRNAs must assemble with the 80 ribosomal proteins and the 5S rRNA. 
In human cells, there are about 200 highly conserved rRNA genes per haploid 
genome. These are found organised into five clusters of tandem head-to-tail repeats, 
and are located on five different chiomosomes (Long & Dawid, 1980). A very high 
density of pol I is found at the active rRNA genes, with approximately one enzyme 
molecule eveiy lOObp, and these sustain a rapid elongation rate (Miller & Beatty, 
1969).
1.8 Class I Gene Promoters.
The DNA intervening between transcribed units, known as the intergenic spacer 
(IGS), contains sequence elements that mediate rRNA expression. In contrast to class
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III gene promoters, the primary sequences of rRNA promoters are not well conserved 
between species. Despite this species specificity, the general layout of promoter 
elements is highly conserved fi’om yeast to humans, containing two sequence 
elements (Moss & Stefanovsky, 2002). These are the upstream control element 
(UCE), which serves to modulate efficiency of transcription, and the core, which is 
essential for transcription initiation and contains the conserved AT-rich ribosomal 
initiator (Perna et al., 1992; Radebaugh et al., 1997). In humans, the 40bp core region 
is positioned overlapping the transcription start site, and the UCE is located between 
nucleotides -234 to -131 (Paule, 1998). The IGS of most species also contains other 
promoter elements, such as enhancers and the proximal terminator. This 
transcriptional teiminator is located just upstream of the UCE, and is able to 
significantly stimulate transcription (Paule & White, 2000).
1.9 The Transcription Machinery of Pol I.
Template recognition in mammals is achieved by the upstream binding factor (UBF). 
This is a modular polypeptide of 97 or 95 kDa, the smaller splice variant being 
inactive (Grummt, 1999). It contains an N-terminal dimerization domain, multiple 
high mobility group (HMG) DNA-binding domains, and a C-terminal acidic tail 
(Reeder et al., 1999). UBF functions as a dimer interacting with sequences in the UCE 
and core elements of the ribosomal promoter (Zomerdijk & Tijan, 1998). To 
accommodate this binding, the HMG boxes in this transcription factor wrap ~180bp 
of DNA around itself in a single turn of -360° to provide a three-dimensional 
structure (Bazett-Jones et al., 1994; Stefanovsky et a l, 1996). This higher-order 
nucleoprotein structure, called the enhancesome, necessitates major chromatin
21
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Figure 1.4
A model for transcription initiation at a class I gene promoter.
Diagram indicating the order of interaction of transcription factors and pol I at a 
human ribosomal promoter. The site of transcription initiation is depicted by +1.
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remodelling, and also recruits a promoter selectivity factor. In humans this is refeiTed 
to as SLl. These two transcription factors interact cooperatively (Bell et al, 1988).
Isolated SLl contains TBP, and tlnee tightly bound associated factor (TAP) subunits, 
TAF]48, TAFi63, and TAFillO (Comai et al., 1992), which are specific for pol I. The 
C-terminal of UBF contacts TBP and TAF[48 in SLl, whereas TAFi63 and TAFiHO 
recognize and bind species-specific promoter sequences just upstream of the start site 
(reviewed by Moss & Stefanovsky, 2002; Paule & White, 2000). These latter two 
subunits cany binding sites for Rrn3. This is a polypeptide that has an essential 
function in linking pol I to SLl at the rDNA promoter (Miller et al., 2001). Additional 
polymerase-associated factors are also recruited along with pol I (Moss & 
Stefanovsky, 2002). One of these is TFIIH, a basal pol II transcription initiation 
factor, which is also required for a postinitiation step in pol 1 transcription (Iben et a l, 
2002). Once pol I and its associated factors have been assembled at the promoter, 
transcription can commence (Figure 1.4).
1.10 Chromatin Structure.
The chromatin structure of the genes transcribed by both pols I and III can be a major 
determinant of their transcriptional activity (reviewed by Paule, 1998; White, 1998). 
The basic unit of chromatin consists of approximately 200bp of DNA and is termed a 
nucleosome. It comprises a disc-shape particle with a diameter of about lln m  and a 
variable length of linker DNA connecting adjacent subunits. In this particle, 146bp of 
DNA is wrapped twice around a histone octamer containing two copies each of the 
core histones H2A, H2B, H3 and H4 (Burlingame et al., 1985; Luger et al, 1997;
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Pruss ei al., 1995; Richmond et a l, 1984). The C-terminal domains of these core 
histones make substantial protein-DNA contacts (Hayes et a l, 1994; Luger et a l, 
1997; Pruss et al, 1995), while the N-terminal tails protrude outside the nucleosome 
(Luger et al, 1997; Wolffe & Pruss, 1996). The two superhelical turns are fixed from 
the outside by histone HI (Hayes & Wolffe, 1993; Pruss et al., 1995). This linker 
histone binds at the point where DNA enters and exits the subunit (Crane-Robinson,
1997). The airays of nucleosomes fold together, forming heavily compacted 30 nm 
fiber structures, which severely limit the accessibility of genes to transcription factors 
(Wolffe, 1990). Therefore, decondensation of such nucleoprotein complexes must 
occur to accommodate the transcription machineiy.
The histone tails protruding from the nucleosome can be modified by histone 
acetyltransferases (HATs) and histone deacetylases (HDAGs) during the cell cycle. 
Acétylation is associated with destabilization of nucleosomes (Grunstein, 1997), 
enabling the transcription apparatus to gain access to the DNA (Bannister & Miska 
2000; Bronwell & Allis, 1996; Tse et al., 1998; Ura et al., 1997). While HDACs 
remove the acetyl groups, allowing condensation of the nucleosome structure (Kuo & 
Allis, 1998). The actions of these enzymes will be discussed in greater detail in 
chapter six.
Nucleosomes have been shown to block the DNA binding of a number of 
transcription factors by obscuring their recognition sites. For example, if a 
nucleosome is positioned over the C block of the 5S rRNA promoter, TFIIIA can no 
longer bind and 5S rRNA synthesis is repressed (Gottesfeld, 1987; Hayes et al., 1991; 
Lee et al., 1993). However, if the nucleosome is located further upstream, leaving the
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C block open, TFIIIA can still gain access and transcription can proceed, but at a 
reduced rate (Almouzni et al., 1991; Clark & Wolffe, 1991; Hansen & Wolffe, 1994; 
Tremethick et al., 1990).
Deposition of histones onto naked DNA is generally accompanied by a substantial 
decrease in transcriptional activity. This ability of histones to inhibit both initiation 
and elongation is directly proportional to the density of the nucleosomes (Hansen & 
Wolffe, 1992). Class III genes that have been assembled into highly condensed 
structures are incapable of supporting significant levels of transcription (Hansen & 
Wolffe, 1992). In murine chromatin, 95% or more of transcriptionally competent B2 
genes are subject to histone HI-dependent repression (Carey & Singh, 1988). 
Furthermore, it has been demonstrated that transcription of B2 genes increases by -17 
fold upon HI depletion (Russanova et al., 1995).
In the vast majority of eukaryotic cells, only a small subset of rRNA genes are 
selected for transcription. This results in the existence of two distinct types of rRNA 
gene organisation; a nucleosomal type corresponding to the transcriptionally inactive 
gene copies, and a non-nucleosomal type, representing the active copies (Paule,
1998). These transcriptionally active genes and their regulatory sequences are 
organised into more open chromatin conformations (Elgin, 1988; Mathias et ah, 1980; 
Weisbrod, 1982).
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1.11 Coordination of Transcription by Pols I and III.
Protein constitutes most of a cell’s diy mass; therefore, the rapid growth that occurs 
during tumour development requires high rates of protein synthesis. Indeed, Baxter & 
Stamiers (1978) demonstrated that the rate of protein accumulation determines growth 
rate. Furthermore, it has been observed that cells withdraw from the cell cycle and 
quiesce when the rate o f protein synthesis is reduced by 50% (Brooks, 1977; Ronning 
et ah, 1981). Since rRNA and tRNA are essential for protein synthesis, elevated rates 
of biosynthesis would not be possible if  the levels of transcription by pols I and 111 
were limiting.
Actively proliferating eukaryotic cells use -80 % of their energy in producing 
ribosomes and other components of the protein synthetic apparatus (Volarevic et al,
2000). Therefore, transcription by pols I and III is often coregulated so that wastage is 
limited. This is especially important for the production of 5S rRNA, which is required 
in equimolar quantities with the other rRNA transcripts. For example, the outputs of 
mammalian pols I and III increase in parallel following serum stimulation, and 
fluctuate together during passage thi'ough the cell cycle (Klein & Grummt, 1999; 
Mauck & Green, 1974; White et al.„ 1995a).
A combination of shared and distinct strategies may be involved in controlling pols I 
and III during the different stages of the cell cycle. For example, a number of 
phosphatases and kinases control the activity of specific transcription factors. As SLl 
and TFIIIB pass through mitosis, both undergo specific inactivation through 
phosphorylation. This can be mediated by the mitotic kinase cdc2/cyclin B 
(Gottesfeld et al., 1994; Heix et al., 1998; Kuhn et al., 1998). The inactivation of SLl
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reflects the phosphorylation of TAFillO, which compromises binding of UBF (Heix 
et a i,  1998). Similai'ly, TFIIIB repression is due to a specific loss of TAF activity 
(Leresche et a i, 1996; White et al., 1995b), which correlates with the 
hyperphosphoiylation of B rfl. Since TFIID has also been shown to be phosphorylated 
and inhibited at mitosis (Segil et al., 1996), it seems that the inactivation of TBP- 
containing complexes is a general mechanism for transcriptional control during M 
phase.
Protein kinases such as CK2 also regulate the output of pols 1 and III. This enzyme 
forms part of the Wnt signalling pathway (Song et al., 2000: Willert et al., 1997). 
Increases in the level, nuclear localisation and/or activity of CK2 are associated with 
cell growth and proliferation (Belenguer et al., 1989; Bose et al, 1999; Orlandin et 
al., 1998). Moreover, it has been demonstrated that CK2 induces the synthesis of 
rRNA and tRNA, a function that may be important for its growth promoting capacity 
(Belenguer et al, 1989; Ghavidel & Schultz, 1997,2001; Hockman & Schultz, 1996; 
Johnston et al., 2002). In the pol III system, CK2 regulates preinitiation complex 
assembly, as phosphoiylation of TFIIIB by this enzyme appears to be necessary for 
efficient interaction with TFIIIC both in vitro and in fibroblasts (Johnston et al., 
2002). In rats, CK2 has been shown to stably interact with pol I itself, phosphorylating 
its largest subunit (Hannan et al., 1998). In addition, the C-terminal tail of UBF is 
heavily phosphoiylated by CK2 in mammals (Voit & Grummt, 2001; Voit et al., 
1992,1995). Removal of this region or phosphatase treatment of intact UBF blocks 
transcriptional activation (O’Mahony et al., 1992; Tuan et al., 1999; Voit et al., 
1992). Indeed, UBF phosphorylation regulates the ability of its C-terminal tail to bind 
and recruit SLl (Kihm et al., 1998; Tuan et al., 1999). Thus, phosphoiylation controls
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promoter recruitment of the TBP-containing initiation factor (SLl or TFIIIB) in hoth 
the pol I and pol III systems.
Other kinases are also involved in regulating assembly of the pol I and III preinitiation 
complexes. UBF can be phosphoiylated at Ser484 by cdk4/cyclin D1 and cdk2/cyclin 
E, both in vitro and in NIH3T3 cells (Voit et a l,  1999). At the end of G1 phase, UBF 
also gets phosphoiylated at Ser388 by cdk2/cyclin E and cdk2/cyclin A (Voit & 
Grummt, 2001). It has been demonstrated that the phosphorylation status of UBF at 
this residue regulates its interaction with pol 1 (Voit & Grummt, 2001).
112 Transcriptional Repression by Tumour Suppressor Genes.
In healthy cells, pols I and III are subject to repression by the tumour suppressors RB 
and p53 (Cairns & White, 1998; Cavanaugh et a l, 1995; Chesnokov et a l,  1996; 
White et a l, 1996; Zhai & Cornai, 2000). The importance of controlling their output 
is clearly indicated by the fact that they are targeted by two major and unrelated 
tumour suppressors. Since the function of p53 and/or RB is compromised in most 
human cancers, it seems likely that pols I and III will be released from repression in 
the majority of tumours.
1.12.1 Repression of Pol III Transcription by RB.
The retinoblastoma protein (RB) is a 110 kDa nuclear phosphoprotein that is believed 
to be constitutively expressed by most normal cycling cells in mammals. It functions
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as a tumour suppressor and growth inhibitor by regulating the activity of several key 
transcription factors (reviewed by Kouzarides, 1995; Weinberg, 1995a; Whyte, 1995).
Two additional proteins have been classified as RB-like proteins, p i07 and p i30. 
These share 30-35% identity at the amino acid level (reviewed in Grana et al., 1998; 
Herwig & Strauss, 1997; Mulligan & Jacks, 1998). As most of their homology lies 
within a bipartite region called the pocket domain, these thiee proteins are referred to 
as the pocket proteins. This pocket is composed of an A domain (amino acids 379 -  
572) and a B domain (amino acids 646 -  772), which are highly conserved between 
species and related proteins, and separated by a non-conserved spacer sequence 
(Herwig & Strauss, 1997; Knudson & Wang, 1997). A number of common target 
proteins have been found to interact with the pocket domains of all three proteins, 
including the members of the E2F family of cellular transcription factors and the 
oncoprotein products of several DNA tumour viruses (reviewed in Dyson, 1998; 
Herwig & Strauss, 1997; Mulligan & Jacks, 1998; Taya, 1997).
RB is able to inhibit transcription at all of the pol III templates (White et al., 1996; 
Larminie et a l, 1997). Overexpression of RB represses transcription of pol III 
reporters in transfected cells, whereas control pol II promoters are unaffected (White 
et al., 1996). Endogenous levels of RB have also been shown to control pol III in vivo. 
Analysis of the RB-deficient human osteosarcoma cell line SA0S2 and primaiy 
fibroblasts from RB-deficient mice demonstrates elevated levels of pol III activity in 
the absence of functional RB protein (White et al., 1996).
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RB appears to regulate pol III transcription by targeting TFIIIB (Chu et ah, 1997; 
Larminie et a i, 1997; Sutcliffe et ah, 1999,2000). Recombinant RB binds to TFIIIB 
in vitro and represses its activity (Chu et ah, 1997; Larminie et ah, 1997). 
Furthermore, immunoprécipitation and cofractionation experiments have indicated 
that a population of endogenous RB molecules stably associates with TFIIIB at 
physiological concentrations (Larminie et ah, 1997; Sutcliffe et ah, 2000). This 
interaction is diminished or abolished in SA0S2 cells, which contain only truncated 
RB (Larminie et ah, 1997). In addition, the activity of TFIIIB was shown to be 
specifically elevated in primary fibroblasts from RB-deficient mice (Larminie et ah,
1997). RB exerts this repression on pol III transcription by disrupting key interactions 
between TFIIIB and other components of the basal pol III transcription apparatus. 
Sutcliffe et ah (2000) showed that the binding of TFIIIB to TFIIIC2 can be blocked 
by RB. In addition, RB dismpts the interaction between TFIIIB and pol III (Figure 
1.5).
TFIIIB is targeted for repression not only by RB but also by its relatives p i07 and 
pl30 (Sutcliffe et ah, 1999). This has been demonstrated by a combination of in vitro 
and in vivo experiments. Recombinant p i07 and p i30 will both bind to TFIIIB and 
repress a variety of class III genes in cell extracts and in transfected cells. 
Furthermore, endogenous p i07 and p i30 were shown by cofractionation and 
CO immunoprécipitation analyses to associate stably with endogenous TFIIIB 
(Sutcliffe et ah, 1999). Disruption of this interaction in vivo results in a marked 
increase in pol III transcription (Sutcliffe et a i, 1999). Furthermore, fibroblasts 
derived from p i07-/- p i30-/- double-knockout mice display elevated levels of pol III 
transcripts (Sutcliffe et ah, 1999). The ability to bind and repress TFIIIB is therefore
30
Chapter 1______________________________________________________ Introduction
Figure 1.5
Effects of RB on pol III transcription.
Schematic representation of the effects that RB can have on pol III initiation 
complexes. Cyclin-dependent kinases relieve RB mediated repression of TFIIIB at the 
Gl/S phase transition.
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a feature of each of the pocket proteins; this is consistent with deletion and 
substitution analyses which have shown that regulation of pol III transcription by RB 
is dependent on the pocket domain (Chu et a i,  1997; White et al., 1996).
The functions of the pocket proteins are subject to cell cycle control (reviewed in 
Grana et al., 1998; Herwig & Strauss, 1997; Mittnacht, 1998; Mulligan & Jacks, 
1998; Taya, 1997), with their phosphoiylation status fluctuating through the different 
stages of the cell cycle. Hypophosphoiylated proteins predominate during GO and 
early G1 phases, but phosphoiylation by cyclin D- and E-dependent kinases relieves 
the G1 restriction point and permits entry into S phase (Goodrich et a l, 1991; Hinds 
et al., 1992). For much of the mammalian cell cycle, there is an inverse correlation 
between the activity of the pocket proteins and the level of pol III transcription. Thus, 
expression of class III genes is low during GO and early G1 phases and then increases 
at the G l/S transition (Mauck & Green, 1974; White et al., 1995a). It has been 
demonstrated that it is the hypophosphoiylated form of RB that associates with 
TFIIIB during GO and early G1 phases, and that this interaction substantially 
decreases as cells approach S phase (Scott et al., 2001). p i30 also interacts with RB in 
this cell cycle-dependent manner (Scott et al., 2001). Consistent with these 
observations, pol III transcription is stimulated strongly when cells are transfected 
with vectors encoding cyclin D/cdk4 and cyclin E/cdk2 (Scott et ah, 2001). Once RB 
and its relatives have been silenced through phosphoiylation, they remain in this 
inactive state until the start of the next G1 phase (Grana et al., 1998; Herwig & 
Strauss, 1997; Mittnacht, 1998; Taya, 1997).
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1.12.2 Repression of Pol I Transcription by RB.
In vitro experiments have demonstrated that RJB can suppress the synthesis of rRNA 
by pol I (Cavanaugh et ah, 1995; Voit et a l,  1997). The physiological relevance of 
these findings was confirmed using immunofluorescence analyses to directly visualise 
the site of pol I transcription, the nucleolus (Rogalsky et a i, 1993; Cavanaugh et a l, 
1995). This approach demonstrated that RB accumulates in the nucleolus when cells 
stop growing and begin to differentiate, in parallel with a decrease in pol I activity. 
This is also the case in confluent fibroblasts (Hannan et aL, 2000b), where the levels 
o f rRNA transcription decreased -five fold, which correlates with increasing amounts 
of the hypophosphorylated form of RB in the nucleolus. More direct evidence 
regarding the regulation of pol I by RB in vivo has been provided by transient 
transfections. These experiments showed that a RB expression vector can repress a 
cotransfected rDNA promoter (Hannan et a i ,  2000b; Pelletier et aL, 2000). Inhibition 
of rRNA gene transcription is consistent with the RB-mediated negative regulation of 
cellular proliferation by preventing the progression of the cells from G1 to S phase.
p i30 is also involved in repressing pol I transcription (Ciarmatori et ah, 2001; Hamian 
et aL, 2000a). Although pol I transcription is unaffected in RB-knockout fibroblasts, 
Rb-/- p i30-/- double knockouts express -50%  more 18S and 28S rRNA than matched 
wild-type cells (Ciarmatori et aL, 2001). This implies that rRNA synthesis in living 
cells is subject to redundant control by endogenous RB and pi 30. Despite a high 
degree of homology and functional overlap with RB and p i30 (Mulligan & Jacks, 
1998), the third pocket protein p i07 seems unable to regulate pol I transcription 
(Ciarmatori et aL, 2001; Hannan et aL, 2000a; Voit et aL, 1997).
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The pol I transcription factor UBF has also been identified as an RB-binding protein 
by screening a cDNA expression library with purified RB as a probe (Shan et aL, 
1992). Subsequent studies have confinned the ability of recombinant RB to bind 
specifically to UBF (Cavanaugh et aL, 1995; Voit et aL, 1997). Furthermore, 
immunoprécipitation experiments have revealed that RB associates with UBF when 
present at physiological ratios, and that this interaction increases when cells down- 
regulate pol 1 transcription as their rate of growth decreases (Cavanaugh et aL, 1995).
Again, p i30, but not p i07, also has the ability to bind and inactivate UBF (Ciarmatori 
et aL, 2001; Hannan et aL, 2000a). This pol I-sepcific transcription factor 
coimmunoprecipitates exclusively with the hypophosphorylated form of RB (Hannan 
et aL, 2000b), implying that the interaction between UBF and RB is regulated by 
cyclin-dependent kinase activity.
The precise mechanism that RB uses to inhibit pol I transcription is not yet clear. 
Several different groups have suggested alternative pathways that could lead to the 
down regulation of rRNA synthesis. Voit et al. (1997), found that RB can disrupt the 
DNA-binding activity of UBF, but it has also been demonstrated that it can interfere 
with the interaction between UBF and SLl (Hannan et aL, 2000a). In addition, RB 
competes with the acetyltransferase CBP for UBF binding, and thereby suppresses the 
acétylation of UBF that activates pol I transcription (Pelletier et aL, 2000) (Figure 
1.6).
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Figure 1.6
Effects of RB on pol I transcription.
Schematic representation of the effects that RB can have on pol I transcription. 
Binding of RB to UBF disrupts its interactions with DNA, SLl and CBP.
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1.12.3 Repression of Pol III Transcription by p53.
p53 protects cells in response to physiological stress conditions by either activating or 
repressing a variety of cellular promoters (Cox & Lane, 1995; Giaccia & Kastan, 
1998; Ko & Prives, 1996; Levine, 1997; Sionov & Haupt, 1999; Vogelstein et aL, 
2000). A well eharacterized example is the p21/WAF/CIP gene, which is activated by 
p53 and plays an important role in G1 arrest (El-Deiry et aL, 1993). Overexpression 
of p53 has a repressive effect on transcription of genes transcribed by pol III. This has 
been demonstrated both in vitro and in transfected cells (Cairns & White, 1998; 
Chesnokov et al., 1996). Furthermore, the synthesis of tRNA and 5S rRNA in vivo is 
elevated four to six-fold following the targeted disruption of the p53 gene in knockout 
mice (Cairns & White, 1998).
There are at least thiee distinct regions of p53 that contribute to its capacity to 
regulate transcription by pol III. These are located in both the N- and C-terminal 
domains, as well as the central core (Stein et aL, 2002b). Regulation of pol III 
transcription by p53 does not require sequence-specific DNA recognition. Instead, the 
pol III system is repressed tlirough interactions of p53 with TFIIIB (Cairns & White, 
1998; Chesnokov et aL, 1996). This is mediated through direct contacts with the TBP 
subunit (Crighton et aL, 2003). Furthermore, overexpressing TBP can reverse 
inhibition of tRNA gene transcription by p53. Coimmunoprecipitation assays have 
revealed that p53 does not disrupt the direct interaction between the TFIIIB subunits 
TBP and B rfl, but prevents the assoeiation of Brfl complexes with TFIIIC2 and pol 
III, thereby impeding the formation of functional transcription complexes (Crighton et 
aL, 2003) (Figure 1.7).
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Figure 1.7
Effects of p53 on pol III transcription.
Schematic representation of the effects that p53 can have on pol III transcription. 
Binding of p53 to TBP prevents initiation complex assembly.
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1.12.4 Repression of Pol 1 Transcription by p53.
Less research has been carried out to examine the molecular mechanism of pol I 
transcriptional inhibition by p53, Zhai & Comai (2000) have shown that the human 
rRNA promoter can be inhibited by overexpression of wild-type, but not mutant, p53, 
and, furthermore, that recombinant p53 inhibits rRNA transcription in a cell-free 
transcription system. In agreement with these results, p53-null epithelial cells display 
increased pol I transcriptional activity compared to that of epithelial cells expressing 
p53. Elevated levels of pre-rRNA were also observed by another group that examined 
fibroblasts from p53 knockout mice (Budde & Grummt, 1999).
p53 represses pol I transcription by directly interfering with the assembly of 
productive transcriptional machinery on the rRNA promoter. Protein-protein 
interaetion assays indicate that p53 binds to SLl. This interaction is mostly mediated 
by direct contacts with TBP and TAFT 10. Thiough this interaction, p53 prevents SLl 
from binding UBF, and consequently represses rRNA synthesis (Zhai & Comai, 
2000) (Figure 1.8).
1.13 Deregulation of Pols 1 and 111 in Carcinogenesis.
Cancers arise as a result of cumulative genetic changes in somatic cells. The 
progression of normal cells to tumour cells involves alterations or mutations in 
tumour suppressor genes and oncogenes. These changes often result in the 
deregulation of an array of genes with different functions. Indeed, many studies have
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Figure 1.8
Effects of p53 on pol I transcription.
Schematic representation of the effects that p53 can have on pol I transcription. 
Binding of p53 to SLl prevents initiation complex assembly.
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observed that the abundance of pol I and III transcripts are abnormally elevated in 
transformed and tumour cell lines (Gottesfeld et aL, 1996; Larminie et aL, 1999; Scott 
et aL, 1983; Wang et aL, 1995; 1997; White et aL, 1990; Ying et aL, 1996; Zhai & 
Comai, 1999).
1.13.1 Inactivation of RB.
The RB pathway is frequently deregulated in tumours; in fact it has been suggested 
that this pathway may be disrupted in all human malignancies (Weinberg, 1995). 
Inactivating mutations in RB have been found in a variety of human tumours, 
including retinoblastomas, where the gene was first identified (Friend et aL, 1986), 
small-cell lung carcinomas, sarcomas, and bladder carcinomas (Weinberg 1995). 
Mutational events range from point mutation to chromosomal deletion, and invariably 
affect the pocket region (Hu et aL, 1990). Pocket domain mutations abolish the ability 
of RB to repress both the activities of pols I and III (Cavanaugh et aL, 1995; Chu et 
aL, 1997; Hannan et aL, 2000a; Larminie et aL, 1999; White et aL, 1996).
In many human malignancies, the function of RB, as well as p i30 and pl07, is lost 
due to the disruption of upstream control pathways (reviewed by Grana ei aL, 1998; 
Mulligan & Jacks, 1998). The most common mechanism by which this occurs is 
thiough constitutive phosphoiylation by cyclin-dependent kinases, which are 
hyperactive in many cancers (reviewed by Bates & Peters, 1995; Hunter & Pines, 
1994). For example, in breast cancers the cyclin D1 gene is amplified in about 20% of 
cases, and its overexpression is detected in about half of all cases (Bartkova et aL, 
1994; Buckley et aL, 1993; Gillet et aL, 1994, Lammie et aL, 1991; Schuuring et aL,
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1992). Overexpression of cyclin E has also been associated with several types of 
cancers (Keyomarsi et ah, 1994). In addition, negative regulators of cyclin-dependent 
kinases, such as p i6, are also found to be inactivated in a high percentage of human 
tumours. This occurs through point mutation, méthylation, or deletion (Rocco & 
Sidransky, 2001).
1.13.2 Inactivation of p53.
The function of p53 is thought to be compromised in over 80% of human tumours 
(Lozano & Elledge, 2000). Mice that are homozygously null for the p53 gene are 
strongly predisposed to cancer, such that 74% develop tumours by the age of six 
months (Donehower et aL, 1992). Furthermore, inherited mutations can cause Li- 
Fraumeni syndrome, a familial cancer predisposition in humans (Varley et a l, 1997). 
The primaiy fibroblasts from these patients often display abnormally elevated levels 
of pol III transcription (Stein et aL, 2002a).
About half of all sporadic tumours contain mutations of one p53 allele coupled to 
deletion of the second allele (Hollstein et aL, 1991,1994). In most cases, the mutation 
lies in the central core of p53 (Bullock et aL, 2000). The most common substitution 
detected in human cancers converts the arginine 175 residue of the core domain of 
p53 to a histidine residue (Ryan & Vousden, 1998). This change abolishes the ability 
of p53 to repress pols I and III, both in vitro and in vivo (Stein et aL, 2002a; Zhai & 
Comai, 2000). Furthermore, this mutation is associated with high tumourigenicity 
and an extremely poor prognosis in patients (Goh el aL, 1995). Loss of p53 function 
can also occur by inactivation of the p53 protein through association with viral
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proteins or with the MDM2 cellular oncoprotein (Hollstein et aL, 1991; Momand et 
aL, 1998). Inactivation of p53 through association with these proteins has been shown 
to release pol III from repression (Stein et aL, 2002a).
1.13.3 Deregulation by Viruses.
Transforming agents involved in carcinogenesis have also been shown to stimulate the 
activity of pols I and III. Among these agents are several viruses encoding 
oncoproteins that have the ability to bind and neutralize tumour suppressor genes. 
This stimulation of transcription in many cases seems to reflect a general requirement 
for increased biosynthetic capacity. However, transformation by adenovirus increases 
pol III transcription to enable high levels of expression of the viral VAI and VAII 
gene products during late infection (Soderlund et aL, 1976; Weinmann et aL, 1974). 
During the course of this infection, adenoviruses express the oncoprotein El A. As 
well as binding and inactivating the pocket proteins, E l A also stimulates pol III 
transcription through increasing TFIIIC2 activity (Hoeffler & Roeder, 1985; Sinn et 
al, 1995; Yoshinaga et a l, 1986). This event is associated with a selective increase in 
the cellular concentration of the TFIIIC 110 subunit and a concomitant rise in the ratio 
of the active-to-inactive forms of TFIIIC2 (Sinn et al, 1995), However, template 
commitment assays have also indicated that overall TFIIIC concentration is increased 
in extracts prepared after thirty hours of adenovirus infection (Yoshinaga et al 1986). 
Therefore, it may be that adenovirus acts initially by converting extant TFIIIC2b into 
TFIIIC2a, and then subsequently reinforces this effect by inducing an increase in 
TFÏIIC2 abundance (White, 1998).
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The oncoproteins of several other DNA tumour viruses have also been shown to 
increase pol III transcription. These include the large T-antigens of SV40 and 
polyomavirus (Carey et ah, 1986b; Felton-Edkins & White, 2002; Larminie et aL, 
1999; Scott et al, 1983; Singh et aL, 1985). RB mediated repression of pol III 
transcription has been shown to be reversed by El A and the large T antigens of SV40 
and polyomavirus, both in vitro and in vivo (Felton-Edkins & White, 2002; Larminie 
et aL, 1999; White et al., 1996). Furthermore, the interaction between RB and TFIIIB 
is diminished substantially in fibroblasts transformed by these viruses (Felton-Edkins 
& White, 2002; Larminie et aL, 1999). In addition, transformation by SV40 and 
polyomavirus also increases the levels of the TFIIIC2 subunits, in particular the 
TFIIIC 110 subunit. This reflects an overproduction of the corresponding mRNAs 
(Larminie et aL, 1999; Felton-Edkins & White, 2002). In the pol I system, SV40 
infection has a striking effect on rRNA half life, which increases from 72 hrs in 
primary human WI38 fibroblasts to 700 hrs in SV40-transformed derivatives 
(Liebhaber ei aL, 1978). This is not a response to changes in growth rate, since rRNA 
stability is the same in serum-starved or rapidly growing WI38 cells (Liebhaber et aL, 
1978). Immunoprécipitation experiments have revealed that the large T-antigen 
directly binds to SLl, in vitro as well as in SV40-infected cells (Zhai et aL, 1997). It 
has been suggested that this interaction occurs by direct association with three SLl 
subunits, namely TBP, TAF;48, and TAFT 10 (Zhai et aL, 1997).
Hepatitis B virus (HBV) is strongly linked to the development of hepatocellular 
carcinoma (Kim et aL, 1991). It encodes the oncoprotein X, which can induce liver 
cancer in transgenic mice (Kim et aL, 1991). X has been shown to stimulate 
transcription by both pol I and pol III (Aufiero & Schneider, 1990; Wang et aL,
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1995,1997,1998). This coordinated activation can be explained by an increase in the 
level of TBP (Wang et aL, 1995,1997,1998). The effect is likely to be direct, since it 
can be obtained with recombinant TBP in vitro and also by transfecting cells with a 
TBP mutant that is specifically defective in supporting pol II transcription (Wang et 
aL, 1997,1998). Johnson et al. (2000) demonstrated that this occurs through promoter 
activation of TBP by the X oncoprotein, which occurs in a Ras-dependent manner that 
requires signalling through the Raf/MEBC/Erk cascade (Johnson et aL, 2000).
One of the most clinically important viruses involved in carcinogenesis is the human 
papillomavirus. This virus encodes two major oncoproteins E6 and E7, which can 
bind to and inactivate p53 and RB, respectively (Dyson et aL, 1989; Münger et aL, 
1989a). Cavanaugh et aL (1995) demonstrated that E7 is able to dissociate RB from 
UBF in vitro. Fuitheimore, transfections with the E7 protein stimulate pol III activity 
(Larminie et aL, 1999; Sutcliffe et aL, 1999). In addition to this, pol III transcriptional 
repression by p53 can be overcome by E6 (Stein et aL, 2002a). The transforming 
activities of this virus will be discussed in greater detail in chapter three.
1.13.4 Activation of Cellular Oncogenes.
As well as the exogenous viral oncogenes, several endogenous cellular genes have 
been demonstrated to cause cancer when deregulated. Among these are the 
intracellular messenger ras, and the nuclear-acting myc genes, both of which have 
been shown to affect the transcriptional activity of pols I and III.
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Ras is commonly targeted for deregulation in carcinogenesis. The Yi-ras, ¥^-ras, N- 
ras, and rho genes constitute a conserved mammalian family encoding structurally 
related proteins (Ishil et al, 1985; Stork et al, 1991). These are plasma membrane- 
associated guanine nucleotide-binding proteins that exhibit GTPase activity, and have 
a molecular mass of 21 kDa (Rozenberg & Howard, 1994). Mutant ras genes 
encoding altered proteins are found in many human and rodent tumour cells and are 
capable of the malignant transformation of NIH 3T3 cells, an established murine cell 
line (Ishii et al, 1986).
The oncogenic forms of Ras differ from their normal counterparts by mutations that 
result in amino acid substitutions at positions 12, 13, or 61 in the phosphate-binding 
domain of the protein (reviewed by Barbacid, 1987). Such mutations activate a 
number of different signal transduction cascades. One of these is the 
Ras/Raf/Mek/Erk cascade (Daum et aL, 1994). Recent studies have shown that Erk 
can stimulate both pol I and III transcription. With the pol I system, UBF is 
phosphoiylated by Erk (Stefanovsky et aL, 2001), and this can result in a rapid 
induction of rRNA synthesis (Stefanovsky et aL, 2001). More recently, it has also 
been reported that Erk-dependent phosphorylation of the murine factor TIF-IA 
(known as Rm3 in humans) is required for rRNA transcription (Zhao et aL, 2003). In 
the pol III system, Erk activates TFIIIB by binding and phosphorylating its Brfl 
subunit (Felton-Edkins et aL, 2003). Coimmunoprecipitation assays have revealed 
that TFIIIB interactions with both TFIIIC and pol III are sensitive to Erk activity. 
Consequently, it has been demonstrated that promoter occupancy by Brfl and pol III 
at endogenous tRNA genes decreases when Erk is inactivated (Felton-Edkins et aL, 
2003). In addition to these effects, it has been demonstrated that constitutive
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activation of Ras induces cyclin D1 overexpression (Filinus et aL, 1994; Kerklioff & 
Rapp, 1997; Liu et aL, 1995; Sewing et aL, 1997; Winston et aL, 1996). This is likely 
to derepress pols I and III through hyperphoshorylation of RB.
Ras signalling is also involved in the induction of c-Myc expression (Kerkhoff & 
Rapp, 1998). The myc genes encode nuclear phosphoproteins that function as 
transcriptional regulators controlling cell proliferation, differentiation, and apoptosis 
(Evan et aL, 1992; Hermeking et aL, 1994; Marcu et aL, 1992). A strong causal link 
between c-Myc deregulation and malignancy has been established by the frequent 
deregulation of c-Myc in many different types of cancers, and by the ability of c-Myc 
expression vectors to function as potent transforming agents in primary cultures and 
in transgenic mice (DePinho et aL, 1991). A number of alterations affect c-Myc 
expression in various neoplasms, including gene amplification, chromosomal 
translocation, insertional mutations, altered transcriptional elongation rates, and 
prolonged mRNA half-life (Dang, 1999).
In c-Myc null cells, marked decreases in net RNA synthesis have been observed 
(Mateyak et aL, 1997). Since rRNA constitutes the bulk of cellular RNA, the c-Myc 
null phenotype could be explained by defects in pol I and III transcription. Indeed, 
anti-Myc antibodies and some c-Myc peptides from conserved regions of the c-Myc 
protein enhance the turnover of rRNA synthesized in homogenates o f Xenopus laevis 
oocyte nuclei (Gibson et aL, 1992). It has also recently been demonstrated that 
TFIIIB is a target for c-Myc (Gomez-Roman et aL, 2003). Binding of c-Myc to 
TFIIIB directly activates pol III transcription at tRNA and 5S rRNA genes (Gomez- 
Roman et al., 2003).
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1.13.5 Cellular Transformation.
In addition to the cases already described, modulation of the relative levels of pols I 
and III activity has also been noted in response to several other transforming agents. 
These include transformation by several other viral regulatoiy proteins, such as the 
immediate early protein of pseudorabies virus and the Tax protein of human T-cell 
leukaemia virus type I, which stimulate pol III transcription, while infection by 
poliovirus has a repressive effect (Ahlers & Feldman, 1987; Fradkin et al, 1987; 
Gaynor et al, 1985; Gottesfeld et al., 1996; Piras et al., 1996). In addition, chemical 
carcinogens can also modify their transcription activities. An example of this is the 
tumour-promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), which 
has been shown to rapidly increase rRNA and tRNA synthesis in dividing and 
nondividing Drosphilia cells (Chao & Pellegrini, 1993; Garber et al., 1991,1994; 
Vallet et al., 1993; Weber et al., 1991).
Although pols I and III have been shown to respond to a broad range of transforming 
agents in cultured cells, very little is known about the levels of transcription by these 
polymerases in human tumours. Two studies have addressed this, and have shown that 
certain pol III transcripts are abnormally abundant in tumours relative to normal tissue 
from the same patient. Chen et al. (1997a) showed that the pol III transcript 7SL is 
abnormally abundant in 19 different types of tumour tissues. Furthermore, Winter et 
al. (2000) showed that 7SL RNA, tRNA and 5S rRNA transcripts are overexpressed 
in ovarian carcinomas, along with the pol III specific factor TFIIIC2.
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1.14 Aims.
As carcinomas develop and undergo changes in gene expression, the demands on the 
protein biosynthetic machinery are likely to be affected. The aim of this study was 
therefore to investigate transcription by pols I and III in cervical, breast and colorectal 
tumour biopsies in comparison to matched normal samples, to examine if deregulation 
occurs, and to identify transcription factors that may contribute to this. The effects of 
the hi stone deacetylase inhibitor TSA on the expression of pol III genes in matched 
transformed and untransformed cells was also assessed to determine whether elevated 
transcription after transformation results from abnormal acétylation.
48
Chapter 2 
M aterials & M ethods
49
Chapter 2_______________________________________________Materials & Methods
2.1 Cell Culture.
BALB/c 3T3 (A31), SV3T3 C138, SV3T3 C149, C33A and HeLa cells were cultured 
in DMEM (Dulbecco’s Modified Eagle Medium). MCF-7 cells were cultured in 
RPMI 1640. Both types of media were supplemented with 10% fetal calf serum (FCS, 
Sigma), 2 mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin. The 
cells were grown in a humidified atmosphere containing 5% CO2 at 37^C. Cell culture 
was performed in a class II hood, using aseptic technique and sterile equipment and 
reagents. Cells were passaged when subconfluent, approximately every 2 to 3 days, by 
treatment with buffered tiypsin-EDTA (0.05% tiypsin, 0.02% EDTA). Cell lines were 
stored by cyro-fleezing, in a solution of 72% DMEM or RPMI, 20% FCS and 8% 
dimethylsulphoxide (DMSO). For trichostatin A (TSA) (Sigma) treatment of A31, 
C138 and C149 cells, cells were grown to 40% confluency and then treated with 100, 
200 or 300 nM TSA for 48 hours.
The W12 subclones 20863 and 20861, which contain episomal or integrated HPV16 
DNA respectively (Jeon et a l, 1995), were cultured on mitomycin-C treated J2 3T3 
fibroblast feeder layers in DMEM supplemented with 10% FCS, 2 mM glutamine, 8.4 
ng/ml cholera toxin, 0.4 mg/ml hydrocortisone, 10 ng/ml EOF and 1.2 mM Ca^ "^ . 
Episomal maintenance or integration of viral DNA was confirmed by preparation of 
total genomic DNA and low molecular weight-enriched genomic DNA isolated by the 
Hirt method (Hirt, 1967), followed by Southern blotting using a whole HPV16 
genome probe.
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2.2 Preparation of Total Cellular RNA.
Total cellular RNA was extracted from cells grown in 10 cm tissue culture dishes 
using TRI reagent (Sigma), according to the manufacturer’s instructions. Media was 
aspirated off the culture plates, and cells were haiwested by scraping in 1 ml of TRI 
reagent per dish, and transferred to sterile eppendorf tubes. 0.2 ml of chloroform was 
then added to each tube, and the samples vortexed. Subsequently, they were 
centrifuged at 13000g for 15 minutes at 4^C. This resulted in separation of the 
samples into 3 phases: a lower organic phase containing protein, a middle interphase 
containing precipitated DNA, and an upper aqueous phase containing the RNA. The 
upper phase from each sample was carefully transferred to fresh eppendorf tubes, and 
0.5 ml of isopropanol added. The tubes were then mixed thoroughly and were 
incubated for 5-10 minutes at room temperature. Following this, the samples were 
centrifuged at 13000g for 10 minutes at 4°C. The supernatant was then removed and 
the remaining RNA pellet was washed with 1 ml of 75% ethanol made up with 
diethypyrocarbonate (DEPC)-treated H2 O (0.1% DEPC). The samples were vortexed 
briefly, microcentrifuged at 7000g for 5 minutes at 4°C, and the supernatant aspirated 
off. RNA pellets were resuspended in appropriate volumes of DEPC H2O, in the range 
of 10-30 pi. Samples were stored at -8 0 ”C. RNA concentration was determined by 
UV spectrophotometry using the calculation: RNA concentration (pg/ml) = 
absorbance at 260 mn x 40 x dilution factor.
Total cellular RNA was also extracted from human tissue samples. Cervical and 
breast biopsy material was obtained from the University Hospital of Heraklion, Crete, 
Greece, and colon biopsy material was obtained from the Institute for Cancer Studies, 
Birmingham, UK, all according to ethical guidelines. Tissue was removed surgically
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and snap-frozen on dry ice. Frozen samples were crushed, and then ground in a 
homogeniser in 1 ml of TRI reagent. RNA was then extracted, as previously detailed.
2.3 Northern Blot Analysis.
20 pg total RNA was diluted to a total volume of 10 pi in DEPC H2O, and this was 
mixed with an equal volume of 2 X RNA sample buffer ( I X  MOPS [20 mM MOPS 
pH 7.0, 8 mM sodium acetate, 1 mM EDTA pH 8.0], 4.4 M fonnaldehyde, 54% 
formamide). The samples were incubated at 65”C for 15 minutes to denature the 
secondary structure of RNA, and then immediately cooled on ice to prevent any 
renaturation. 2 pi of 10 X RNA loading buffer (50% glycerol, 1 mM EDTA, 0.25% 
bromophenol blue, 0.25% xylene cyanol) and 2 pi of 1 mg/ml ethidium bromide was 
added to each sample. The samples were then loaded onto a denaturing formaldehyde 
1% agrose gel (1% agrose, 2.2 M formaldehyde, 1 X MOPS) that had been pre-run in 
1 X MOPS for 20 minutes at 40V. After electrophoresis for a further 5 hours at 40V, 
the fractionated RNA was visualised under a UV transilluminator and photographed.
The gel was then immersed in 20 X SSC (3 M NaCl, 0.3 M sodium citrate pH 7.0) 
and was washed by gentle shaking for 10-15 minutes. The gel was then placed 
inverted on a wick of Whatmann 3MM chiomatography paper fed from a reservoir of 
20 X SSC. A piece of pre-soaked Hybond N nitrocelluose filter (Amersham) which 
had been cut to size was then placed over the gel, followed by 2 pieces of pre-soaked 
Whatmann paper, cut to size, and a stack of paper towels. This was weighed down 
with a 500 g weight ensuring a tight connection between layers. Pieces of
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autoradiography film were placed at the edges of the gel to block the towels from 
directly contacting the wick. The capillary transfer of RNA from the gel to the filter 
was allowed to proceed overnight. The nitrocellulose was then placed to diy and the 
RNA fixed to the membrane by UV-crosslinking (1200 pJ). It was then washed with 
DEPC H2O and stored in Saran wrap until ready to hybridise.
To locate the RNA of interest, hybridisation was performed with a high specific 
activity radiolabelled DNA probe. The B2 gene probe was prepared from a 240bp 
jGco.RI-PstI fragment firom pTB14, and the ARPP PO probe was prepared from a Ikb 
EcoRl-Hindlll fragment from mouse cDNA. The probes were labelled by random 
oligonucleotide priming using a Megaprime DNA Labelling Kit (Amersham). 25 ng 
of purified DNA template was denatured by heating at 95°C for 5 minutes in the 
presence of random hexamer oligonucleotide sequences that can anneal to the DNA 
on the slow cooling of the mixture to room temperature. 10 pi of reaction buffer 
(dATP, dGTP, dTTP in Tris pH 7.5, |3-mecaptoethanol and MgCL), 2 pi (2U) DNA 
polymerase I Klenow fragment, and 50 pCi of [a^^P] dCTP (Amersham) were added 
to initate labelling. This reaction was allowed to proceed for 1 hour at 37°C. The 
labelled DNA was then denatured by heating at 100°C for 5 minutes, and was then 
chilled on ice until ready for use.
While the probe was being prepared, the nitrocellulose was prehybridised by rotation 
in a hybridisation oven for 45 minutes at 45°C in 10 ml of hybridisation buffer (0.2M 
sodium phosphate buffer pH 7,2, 1 mM EDTA, 1% BSA, 7% SDS, 45% formamide 
in DEPC H2O). The radiolabelled probe was then added to 10 ml of fresh hybridisation 
buffer and incubated with rotation at 45°C overnight. The filter was then washed
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twice for 5 minutes at 65”C, and then twice for 15 minutes at 65°C in hybridisation 
wash solution (40 mM sodium phosphate buffer pH 7.2, 1 mM EDTA and 1% SDS). 
The filter was then exposed to autoradiogiaphy film overnight at -80"C. To reprobe 
the filter, it was added to boiling DEPC H2O for 4 minutes and prehybridised and 
probed, as previously described.
2.4 RNA 6000 Nano Assay.
To prepare the gel-dye mix, 400 pi of RNA gel matrix (from RNA 6000 Nano Assay 
Kit, Agilent Technologies) was placed onto a spin filter. This was microcentrifuged at 
1500g for 10 minutes. 130 pi of the filtered RNA gel matrix was then placed into an 
eppendorf tube and mixed with 2 pi of RNA dye concentrate by vortexing. To load 
the gel-dye mix, a RNA chip (RNA 6000 Nano LabChip, Agilent Technologies) was 
placed on the Chip Priming Station, and 9 pi of the gel-dye mix was dispensed into 
the appropriate well. The Chip Priming Station was then closed and the plunger 
pressed until it was held by the clip. The chip was then checked for air bubbles. 9 pi 
of the gel-dye mix was then pipetted into 2 further wells. 5 pi of RNA 6000 Nano 
Marker (Ambion) was then loaded into the ladder well, and then into each of the 12 
sample wells. A further 1 pi of this marker was added to the ladder well, and 1 pi of 
each of the samples (approximately 200 ng/pl) was added to the 12 sample wells. The 
chip was then placed in an adapter and vortexed for 1 minute. The chip was then run 
in the Agilent 2100 Bioanalyzer. This piece of equipment assesses the purity and 
integrity of the RNA and allows concentration to be measured. When an electrical 
voltage is applied to the microchip, the sample migrates through micochannels etched
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in the chip surface. As the sample moves, RNA of different sizes separate according 
to their mass. Intercalating dye within the sieving matrix allows the migrating RNA to 
be detected. The Agilent 2100 Bioanalyzer uses a laser for excitation of intercalating 
fluorescent dyes, and through connection to a computer depicts results as 
electropherograms.
2.5 RT-PCR.
cDNAs were prepared using 3 pg of RNA. Primer annealing was carried out at 80°C 
for 10 minutes with 200 ng of random hexamers (Roche), in a final volume of 24 pi. 
Reverse transcription (RT) was then performed for 1 hour at 42°C using 400 U of 
Superscript 11 reverse transcriptase (Life Technologies), 1 X First Strand buffer (Life 
Technologies), 10 mM dithiotreitol (DTT), and a 0.5 mM concentration of each 
deoxynucleoside triphosphate (dNTP) (Promega), in a total volume of 40 pi. This 
reaction was stopped by incubation at 70°C for 15 minutes.
PCRs were carried out using a Proteus II thermal controller (MJ Research, Helena 
Bioscience). Amplifications were performed using 2 pi cDNA with 20 pmol of 
relevant primers under various cycling parameters. Reaction mixtures also contained 
0.5 U Tag DNA polymerase (Promega), 1 X Taq DNA polymerase buffer (Promega),
1.5 mM MgCL, 1 pCi of [a-^^P] dCTP (Amersham), and 0.2 mM of each dNTP, in a 
total volume of 20 pi.
55
Chapter 2_______________________________________________Materials & Methods
ARPP PO -  265bp 
95°C 2 mm
95 1 mirh.
58 30 secp20-25 cycles
72 1 mirr
72 3 mill
Forward 5’ -  GAG CTG GAA GTC CAA CTA CTT C - 3 ’ 
Reverse 5’ -  TGA GGT CCT COT TGG TGA AC A C -  3’
B 2 -9 0 b p
95°C 3 min 
95 30 see.
55 30 secL-15-20 cycles
72 3 0 seJ
72 5 min
Forward 5’ -  GGG GGT GGA GAG ATG GGT -  3’ 
Reverse 5’ -  GGA TGT GGT TGG TGG GAT -  3’
Bdpl -  293bp
95"G 2 min
95 1 miiv.
56 1 min ^25-30 cycles
72 1 miaJ
72 5 min
Forward 5’ -  GGT GAT AGA GAT ACT GGT G -  3’ 
Reverse 5’ -  GGA GAG AGA AGA ATG TTC TG -  3’
Brfl -  90bp
9 5 T  2 min
95 1 miin
60 1 min j.25-30 cycles
72 1 minJ
72 5 min
Forward 5’ -  GAG CCA GAA TGG ATG ACT TGA G -  3’
Reverse 5’ -  AAA TTC GGT GAG GGT GTT GGG GAG GG -  3’
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c-Mvc -  338bp
94”C 5 min
94 30 sec
65 1 min 125-30 cycles
72 1 minJ
72 5 min
Forward 5’ -  TCC AGC TTG TAG GTG GAG GAT GTG A -  3’ 
Reverse 5’ -  GGT GGA GGA GAA GGT GAT GGA GAG T - 3 ’
Cvclin D1 -  140bp 
9 5 T  5 min
95 1 mim^
6 8  30 sec[25-30 cycles
72 1 mi J
72 5 min
Forward 5’ -  GGT GTG GTA GTT GAA ATG TGT GGA GAA GG -  3’ 
Reverse 5’ -  TGG AGG GAG AGG A AG GGG TGG AGG TAG - 3 ’
Cvclin D2 -  112bp 
94”G 2 min
94 15 sec
62 30 secL25-30 cycles
72 30 seel
73 5 min
Forward 5’ -  GTG GGG GGA GGT AGA TGA TA -  3’
Reverse 5’ -  TGG GTT ATG GTG TAG TTG AAA TAG G -3'-
M R P -232bp
95'^G 3 min
95 30 sec
58 30 secj20-25 cycles
72 30 secJ
72 5 min
Forward 5’ -  GGT GGT GAA GGG GGT TAT G -  3’
Reverse 5’ -  GGT GGG GGG AGA GGG AG -  3’
57
Chapter 2 _____________________________________________Materials & Methods
Rrn3 -  181bp
95“C 3 min
95 30 see.
55 30 seck25-30 cycles
72 30 seel min
72 5 min
Forward 5’ -  GGA AGA GAG AGA GGA TAT AG -  3’ 
Reverse 5’ -  GGA CAC TTG AGA GCC AAG -  3’
TBP -154bp
95°C 3 min
95 1 mire
57 1 min L30-35 cycles
72 1 mirJ
72 5 min
Forward 5’ -  CCT GCC ACC TTA CGC TGA G - 3 ’ 
Reverse 5’ -  GGT GGT GGT GGG TTT GTT G -  3’
TFIIB -  262bp
95°G 3 min
95 30 seel
57 30 s e ^ 25-30 cycles
72 30 sec
72 5 min
Forward 5’ -  GGA GAG AGA ATG AAT GTA G -  3’ 
Reverse 5’ -  GAG TTG TAA TGA AAT GGA GAG -  3’
TF1IIC63 -  300bp 
95°G 3 min
95 1 mirK
62 1 min 125-30 cycles
72 1 minJ
72 5 min
Forward 5’ -  GGG GAG ATG TTC TAG GAG TTA TGG G -  3’
Reverse 5’ -  ATG GGT TGA AGT GGT GGT GC -  3’
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TFIIIC  9 0 -210bp 
95°C 3 min
95 1 min
58 30 secl25-30 cycles
72 1 mini
72 5 min
Forward 5’ -  AAA CAG AAG TTG CTG AGT GC -  3’ 
Reverse 5’ -  ATG GTC AGG GGA TTG TGG -  3’
T FIIIC 102-184bp
95°G 3 min
95 1 min.
60 30 secL-25-30 cycles
72 1 mini
72 5 min
Forward 5’ -  GGT AGT AAT GTG GGT TAT GTG TGG -  3’ 
Reverse 5’ -  GGA GAA GTA AGA TGA TTG GG -  3’
T F m C llO  303bn 
95°G 3 min
95 1 m in
62 40 secL20-25 cycles
72 40 seJ
72 5 min
Forward 5’ -  GTT TGT TGA GAG ATG TGA AAG G -  3’ 
Reverse 5’ -  GGA GAA GGG GTG TGA AAG TGG -  3’
TFIIIC220 -  144bp 
95”G 3 min 
95 20 sec
62 30 sec[20-25 cycles
72 30 secT
72 10 min
Forward 5’ -  TGG AGG GAG AGG TTG AGA G G -3 ’ 
Reverse 5’ -  GGA TTG AGT GTT GGT GGG GT -  3’
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tRNA '^'g-74bp
9 5 T  2  min
95 30 sec
65 30 seel 25-30 cycles
72 15 secJ
72 5 min
Forward 5’ -  GGC TGT GTG GGG GAA TGG ATA -  3’ 
Reverse 5’ -  TTC GAA GGG AGA AGG TTT GAA TTG GTC
tRNA‘'°"-88bp
95°C 3 min
95 30 seci
6 8  30 sec^5-30 cycles
72 30 sec
72 5 min
Forward 5’ -  GTG AGG ATG GGC GAG TGG TGT AAG GGG C C - 3 ’ 
Reverse 5’ -  GGA GGG GTG GAT AGG GAG AGG AGA AGA CGC -  3’
tRNA^“ -74bn
95“C 3 min
95 30 sec
54 30 sect 25-30 cycles
72 30 secT
72 5 min
Forward 5’ -  GGA TGA TGG TGA GTG GTG -  3’ 
Reverse 5’ -  GGT GGA ATT GAA CCA CTG -  3’
UBF — 205bp
95°G 3 min
95 30 seCj
57 30 sec^5-30 cycles
72 30 sec
72 5 min
Forward 5’ -  GGA GTG GAA GTG GGA GTG -  3’ 
Reverse 5’ -  CCT GAT GGT GAT GGT GGT C -  3’
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5 S rR N A -107bp  
95"C 3 min
95 30 secj
58 30 secrl8-23 cycles
72 1 min-^
72 5 min
Forward 5’ -  GGC ATA CCA GCC TGA AGG G -  3’ 
Reverse 5’ -  GAG GAG GGG GTA TTG GGA G G -3
5 .8S rR N A -158bp
9 5 T  3 min 
95 30 seci
59 30 secr20-25 cycles
72 30 sec
72 5 min
Forward 5’ -  GGA GTG TTA GGG GTG GAT G -  3’ 
Reverse 5’ -  GAG GGT GAG AGA GGG GTA G -  3’
7SK -247bp
95”G 3 min
95 30 sec|
57 30 secr25“30 cycles
72 30 sec
72 5 min
Forward 5’ -  GGA TGT GGT TGG GAG ATG TG -  3^  
Reverse 5’ -  GGT TGT GGT AGA AAT GGA G -  3’
7SL -150bp
94“G 2 min 
94 1 mirhj
70 30 secH 5-20 cycles
72 30 seer
72 2 min
Forward 5’ -  GTG TGG GGA GTA AGT TGG GGA TGA ATA TGG -  3’ 
Reverse 5’ -  TAT TGA CAG GCG GGA TGG GAG TAG TGA TG -  3’
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18S rR N A -302bp
95°C 3 min
95 30 sec)
54 30 secj 25-30 cycles
72 30 sec
72 5 min
Forward 5’ -  GGT TGA TCC TGG GAG TAG -  3’ 
Reverse 5’ -  GGA GGT TAT CTA GAG TGA G -  3’
28S rR N A -440bp 
95°G 3 min
95 30 seci
64 30 sec^5-30 cycles
72 30 sec
72 5 min
Forward 5’ -  GGA GGA GAG GGA TAG TGA AG -  3’ 
Reverse 5’ -  GGA GGA GGG AGG GAG GGA G -  3’
Reaction products were resolved on 7% polyacrylamide sequencing gels containing 
7 M urea and 0.5 X TBE (45 mM Tris, 45 mM boric acid, 0.625 mM EDTA pH 8.0). 
Gels were pre-run for 30 minutes at 40W in 0.5 X TBE. 2 pi of each sample after 
dilution 1:1 with formamide running buffer (98% formamide, 0.01% bromophenol 
blue, 0.01% xylene cyanol, 5 mM EDTA) was loaded on the gel after being boiled at 
100°G for 2 minutes and transferred to ice. Electrophoresis was carried out for 1 hour 
at 40W and the gel was vacuum-dried at 80®G for 1 hour. Radioactivity was then 
visualised by autoradiography.
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2,6 Preparation of Genomic DNA.
DNA was also isolated from the cervical biopsy material. After the addition of 
chloroform to TRI reagent and isolation of RNA from the biopsy samples (as detailed 
in the preparation of RNA, section 2.2), DNA was precipitated by the addition of 
0.3 ml of 100% ethanol. After mixing thoroughly and incubating for 2-3 minutes at 
room temperature, the samples were centrifuged at 2000g for 5 minutes at 4°C. The 
DNA pellet was then washed twice in 0.1 M sodium citrate, 10% ethanol solution. 
During each wash the pellet was allowed to stand for 30 minutes. Samples were then 
centrifuged at 2000g for 5 minutes at 4°C. Pellets were then resuspended in 1.5 ml 
75% ethanol and allowed to stand for 20 minutes at room temperature. The samples 
were then microcentrifuged at 12000g for 5 minutes at 4”C, and the supernatant 
aspirated off. DNA pellets were allowed to air diy and were then resuspended in 
appropriate volumes of 8  mM NaOH, typically 50 pi. The samples were then 
centrifuged at 1 2 0 0 0 g for 1 0  minutes to remove insoluble material, the supernatant 
was then transfened to a fresh tube, and the pH adjusted to 8.4 using HEPES ( 6 6  pi of 
0.1 M HEPES free acid/ml DNA solution). Samples were stored at -80°C. DNA 
concentration was determined by UV spectrophotometry using the calculation: DNA 
concentration (pg/ml) = absorbance at 260 mn x 50 x dilution factor.
2.7 PCR.
Genomic DNA from H PV ll infected samples was PCR amplified as described in 
section 2.5. Amplifications were performed using 2 pi DNA with 20 pmol ARPP PO 
or Bdpl primers.
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ARPP P 0 -265bp
95°C 10 min
95 1 mim.
58 30 seckzi cycles
72 1 minJ
72 3 min
Forward 5’ -  GAC CTG GAA GTC CAA CTA CTT C - 3 ’ 
Reverse 5’ -  TGA GGT CCT CCT TGG TGA ACA C ~ 3’
Bdpl -  308bn
95°C 10 min
95 1 min.
57 1 min U30 cycles
72 1 mind
72 5 min
Forward 5’ -  CCA GTC TCA GTA GCT TG -  3’ 
Reverse 5’ -  CCT CAC GGC CGC TCA CAG -  3’
2.8 Preparation of Whole Ceil Extracts.
Whole cell extracts were prepared from cells grown in 10 cm tissue culture dishes. 
Plates of cells were placed on ice and washed twice with 5 ml of chilled phosphate 
buffered saline (PBS) (170 mM NaCl, 3.4 mM KCl, 1 mM Na2HP0 4 , 2 mM KFI2PO4, 
pH 7.2). They were then harvested by scraping in 5 ml PBS. Cells were collected in 
50 ml Falcon tubes and pelleted by centrifugation at 12000g for 8  minutes at 4°C. The 
supernatant was discarded and the cells were resuspended in 1 ml of PBS, and 
transferred to eppendorf tubes. They were then briefly micro centrifuged at 4“C, and 
the PBS was removed. Volumes of cell pellets were then estimated by comparison 
with pre-measured volumes of water (50-150 p.1). The cells were resuspended in an 
equal volume of freshly prepared chilled microextraction buffer (450 mM NaCl, 50
64
Chapter 2_______________________________________________Materials & Methods
mM NaF, 20 mM Hepes pH 7.8, 25% glycerol, 1 mM DTT, 0.5 mM PMSF, 0.2 mM 
EDTA, 40 pg/ml bestatin, 1 pg/ml trypsin inhibitor, 0.7 pg/ml pepstatin, 0.5 pg/ml 
aprotinin, 0.5 pg/ml leupeptin). Upon addition of this buffer, the cells were 
immediately snap-frozen on diy ice. Cells were then placed in a 30°C water bath until 
they had just thawed, and then they were immediately returned to dry ice. This freeze- 
thaw procedure was performed a further 2  times to ensure optimal cell lysis. 
Following the final thaw, cells were microcentrifuged at 8000g for 8  minutes at 4°C. 
The supernatants were carefully aliquoted into fresh tubes, and were then stored at 
-80°C.
The protein concentration of the whole cell extracts was determined using Bradford’s 
reagent (Biorad). A standard Bradford assay curve was constructed by measuring the 
absorbance at 595 nm of 0-20 pg of bovine serum albumin (BSA) in 1 ml of 
Bradford’s reagent diluted 1:4 with H2O. Absorbance readings of 1-3 pi of whole cell 
extract added to 1 ml of diluted Bradford’s reagent were converted into protein 
concentrations accordingly.
2.9 Transformation of Competent Cells.
To store and propagate plasmids, E.coli XL-1 Blue supercompetent cells (Stratagene) 
were transformed. Cells stored at -80®C were thawed on ice to prevent loss of 
transformation ability. Typically, 10-20 ng of plasmid DNA was added to the thawed 
cells and mixed gently. This mixture was incubated on ice for 30 minutes; during this 
time the tube was occasionally gently tapped. Following this incubation, cells were
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heat shocked at 42‘^ C for exactly 45 seconds and then transferred to ice for a further 2 
minutes. 450 pi of preheated (42°C) SOC medium (LB broth, 0.04% glucose, 10 mM 
MgS0 4 , 10 mM MgCL) was then added and cells were ineubated at 37 for 1 hour 
on an orbital shaker (225-250 rpm). Typically, 150 pi of the transformation mixture 
was then plated on LB agar (2% LB, 2% agar) plates containing 50 pg/ml ampicillin, 
and then incubated at 37 °C overnight to allow colony formation.
2.10 Preparation of Plasmid DNA.
For large scale plasmid DNA preparation, a single isolated bacterial colony was 
selected from a freshly-streaked plate and used to inoculate 4 ml of LB medium 
containing 50 pg/ml ampicillin. This was incubated at 37°C on an orbital shaker 
(~300rpm) for approximately 6  hours to form a mini-culture, and was subsequently 
used to inoculate 250 ml of LB medium containing 50 pg/ml ampicillin. This was 
then incubated overnight under the same conditions. Cells were then harvested by 
centrifugation at 6000g for 15 minutes at 4°C, and plasmid DNA retrieved using the 
QIAGEN Plasmid Maxi Kit according to the manufacturer’s instructions.
The harvested bacterial cells were resuspended in 10 ml of Buffer PI (500 mM Tris 
pH 8.0, 10 mM EDTA, 100 pg/ml RNase A), and then were lysed by adding 10 ml of 
Buffer P2 (200 mM NaOH, 0.1% SDS). This reaction was allowed to proceed for 5 
minutes at room temperature before neutralizing the lysate by the addition of 1 0  ml of 
chilled Buffer P3 (3 M potassium acetate, pH 5.5). This resulted in formation of a 
precipitate of potassium dodecyl sulphate, and the SDS-denatured proteins,
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chiomosomal DNA and cell debris were co-precipitated in insoluble salt-detergent 
complexes. Plasmid DNA, being circular and covalently closed, renatured con*ectly 
and remained in solution. Precipitation was enhanced by a 20 minute incubation on 
ice. Precipitated debris was then removed by centrifugation at 20000g for 30 minutes 
at 4°C. The supernatant was then promptly removed and applied to a QIAGEN-tip 
500 pre-equilibrated with 10 ml of Buffer QBT (750 mM NaCl, 50 mM MOPS pH 
7.0, 15% isopropanol, 0.15% Triton X-100). This anion-exchange resin, to which 
plasmid DNA is able to bind tightly, was washed twice with 30 ml of Buffer QC (1 M 
NaCl, 50 mM MOPS pH 7.0, 15% isopropanol). The purified plasmid DNA was 
subsequently eluted with 15 ml Buffer QF (1.25 M NaCl, 50 mM Tris pH 8.5, 15% 
isopropanol), and precipitated with 10.5 ml of isopropanol. The sample was then 
centrifuged at 15000g for 30 minutes at 4”C. Following this, the supernatant was 
carefully decanted out leaving the plasmid DNA pellet, which was then washed with 
70% ethanol and recentrifuged. The pellet was finally dried at room temperature for 
5-10 minutes and resuspended in an appropriate volume of sterile water.
2.11 Pol III in vitro Transcription Assay.
In vitro transcription of class 111 genes was reconstituted using 15-20 pg of cell 
extracts and fractionated factors to provide basal pol 111 transcription components and 
250 ng of plasmid DNA containing the pol 111 templates tRNA (a 240bp EcoRl- 
Hindill fragment of human genomic DNA carrying a tRNA gene, subcloned into 
pAT153), or VAl (a 221 bp Sall-Ball fragment of adenovirus 2 DNA containing the 
VAl gene subcloned into pUC18). Reactions were carried out in a 25 pi volume, with 
a final concentration of 12 mM HEPES pH 7.9, 60 mM KCl, 7.2 mM MgCli, 0.28
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mM EDTA, 1.2 mM DTT, 10% glycerol, 1 mM creatine phosphate, 0.5 mM of each 
of rATP, rCTP and rGTP and 10 |iCi [a-^^P] UTP (Amersham).
Cell extracts were preincubated with fractionated factors for 15 minutes at 30°C prior 
to the addition of template and nucleotides required to initiate transcription. 
Transcription was terminated by the addition of 250 pi of IM ammonium 
acetate/0.1% SDS containing 20 pg of yeast tRNA, which stabilises the synthesised 
RNA. Phenol-chloroform extraction of samples was then performed to remove protein 
and DNA by adding 250 pi PhOH/CHClg/IAA of a 25:24:1 ratio. The samples were 
vortexed and microcentrifuged at 13000g for 5 minutes. 250 pi of the upper aqueous 
layer was then transferred to a fresh eppendorf tube containing 750 pi of 96% ethanol 
in order to precipitate the RNA. The samples were thoroughly mixed by inversion and 
left at -20°C overnight. The precipitated RNA was microcentrifuged at 13000g for 20 
minutes, and the supernatant caiefully removed to avoid dislodging the pellet. 750 pi 
of 70% ethanol was added to each sample to wash the pellet. This was carefully 
removed, and the pellets were placed at 47°C for 5-10 minutes to dry. 4 pi of 
formamide loading buffer (98% formamide, 10 mM EDTA pH 8.0, 0.025% 
bromophenol blue, 0.025% xylene cyanol) was added to each sample, which was then 
vortexed for 20 minutes to ensure the RNA was fully resuspended. Samples were 
boiled at 9S^C for 2  minutes and transferred to ice before 2  pi of each was resolved on 
a pre-run 7% polyaciylamide sequencing gel (described in section 2.5).
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2.12 Separation of Proteins by Polyacrylamide Gel Electrophoresis.
Proteins were resolved on denaturing (SDS) polyacrylamide gels by electrophoresis. 
Typically samples were run on 7.8% polyacrylamide minigels (375 mM Tris pH 8 .8 , 
0.1% SDS) with a 4% polyaciylamide stacking gel (125 mM Tris pH 6 .8 , 0.1% SDS). 
Before loading, samples were boiled for 2 minutes in 4 X protein sample buffer (250 
mM Tris pH 6 .8 , 2% SDS, 20% {3-mercaptoethanol, 40% glycerol, 0.5% bromophenol 
blue) and then transferred to ice. After the samples had been loaded, electrophoresis 
was performed in 1 X SDS running buffer (0.1% SDS, 76.8 mM glycine, 10 mM Tris 
pH 8.3), at an initial voltage of 70V while the bromophenol blue dye moved through 
the stacking gel, and a subsequent voltage of 140V after reaching the resolving gel. 
This was carried out for approximately 1 - 1 . 5  hours.
2.13 Western Blot Analysis.
Proteins resolved by SDS-PAGE were transferred to 0.2 pM pore nitrocellulose 
membrane (Biorad) using the BioRad Mini Trans-Blot Electrophoretic Transfer Cell 
system. Transfer was carried out overnight at 4°C in 1 X transfer buffer (76.8 mM 
glycine, 10 mM Tris pH 8.3, 16.5% methanol) at 40V. Membranes were then blocked 
in milk buffer (32.5 mM Tris, 150 mM NaCl, 0.2% Tween-20, 4% skimmed milk 
powder (Marvel)) for 1 hour at room temperature. Membranes were incubated for 2 
houi's with primary antibodies diluted 1 : 1 0 0 0  in milk buffer.
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06-866 anti-acetylated histone H4 UpState
1900-4 anti-pol III (RPC 155) In house
128-4 anti-Brfl In house
4289-4 anti-TFIIICllO In house
C18 anti-TFIIB Santa Cruz
The membranes were then washed 3 times for 3 minutes in fresh milk buffer to 
remove excess primary antibody, before incubating for 1 hour at room temperature 
with the appropriate horseradish peroxidase-conjugated secondary antibody ( 1 : 1 0 0 0  
dilution in milk buffer). The blot was then washed 3 times for 3 minutes in milk 
buffer, followed by a further 2 milk buffer washes lasting for 15 minutes each. After 1 
further 5 minute wash using 1 X TBS (2.5 mM Tris pH 7.6, 15 mM NaCl), the bound 
antibody was detected using the enhanced chemiluminescence method (ECL, 
Amersham) according to the manufacturer’s instructions.
2.14 Chromatin Immunopreciptiation Assay.
Formaldehyde was added directly to plates of cells containing media to a final 
concentration of 1%. They were then incubated at 37°C for 10 minutes. Glycine was 
then added to a final concentration of 0.125 M to stop the crosslinking. The plates 
were then transferred to ice, and 7 ml of the media removed. Cells were then scraped 
in the remaining media, transferred to Falcon tubes, and centrifuged at 500g for 5
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minutes at 4°C. The cells were washed twice by resuspension in 40 ml chilled PBS 
and pelleted by centrifugation at 500g. The supernatant was then decanted off and the 
cells were incubated on ice for 30 minutes in 40 ml of high salt buffer (0.5% NP-40/ 
PBS, 1 M NaCl). Cells were then recentrifuged and washed with 0.5% NP-40/PBS. 
This was followed by hypotonic disruption for 30 minutes on ice with 40 ml of low 
salt buffer (0.1% NP-40, 10 mM Tris pH 8.0, 1 mM EDTA, 0.1 M NaCl). The 
samples were then centrifuged at 500g at 4°C, the supernatant decanted off, and the 
pellets resupended in 1 ml of low salt buffer. Nuclei were then obtained by passing 
the sample through a 26 gauge needle 3 times. The samples were recentrifuged and 
the nuclei resuspended in 2.7 ml of low salt buffer and lysed with 300 pi sarkosyl. 
The samples were then transferred to a sucrose solution (40 ml low salt buffer/100 
mM sucrose) and centrifuged at 4000g for 10 minutes at 4°C. The supernatant was 
then discarded and the pellet was resuspended in 3 ml TE. The process was then 
repeated. The pellet containing the genomic DNA was then resuspended in 2 ml TE, 
and sheai'ed by sonication (Branson sonifier 250, 10 X for 10 second intervals, 30% 
duty cycle).
Sonicated material was adjusted with 1/10 volume of 11 X NET (1.65 M NaCl, 5.5 
mM EDTA, 5.5% NP-40, 550 mM Tris pH 7.4). 10% of each sample was stored at 
4°C to use as input controls. 4 pg of antibody was added to the samples and they were 
incubated overnight at 4°C. Protein-A-Sepharose beads were added for a further 2 
hours and then recovered on Polyprep columns (Biorad). The negative control was 
incubated with beads alone. After washing twice in 10 ml RIP A buffer (50 mM Tris 
pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% deoxyeholate, 1% NP-40), twice in 10 ml of 
LiCl buffer (10 mM Tris, 250 mM LiCl, 0.5% NP-40, 0.5% deoxyeholate, ImM
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EDTA pH 8.0) and twice in 10 ml TE, beads were transferred to 1.5 ml tubes. 
Immunoprecipitated material was then eluted twice with 200 pi of 1% SDS in TE; this 
was carried out by rotating the tubes for 1 0  minutes at room temperature. 5  pi of 
proteinase K was then added to the supernatants and the samples were incubated at 
42°C overnight to degrade proteins and antibodies. DNA was extracted twice using 
400 pi PhOH/ CHCI3/IA A, and ethanol precipitated. The immunoprecipitated DNA 
was then resuspended in 40 pi TE (10 mM Tris pH 8.0, 1 mM EDTA), and quantified 
by PCR.
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3.1 Introduction.
Cervical cancer is among the most common female cancers in many developed 
countries. Out of around 200 different types of cancer, it is ranked the eleventh most 
common cancer in women in the UK, and accounts for around 2% of all female 
cancers. In 1999, there were over 3000 new cases and 1000 deaths from this cancer in 
the UK (Cancer Research UK, 2003a, b). Although there is a higher chance to develop 
cervical cancer later in life, it is the second most common cause of cancer in women 
under the age of 35 (Cancer Research UK, 2003c).
Normally, proliferation occurs only at the basal layer of the cervix generating cells 
that then move outward toward the surface, differentiating into flattened, keratin-rich, 
nondividing cells, and finally being sloughed off from the surface. During cervical 
cancer, the usual pattern of cell division is disrupted and all the layers of the 
epithelium consist of undifferentiated proliferating cells. In the advanced stages of the 
disease cells break out of the epithelium by crossing the basal lamina and begin to 
invade the underlying connective tissue (reviewed in Alberts et al., 1994). Around 
two thirds of cervical cancers are squamous cell carcinomas (Cancer Research UK, 
2003c), arising within a specific region of the cervix referred to as the transformation 
zone. In this area the columnar epithelium located at the junction between the 
ectocervix and endocervix is replaced by squamous epithelium (reviewed in Cho, 
2002). Adenocarcinoma, arising from the endocervical columnar/glandular epithelium 
is the next most common histology (around 15%); a further 15% are poorly specified 
carcinomas (Cancer Research UK, 2003c).
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Risk factors for cervical cancer include sexual behaviour, smoking, human 
immunodeficiency virus, and most importantly human papillomavirus (HPV) 
infection. The etiological association of HPV with cervical cancer is well established 
(Baldwin et al., 2003; zur Hausen, 2000). Over 90% of invasive cervical carcinomas 
have been shown to contain HPV DNA sequences, and precursor lesions have also 
been associated with the presence of HPV DNA (Bosch et al., 1995).
HPVs belong to the Papovaviridae family of viruses. These aie small nonenveloped 
viruses with circular genomes, composed of 8  kb of double stranded DNA (zur 
Hausen, 1996). They have a slow growth cycle, stimulate cell DNA synthesis, and 
replicate within the nucleus. HPVs comprise a heterogenous group of more than 100 
different genotypes that are highly trophic for epithelial cells of the skin and mucous 
membranes. Of those, more than 35 distinct types are known to infect the anogenital 
mucosa (Bernard et al., 1994). These are broadly divided into different categories. 
Low risk HPV types such as 6  and 11 induce benign proliferative lesions. Types 31 
and 33 are classified as intermediate risk, whereas types 16 and 18 are considered 
high risk and can potentially induce neoplastic transformation (Lorincz et al., 1992).
During the initial stages of HPV infection, viral DNA is maintained as episomes in the 
basal layer of stratified epithelia, with a copy number of 50 to 100 copies per cell (del 
Mar Pena & Laimins, 2001). As a pre-malignant HPV infected lesion progresses to 
cervical cancer, the viral DNA often becomes integrated into host cell DNA (Cullen et 
al., 1991; Matsukura et al., 1989). Indeed, the majority of invasive carcinomas 
contain high risk HPV DNA integrated into human chiomosomal DNA as one or 
more tandem copies (Cullen et al., 1991; Durst et a l, 1985; Matsukura et al., 1989).
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Upon integration, most of the open reading frames (ORFs) of the integrated viral 
DNA are lost or interrupted (Schwarz et a i, 1985). The HPV oncoproteins E6  and E7, 
however, aie still expressed. Furthermore, their expression is deregulated, as the ORF 
of the viral transcriptional regulator protein E2 is generally lost during this process, 
and the mRNA encoding E6  and E7 is stabilised (Gripe et aL, 1987; Jeon et a i,  1995; 
Jeon and Lambert 1995). E6  and E7 are constantly expressed in malignant tissue, and 
inhibiting their expression blocks the malignant phenotype of cervical cancer cells. 
They are independently able to immortalize various human cell types in culture, but 
efficiency is increased when they are expressed together (de Villiers et al., 1989; 
Münger et al., 1989a). High risk HPVs may themselves contribute to integration of 
HPV DNA into the host genome. Indeed, studies have shown that the frequency of 
foreign DNA integration is enhanced in cells expressing high risk, but not low risk, 
HPV E6  and E7 (Kessis et al., 1996).
The E6  oncoprotein of high risk HPV types binds to p53 with much higher affinity 
than E6  of low risk HPV types, and this binding appears to promote p53 degradation 
(Scheffner et al., 1990; Werness et al., 1990). The interaction between high risk HPV 
E6  and p53 is mediated by another protein, E6 -AP, that functions as a ubiquitin ligase 
in the ubiquitination of p53 (Huibregste et al., 1991, 1993; Scheffner et al., 1993). 
p53 is polymorphic at amino acid 72, and may contain either a proline or an arginine 
residue at this position. Storey et al. (1998) have revealed that the arginine form is 
more susceptible to degradation by the E6  protein than the proline fonn. Moreover, 
patients with HPV-associated cervical cancer are much more likely to contain the 
arginine form of p53 compared with the rest of the population. This study suggested 
that patients homozygous for arginine-72 p53 are seven times more susceptible to
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developing cei-vical cancer than people with the proline form. Similarly, the E7 
protein of high risk HPV has been shown to bind RB and the related pocket proteins, 
with much greater affinity than its low risk counterpart (Davies et al., 1993; Dyson et 
al., 1989, 1992; Münger et al., 1989b). This binding results in enhanced degradation 
of RB via the ubiquitin-proteosome pathway (Boyer et al., 1996). Therefore, by 
interfering with the two master regulators of the cell cycle, differentiation and 
apoptosis, HPV infection leads to uncontrolled cellular proliferation.
It has been found that most HPV-positive cervical carcinomas and carcinoma-derived 
cell lines lack p53 and Rb mutations; this is unsurprising since high risk infection 
provides a means with which to inactivate these tumour suppressors (Crook et al., 
1991; Scheffner et al., 1991). However, it has been demonstrated that mutation o f p53 
and HPV infection are not mutually exclusive, suggesting that in at least some cases 
the gene mutation confers an additional growth advantage to the HPV infected cell 
(Fujita et al., 1992; Hellend et al., 1993; Kessis et al., 1993). It has also been 
suggested that the acquisition of p53 mutations may play a role in the progression of 
some HPV associated carcinomas, since p53 point mutations have been identified 
more frequently in métastasés arising from HPV-positive cervical carcinomas than in 
primaiy tumours (Crook & Vousden , 1992).
Previous work has shown that HPV 16 E6  and E7 can both upregulate pol III 
transcription. For example, when a vector encoding wild-type p53 is transfected into 
p53-negative osteosarcoma cells, transcription of a pol III reporter gene is repressed. 
This effect can be overcome by expression of the E6  oncoprotein of HPV 16 (Stein et 
al., 2002a). It has also been shown that acute expression of HPV 16 E7 in
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untransformed RB-positive murine fibroblasts activates pol III transcription (Sutcliffe 
et ah, 1999). This is not an indirect response to cell transformation, because pol III is 
also activated by a nontransforming mutant version of E7 that has retained its ability 
to inactivate RB. In contrast, no stimulation is observed with deletions or substitutions 
in the pocket-binding domain of E7. It has also been demonstrated by affinity 
chromatography experiments that an E7 peptide can prevent UBF from binding to RB, 
whereas a mutant E7 peptide lacking the RB binding motif has no effect. Moreover, 
the inhibitoiy effects of RB on rDNA transcription are overcome by E7 (Cavanaugh el 
al., 1995). This suggests that E7 can activate transcription by pols I and III by 
overcoming the repressive effects of the pocket proteins.
Although these observations suggest that HPV 16 infection will increase pol I and III 
output, this remains to be tested in cervical cells, the principle context in which this 
virus impacts on human health. Therefore, the aim of this chapter was to investigate 
the effect of HPV infection in tissue samples removed during cervical biopsies.
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3.2 Results.
3.2.1 Integration of HPV16 Raises Expression of Pol III Transcripts.
During the development of cervical carcinomas, HPV DNA frequently becomes 
integrated into the host genome (Alazawi et al., 2002; Boshart et al., 1984; Scharz et 
al., 1985). This results in elevated expression of both E6  and E7 (Alazawi et al., 2002; 
Jeon et al., 1995; Jeon & Lambert, 1995). To test whether integration of HPV 16 
results in changes in the expression of pol III transcripts, a cervical keratinocyte cell 
line (W12), generated from a squamous epithelial lesion, was investigated. The 
matched subclones 20863 and 20861, which carry either episomal or integrated copies 
of the viral DNA (Jeon et a l, 1995) were compared by RT-PCR. It was found that a 
range of pol III products were upregulated in the cells where HPV 16 was integrated in 
comparison with cells where the viral DNA was episomal (Figure 3.1). tRNA
as well as 5S rRNA were strongly induced following HPV 16 integration, whereas 
the increase in transcription observed with MRP and 7SK was less striking. This 
effect was specific, as no increase in transcription was observed in the mRNA 
encoding acid ribosomal phosphoprotein PO (ARPP PO), which is synthesised by pol 
II. For tRNA and tRNA which contain introns, the RT-PCR primers detect the 
short-lived primary transcript that is considered to provide a strong indicator of 
ongoing transcription, because of its rapid processing into mature tRNA (Winter et 
al., 2000). In all the other cases, steady-state RNA levels were measured. These data 
suggest a marked and specific elevation of pol Ill-dependent gene expression when 
HPV 16 integrates into the genome of cervical cells.
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Figure 3.1
Pot III induction accompanies viral integration.
cDNAs were generated by reverse transcription of total RNA from W12 cells, which 
maintain the HPV 16 genome episomally (subclone 20863; lane 1), and W12G cells 
(subclone 20861; lane 2), which have the HPV 16 genome integrated. These cDNAs 
were PCR amplified using primers specific for tRNA tRNA tRNA 5S 
rRNA, MRP, 7SK and ARPP PO.
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3.2.2 Cervical Biopsies Infected with HPVI6 Express Elevated 
Levels of tRNA and 5S rRNA.
RT-PCR was also used to examine cervical biopsy samples. Initially ten samples were 
examined, seven of which were HPVl 6-positive, and three in which HPV was not 
detected. There was a clear correlation between the presence of HPV 16 and an 
increase in transcription of the pol III templates tRNA and 5S rRNA
(Figure 3.2). Since samples #2, 4, 6, 8 and 10 were normal tissue taken from areas 
adjacent to tumours, it is clear that this increase was independent of the disease status 
of the sample, as the HPV-16 infected normal samples displayed the same increase in 
pol III transcription as the tumours themselves. RT-PCRs show that levels of the 
primary transcript tRNA in one HPV-negative tumour reached those of the least 
active HPV 16-positive biopsy, although this was not the case for the other tRNAs. 
The significant elevation in pol III transcription observed in samples infected with 
HPV 16 when compared with the HPV-negative biopsies was not seen in the pol II 
transcript ARPP PO.
3.2.3 Genes with a Type III Promoter Structure are not
Overexpressed in Cervical Biopsies Infected with HPVI6,
When the pol III transcripts MRP and 7SK were examined, quite different expression 
patterns were observed (Figure 3.3). The presence of HPV 16 in biopsy samples did 
not result in overexpression of these transcripts. While 7SK remained relatively 
constant, MRP varied markedly between samples, but not in a manner that correlated 
with HPV status or tRNA expression. These variations do not reflect differential RNA
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Figure 3.2
The presence of integrated HPV16 DNA in human biopsies correlates with 
elevated expression of tRNA and 5S rRNA.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 
tRNA tRNA tRNA 5S rRNA and ARPP PO.
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extraction or integrity, as they were not found in the pol II derived ARPP PO mRNA 
control.
3.2.4 The Presence of Integrated HPVI6 DNA in Cervical Biopsies
does not Correlate with any Change in Expression of mRNAs 
Encoding TFIIIC2.
As a variety of different genes transcribed by pol III are upregulated in samples 
infected with HPV 16, the different transcription factors utilized at these templates 
were investigated. The five subunits of TFIIIC2, which are necessary for expression 
of tRNA and 5S rRNA, but are not used at type III promoters such as MRP and 7SK 
(Geiduschek & Kassavetis, 2001, Sclrramm & Hernandez, 2002; White, 1998), were 
examined by RT-PCR. Previous studies have shown that all five mRNAs encoding 
the subunits of TFIIIC2 are induced when fibroblasts are transformed by SV40 or 
polyomavirus (Felton-Edkins & White, 2002; Larminie et al., 1999). Furthermore, 
adenoviral infection can selectively increase the level of TFIIICllO (Sinn et al., 
1995). However, it was found that HPV 16 infection did not deregulate transcription of 
the TFIIIC2 subunits. It was observed that the subunit’s expression is not upregulated 
upon HPV 16 infection (Figure 3.4). In fact, the expression of mRNAs encoding these 
subunits varied substantially between the different samples examined, but not in a 
way that reflected either HPV status or tumour status. Furthermore, there was no 
correlation between the relative levels of these mRNAs and pol III transcript 
expression. These data suggest that TFIIIC2 may not be limiting in cervical 
epithelium and that HPV 16 does not induce expression of TFIIIC2 genes.
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Figure 3.3
Genes transcribed by pol III that have a type III promoter structure are not 
overexpressed in cervical biopsy samples infected with HPV16.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 
MRP, 7SK and ARPP PO.
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Figure 3.4
The presence of integrated HPV16 DNA in human biopsies does not correlate 
with any change in expression of mRNAs encoding TFIIIC2.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 
TFIIIC220, TFIIICl 10, TFIIIC102, TFIIIC90, TFIIIC63 and ARPP PO.
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3.2.5 Brfl is Upregulated in Cervical Biopsy Samples Infected with 
HPVI6.
One of the important transcription factors that is utilized at all pol III templates is 
TFIIIB. RT-PCR was therefore used to assay the relative levels of the three subunits 
composing this transcription factor. It has been demonstrated that Bdpl is strongly 
induced in fibroblasts by SV40 and polyomavirus, whereas TBP and Brfl do not 
respond to these viruses (Felton-Edkins & White, 2002). HPV 16 infection in these 
cervical samples did not have this effect. The Bdpl and TBP subunits displayed 
variable levels of mRNA in the different samples examined, which did not reflect 
HPV status or expression of pailicular pol III products. However, the Brfl subunit of 
TFIIIB was upregulated in the samples in which HPVl6 was present (Figuie 3.5). 
This correlated with the samples which displayed elevated levels of tRNA and 5S 
rRNA.
3.2.6 tRNAs and 5S rRNA are not Overexpressed in Cervical Biopsy
Samples Infected with Medium or Low Risk HPVs.
Further cervical biopsies were investigated to examine whether presence of other 
HPV types also induced overexpression of pol III templates. Samples containing 
medium risk HPV33 and low risk H PV ll (Lorincz et a l, 1992) were compared to 
samples infected with HPVl 6 by RT-PCR. It was found that presence of HPV33 and
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Figure 3.5
The Brfl subunit of TFIIIB is upregulated in cervical biopsy samples infected 
with HPV16.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 
Brfl, Bdpl, TBP and ARPP PO.
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HPVl 1 did not increase transcription of tRNA or 5S rRNA in comparison
with the cervical biopsy samples that are HPV16-positive (Figure 3.6). As seen with 
the HPV 16 infected samples, when RT-PCRs were earned out with primers for 7SK 
and MRP no increase in transcription was correlated with the presence of HPV33 or 
H PV ll. However, a dramatic increase in transcription was observed for one of the 
HPVl 1-positive cervical samples (Figure 3.7). The elevated transcription in this 
particular sample was not seen with tRNA or 5S rRNA templates.
3.2.7 Brfl is not Upregulated in Cervical Biopsy Samples Infected
with Medium or Low Risk HPVs.
When the three subunits of TFIIIB were examined in these biopsy samples, it was 
found that Bdpl showed a massive increase in transcription in the same HPVl 1- 
positive cervical sample that displayed overexpression of the 7SK and MRP 
transcripts. Although this suggests that very high levels of Bdpl might activate 7SK 
and MRP gene transcription, there is no clear correlation between Bdpl, 7SK and 
MRP RNAs in the other biopsy samples (Figure 3.8). To investigate these high levels 
of expression in the HPV 11 infected sample, PCRs were carried out on genomic DNA 
to examine if the Bdpl gene had been amplified. However, no evidence of this event 
was discovered (Figure 3.9).
As with the samples infected with HPV 16, there were variations in the levels of TBP 
in the different biopsy samples that were infected with HPV33 or HPVl 1. Brfl levels 
also varied in HPV33, and HPV 11-positive samples, but did not show the substantial
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Figure 3.6
Pol III transcripts are only overexpressed in HFV16 infected cervical biopsies, 
and not in samples infected with medium or low risk HPVs.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 
tRNA '''®, tRNA tRNA 5S rRNA and ARPP PO.
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Figure 3.7
Genes transcribed by pol III that have a type III promoter structure are not 
overexpressed in cervical biopsy samples infected with high, medium or low risk 
HPVs.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 
MRP, 7SK and ARPP PO.
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increase seen in the HPV 16-positive samples. Although the biopsy samples that were 
HPV 16-positive showed a correlation between presence of this high risk virus and 
upregulation of Brfl, the first sample examined (Figure 3.8) did not show elevated 
expression of this mRNA in comparison with the biopsy samples infected with 
medium or low risk HP Vs. This sample also showed the lowest increase in tRNA and 
5S rRNA expression. In contrast to the other biopsy samples examined, this sample 
maintained the viral genome episomally. This is consistent with the results from the 
W12 model, which suggest that pol III activity is enhanced by HPV 16 integration. It 
also raised the possibility that viral integration may also stimulate Brfl expression. To 
test this, the W12 model was investigated to examine whether the cells with integrated 
HPV 16 contain higher levels of Brfl mRNA than cells in which the viral genome 
remains episomal. Indeed, this was found to be true (Figure 3.10).
3.2.8 Raising the Concentration of TFIIIB Stimulates Pol III
Transcription in Cervical Cells.
The correlation observed in biopsy samples between levels of tRNA, 5S rRNA and 
Brfl mRNA suggests that availability of TFIIIB subunits may limit the rate of 
transcription of many pol III templates in cervical epithelium. It was therefore 
investigated whether raising the level of TFIIIB is sufficient to stimulate pol III 
transcription in extracts of cervical cells. These experiments used a crude fraction 
prepared by phosphocellulose chromatography. Upon incubation of ceivical cell 
extracts with a PC-B fraction that is enriched for TFIIIB, transcription of the pol III
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Figure 3.8
The Brfl subunit of TFIIIB is only upregulated in cervical biopsy samples 
infected with high risk HPV16, and not in samples infected with medium or low 
risk HPVs.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 
Brfl, Bdpl, TBP and ARPP PO.
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Figure 3.9
Gene amplification was not detected in the H F V ll cervical biopsy sample that 
displayed massive upregulation of Bdpl mRNA.
Genomic DNA from HPV 11 infected cervical biopsy samples was PCR amplified 
using primers specific for Bdpl and ARPP PO.
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Figure 3.10
Viral integration upregulates expression of Brfl.
cDNAs were generated by reverse transcription of total RNA from W12 cells, which 
maintain the HPV 16 genome episomally (subclone 20863; lane 1), and W12G cells 
(subclone 20861; lane 2), which have the HPV 16 genome integrated. These cDNAs 
were PCR amplified using primers specific for Brfl and ARPP PO.
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templates VAl and tRNA was stimulated in a dose dependent maimer (Figure 
3.11).
3.2.9 Brfl is a Limiting Factor for Pol III Transcription in Cervical 
Cells.
Previous work showed that pol III transcription increases markedly at the G l/S phase 
transition due to a substantial increase in TFIIIB activity as it dissociates from RB and 
pl30 (Scott et al., 2001; White et ah, 1995a). The response to Brfl in both G1 and S 
phases was therefore examined. In experiments carried out by J. Fairley (University of 
Glasgow), cervical cells were transfected with an expression vector encoding Brfl 
and were then synchronized using either thymidine or nocodozole blocks to arrest cell 
cycle progression; after release from these synchi'onizing blocks, the cells were 
harvested in either early G1 or S phase. As previously demonstrated with nuclear run- 
on assays (White et a i,  1995a), pol III transcription is substantially less active before 
the G l/S transition. Transfection of Brfl only marginally increased transcription of a 
5S rRNA gene in S phase, but it strongly stimulated expression in G1 phase cells 
(Figure 3.12). However, Brfl markedly increased tRNA gene transcription in both 
G1 and S phase cells. In contrast, Brfl had no effect on transcription of 7SK. These 
data provide clear evidence that an increase in Brfl levels can selectively stimulate 
synthesis of tRNA and 5S rRNA in cervical cells. This may explain the observed 
correlation in cervical biopsies between levels of these pol III products and the Brfl 
mRNA.
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Figure 3.11
Raising the concentration of TFIIIB in cervical cells stimulates pol III 
transcription of genes encoding VAl and tRNA
C-33A whole cell extracts were prepared and incubated with a phosphocellulose B 
fraction enriched with TFIIIB. In vitro transcription assays were then carried out with 
the pol III templates VAl or tRNA^^“.
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Figure 3.12
Raising the concentration of Brfl in cervical cells stimulates pol III transcription 
of genes encoding tRNA and 5S rRNA, but not 7SK RNA.
(A) Transcription of a 5S rRNA gene using extracts made from HeLa cells transfected 
with empty vector (lOpg lanes 1 and 4; 5pg lanes 2 and 5) and pcDNA3HA.BRF 
(5pg lanes 2 and 5; lOpg lanes 3 and 6). After transfection, the cells were 
synchronized in S (lanes 1-3) or G1 (lanes 4-6) phases prior to harvesting. (B) As 
above, except that a tRNA gene was used as transcription template. (Q  
Transcription of a 7SK gene using extracts made from HeLa cells transfected with 
empty vector (lanes 1 and 3) or 10 pg of pcDNA3HA.BRF (lanes 2 and 4). After 
transfection, the cells were synchronized in G1 (lanes 1 and 2) or S (lanes 3 and 4) 
phases prior to harvesting. Experiments carried out by J. Fairley, University of 
Glasgow.
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3.2.10 Pol I Transcripts are Overexpressed in HPV16 Infected
Cervical Biopsy Samples.
RT-PCRs were also carried out to investigate if the presence of HPV in cervical 
biopsy samples would have an effect on pol I transcription. It was found that the three 
processed transcripts of pol I, 5.8S rRNA, 18S rRNA and 28S rRNA, each showed 
overexpression in the samples infected with HPV 16 (Figure 3.13). These are the same 
samples which displayed elevated levels of pol 111 transcription. As seen with the pol 
111 transcripts tRNAs and 5S rRNA, this overexpression only occurred in cervical 
biopsy samples infected with high risk HPV16 and not in the medium risk HPV33, or 
low risk HPVl 1 infected samples (Figure 3.14).
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Figure 3.13
Pol I transcripts are overexpressed in HPV16 infected cervical biopsy samples.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 28S 
rRNA, 18S rRNA, 5.8S rRNA and ARPP PO.
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Figure 3.14
Pol I transcripts are only overexpressed in HPV16 infected cervical biopsies and 
not in samples infected with medium or low risk HPVs.
cDNAs were generated by reverse transcription of total RNA extracted from normal 
and tumour tissues. These cDNAs were PCR amplified using primers specific for 28S 
rRNA, 18S rRNA, 5.8SrRNA and ARPP PO.
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3.3 Discussion.
The presence of the high risk HPV 16 in human cervical biopsy samples, but not lower 
risk HPVs, correlates with a specific increase in the expression of genes encoding 
tRNA and 5S rRNA. This was shown by RT-PCR to correlate with the
expression of Brfl. It was also found that raising the concentration of Brfl in cervical 
epithelial cells increases transcription of tRNA and 5S rRNA genes.
It was also demonstrated that the integration status of the virus correlates with pol 111 
transcription. In a sample in which the HPV 16 genome is maintained episomally, 
levels of Brfl as well as the aforementioned pol 111 transcripts were overexpressed to 
a lesser extent than in the samples in which the HPV 16 genome was integrated. Thus, 
Brfl appears to have a major role in regulating the expression of the pol 111 transcripts 
tRNA and 5S rRNA. Due to the very limited amounts of biopsy material available, it 
was not possible to analyse this transcription factor at the protein level. Therefore, in 
interpreting these results, the assumption is made that transcription factor levels in 
these tissue samples reflect the expression of their corresponding mRNAs. Thus, it is 
assumed that tumours with high Brfl mRNA are likely to have elevated Brfl protein 
content. However, this might not be the case, as posttranscriptional controls may have 
a significant influence.
Unlike SV40, polyomavirus, and adenovirus (Felton-Edkins & White, 2002; Larminie 
et al., 1999; Sinn et al., 1995), the presence of HPV did not deregulate expression of 
the mRNAs encoding the TF111C2 subunits. Evidently, TFI11C2 expression does not 
respond to all types of DNA tumour virus. Another group has shown that the 
oncoprotein from a further DNA virus, HBV, stimulates pol 111 transcription by
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increasing TBP expression (Wang et al., 1997). Although the levels of TBP mRNA 
fluctuated dramatically in the cervical biopsies analysed, they did not correlate with 
any of the pol III transcripts examined. It has also been demonstrated that SV40 or 
polyomavirus transformed fibroblasts display increased levels of Bdpl (Felton-Edkins 
& White, 2002). In the cervical biopsy samples, like TBP, the levels of Bdpl mRNA 
varied markedly, showing little correlation with expression of pol III templates, 
suggesting that both factors may be in relative excess for pol III transcription in the 
cervix.
7SK and MRP RNAs respond very differently from tRNA and 5S rRNA. In the W12 
model system, cells which have the HPV 16 integrated into the host genome show 
slightly higher expression of these transcripts than the cells that maintain HPV 16 
episomally. However, 7SK and MRP levels in human tissue do not correlate with viral 
status. It was also observed that raising the concentration of Brfl in cervical epithelial 
cells had no effect on transcription of 7SK. The distinct response of 7SK and MRP 
might reflect their very different promoter arTangements from those of 5S rRNA and 
tRNA genes. Unlike tRNA and 5S rRNA genes, which have internal promoters, 7SK 
and MRP genes do not utilize TFIIIC2 or Brfl (Schramm & Hernandez, 2002). 
However, they do require TBP and Bdpl (Schramm & Hernandez, 2002), and it is 
striking that 7SK and MRP are both expressed at high levels in a tumour that 
selectively overproduces Bdpl. However, neither TBP nor Bdpl mRNA expression 
correlates with 7SK or MRP RNA in the other biopsy samples. Availability of some 
other factor (e.g. PTF) may therefore limit transcription from external pol III 
promoters in cervical epithelium. These results suggest that transcription of MRP and 
7SK genes might be activated by very high levels of Bdpl, even if it is not normally
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limiting. It is not clear what caused the dramatic overexpression of Bdpl mRNA in 
the tumour in biopsy #14, but no evidence for gene amplification was found.
As well as conelating with an increase in pol III transcription, infection of cervical 
epithelium with HPV 16 also correlated with elevated levels of pol I products. The 
three processed transcripts, 5.8S rRNA, 18S rRNA and 28S rRNA, were found to be 
overexpressed in samples that were HPV 16-positive, but not in samples infected with 
HPV33 or HPVl 1.
Alterations in the levels of pol 1 and pol III transcription in HPV 16 infected cervical 
samples may be explained by the fact that this high risk virus expresses the 
oncoproteins E6 and E7 which can inactivate tumour suppressor genes (Larminie et 
ah, 1999; Stein et al., 2002a; Sutcliffe et ah, 1999). E6 is able to inactivate p53, 
which causes the pol III transcription factor TFIIIB and the pol I transcription factor 
SLl to be released from repression. E7 inactivates RB, which also causes the release 
of TFIIIB, and the pol I transcription factor UBF (Figure 3.15). Both these 
oncoproteins from high risk HPV 16 bind to these tumour suppressors with a higher 
affinity than the proteins from lower risk HPVs. This might explain why HPV33 and 
HPVl 1 do not elevate pol III transcription. Viral integration stimulates production of 
E6 and E7 and also correlates in cultured W12 cells with increased levels of pol III 
transcripts and Brfl mRNA, although no increase was observed when the processed 
transcripts o f pol I were examined in this system (data not shown). It is striking that 
HPV 16 seems to have evolved an additional mechanism for activating the pol III 
system. The benefit for HPV 16 of targeting Bifl can be readily explained by the fact
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that it is limiting for tRNA and 5S rRNA synthesis in cem cal cells. Clearly, the most 
effective transcriptional response can be obtained by regulating a limiting factor.
Activation of pols I and III was seen to occur as an early response that precedes 
transformation, as transcriptional upregulation is seen in premalignant cervical biopsy 
samples, relative to uninfected normal tissue. The high rates of synthesis of tRNA and 
rRNA may be advantageous to the virus, perhaps by raising translational capacity to 
facilitate production of viral proteins. It is striking that this mechanism is associated 
with the highly oncogenic HPV 16, but is not apparent with HPV types that are less 
likely to promote malignant progression.
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Figure 3.15
Model showing the effect of HPV16 on pol I and pol III transcription.
In uninfected cervical epithelial cells, rates of pol I and pol III transcription are 
repressed by the tumour suppressor proteins p53 and RB. Presence of HPV 16 triggers 
an increase in the levels of the TFIIIB subunit Brfl, whilst the E6 and E7 viral 
oncoproteins bind to p53 and RB respectively, thereby derepressing TFIIIB and the 
pol I transcription factors SLl and UBF.
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4.1 Introduction.
Breast cancer is by far the most common cancer for women. More than one in four of 
all female cancers in the UK occur in the breast. In 1999, there were approximately 
41,000 new cases and 13,000 deaths from this cancer in UK women (Cancer Research 
UK, 2003a, b). Breast cancer can also occur in men. In the UK there are around 300 
cases diagnosed in men each yeai' (Cancer Research UK, 2003a). The development of 
breast cancer results from the inteiplay of dietary, lifestyle and environmental factors 
on the genetic background of the individual. Hormone levels have also been 
implicated in breast cancer. Recently, strong links between hormone replacement 
therapy and the development of such cancer have been established. A study involving 
a million women has concluded that women taking combination hormone replacement 
therapy may be twice as likely to develop breast cancer (Beral et a l,  2003).
Breast carcinoma arises from the epithelium of the mammary gland. The transition 
from normal to malignant breast epithelium involves a transformation of the breast 
epithelium from normal to hyperplastic, followed by the appearance of atypia in 
association with the hyperplasia, ultimately becoming malignant. Malignant cells 
continue to evolve from non-invasive carcinoma to invasive carcinoma and, 
ultimately, to cells with metastatic potential (Couch & Weber, 2002).
The best-studied risk factor in the development of breast cancer is a family hlstoiy of 
the disease. It is estimated that 15 to 20 % of women with breast cancer fall into this 
categoiy, with approximately 5% of breast cancers attributable to dominant 
susceptibility alleles. Two major breast cancer susceptibility genes (BRCAl and 
BRCA2) have been identified (Miki et a l, 1994; Tavtigian et a l,  1996; Wooster et
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a i,  1995). These encode multifunctional proteins involved in maintaining genomic 
stability, the cellular response to DNA damage, transcriptional regulation, and cellular 
proliferation (Welcsh et al., 2000).
BRCAl is a highly penetrant breast cancer susceptibility gene on chromosome 17q21 
(Miki et al, 1994). It is thought to account for 20 to 30% of inherited breast cancers 
(Couch et a l, 1997; Frank et a l,  1998; Shattuck-Eidens et a l, 1997; Stoppa-Lyonnet 
et a l, 1997). Families with germ-line mutations in BRCAl have an autosomal 
dominant inlieritance pattern of breast cancer, as well as an increased incidence of 
ovarian cancer. Over 250 different disease-causing mutations, scattered throughout 
the gene have been discovered (Blackwood & Weber, 1998; Couch & Weber, 1996). 
These variants are distributed along the entire coding region of the gene.
BRCA2 is a highly penetrant breast cancer susceptibility gene on chromosome 13ql2- 
13 (Wooster et a l, 1994). It is thought to account for 10 to 20% of inherited breast 
cancers (Szabo & King, 1997). Families with germ-line mutations in BRCA2 also 
have an autosomal dominant inheritance pattern of breast cancer, an increased 
incidence of ovarian cancer that is less striking than that with BRCAl, and an 
increased incidence of male breast cancer. Over 100 mutations have been described in 
BRCA2 (Couch et a l, 1996; Lancaster et a l, 1996; Miki et a l, 1996; Phelan et a l, 
1996; Serova et al., 1997; Wooster et a l,  1994). Like BRCAl, these are not confined 
to a paiticular region of the gene.
Other familial breast cancer diseases include the rare Li-Fraumeni syndrome, where 
mutations in p53 are inherited (Malkin et ah, 1990; Srivastava et al., 1990).
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Individuals affected by this disease are susceptible to various types of cancer, 
predominantly breast carcinomas, soft tissue sarcomas, and brain tumours. 
Approximately half the members of Li-Fraumeni families who inherit a mutated p53 
allele develop cancer before they reach 30 years of age (Varley et ah, 1997). It has 
been found that pol III transcriptional activity is often highly elevated in primary 
fibroblasts from Li-Fraumeni patients, especially if germline p53 mutation is followed 
by loss of the remaining allele (Stein et ah, 2002a).
In addition to individuals with Li-Fraumeni syndrome, p53 is also found mutated in 
patients with sporadic breast cancer. In fact, alterations in this tumour suppressor gene 
are the most frequent genetic changes found in breast cancer, and have been detected 
in 15-45% of human breast cancer specimens in several studies (Andersen et aî., 
1993; Deng et al., 1994; Elledge et al., 1993; Saitoh et al., 1994). These changes often 
result in overexpression of mutant p53 protein, which is associated with poor 
prognosis (Allred et al., 1993; Isola et al., 1992; Silverstrini et al., 1993; Thor et al.,
1992). Nuclear accumulation of this protein is found predominantly in the more 
advanced tumours (Domagala et ah, 1993; Isola et al., 1992). This agrees with results 
obtained with transgenic p53 knockout mice (Kemp et al., 1993), which suggest that 
absence of wild-type p53 is important for progression, rather than initiation, of tumour 
development.
Rb also plays a role in breast cancer, but it has not yet been as well characterised as 
p53. Estimates suggest that Rb may be mutated in approximately 20% of breast 
cancers (Fung & T’Ang, 1992). Loss of RB expression correlates with the 
progression of the disease, and especially with the inability of cells to differentiate. A
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study of 197 breast cancer specimens using immunohistochemistry suggested that loss 
of RB expression was correlated with the presence of lymph node metastasis (Sawan 
et al., 1992).
As well as containing mutations in the tumour suppressor genes p53 and Rb, sporadic 
breast cancers have also been shown to contain activated cellular oncogenes such as 
myc. Several reports indicate that genetic alterations of c-myc play an important role 
in the induction and progression of human breast cancer (Leder et al., 1986; Roux- 
Dosseto et al., 1992; Sierra et al., 1999; Watson et al., 1993, 1996). The presence of 
c-myc amplification has been demonstrated in 10-40% of breast cancers (Berns et al., 
1992, 1996; Cluzan et al., 2001; Pertscuk et ah, 1993; Watson et ah, 1993, 1996). 
Overexpression of c-Myc has been related to poor prognosis (Bems et ah, 1992, 1996; 
Borg et ah, 1992), and is thought to occur at an early stage of breast cancer 
(Pietilainen et ah, 1995; Watson et ah, 1993). This overexpression to some extent 
conelates with gene amplification, but not all tumours with c-myc amplification 
display increased levels of this oncoprotein, and some tumours display c-Myc 
overexpression without gene amplification (Bruggers et ah, 1998; Pertscuk et ah,
1993).
Another proto-oncogene that is sometimes altered in breast cancer is ras. Although 
mutations in the coding region of ras occur in less than 10% of breast cancers, there is 
evidence that the Ras signalling pathway may be deregulated in breast cancer more 
frequently (reviewed in Couch & Weber, 2002). In a study of 85 breast cancer 
specimens, immunohistochemical staining was used to detect the presence of multiple 
oncogene products, including H-Ras (Bland et ah, 1995). Coexpression of c-Myc and
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H-Ras with c-Fos correlated with an increased likelihood of recurrence, and decreased 
survival. Immediate or eai'ly co-expression of the three oncogene products in 
neoplastic transformation resulted in an aggressive phenotype in invasive carcinoma 
cells (Bland et al., 1995). In addition to its role in sporadic tumours, there is evidence 
to suggest that H-ras alleles are associated with inherited susceptibility to breast 
cancer (Conway et al., 1995). It has been suggested that these alleles may be 
associated with altered penetrance of the BRCAl gene (Phelan et a l, 1996).
Analysis of breast cancer cells has shown frequent mutations in a number of genes, 
however, it is not yet cleai’ which genetic changes are most important and whether 
they generally arise in a particular order. As a developing breast carcinoma grows and 
undergoes these changes in gene expression, the demands on the protein biosynthetic 
machinery are likely to be affected. This chapter therefore investigates transcription 
by pols I and III in breast tumours, to examine if deregulation occurs.
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4.2 Results.
4.2.1 Pol III Transcripts are Overexpressed in Half of the Breast
Tumour Biopsies Examined.
It has been previously shown that ovarian tumours overexpress some pol III 
transcripts (Winter et aL, 2000). To investigate pol III transcription in breast tumours, 
RT-PCR reactions were carried out with cDNAs generated using RNA extracted from 
the matched normal and tumour breast tissue samples. Using primers specific for 
tRNA 5S rRNA, and 7SL it was found that half of the tumour samples
examined (#1, 5, 6) had elevated levels of these transcripts in comparison to the 
matched normal samples (Figure 4.1). The other tln'ee tumour samples displayed 
decreased levels of these transcripts. These changes are specific, as the levels of 
mRNA encoding the RNA polymerase II transcript ARPP PO remained constant.
4.2.2 Genes with a Type III Promoter Structure are Overexpressed 
in Breast Tumour Biopsy Samples.
To examine if genes with type III promoter structures display the same expression 
pattern as observed with the type I and II promoters, MRP and 7SK transcripts were 
examined. As previously seen in cervical samples, it was found that in breast tumours 
these transcripts displayed quite different expression patterns than the other pol III 
genes examined (Figure 4.2). RT-PCRs revealed that both MRP and 7SK were 
upregulated in five of the six breast tumour samples examined in comparison with the
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Figure 4.1
Pol III transcripts are overexpressed in half of the breast tumour biopsy samples 
examined.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour tissues. These cDNAs were PCR amplified using primers specific 
for tRNA tRNA 5S rRNA, 7SL and ARPP PO. N -  normal, T = tumour.
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matched normal breast samples. The exception to this upregulation was the tumour 
sample from patient #3, which displayed a decrease in the level of these pol III 
transcripts. Interestingly, the samples from this patient also showed a large decrease in 
the transcription of other pol III transcripts examined in Figure 4.1.
4.2.3 Transcription of the TFIIIC2 Subunits is Co-rcgulatcd in 
Breast Biopsy Samples.
To further investigate this deregulation, the assembly factors used to initiate 
transcription were investigated. The TFIIIC2 subunits which are utilized at type I and 
II promoters were examined by RT-PCR. It was observed that all the subunits of 
TFIIIC2 were upregulated in the breast tumour samples fr om patients #1 and 6, when 
compared to matched normal tissue (Figuie 4.3). These samples displayed elevated 
levels of all of the pol III transcripts examined. The tumour sample from patient #5, 
which showed upregulation of pol III transcripts, did not display elevated levels of the 
TFIIIC2 subunits when compared to the noimal tissue. The five subunits of TFIIIC2 
were co-regulated in the biopsy samples, with the exception of patient #4. The relative 
levels of mRNAs for each subunit fluctuated by approximately the same amount when 
tumour biopsies were compared to normal breast tissue in each of the patients. In the 
biopsy samples from patients #2, 3 and 5, levels of TFIIIC2 were observed to be 
lower in the tumour samples relative to the matched normal tissue. The tissue samples 
from patient #4, did not display this co-regulation. Expression of TFIIICllO and 
TFIIIC63 was found to be elevated in this breast tumour sample in comparison with 
the normal tissue. TFIIIC220 and TFIIIC102 remained relatively constant between the
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Figure 4.2
Genes transcribed by pol III that have a type III promoter structure are 
overexpressed in breast tumour biopsy samples.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour tissues. These cDNAs were PCR amplified using primers specific 
for MRP, 7SK and ARPP PO. N = normal, T = tumour.
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normal and tumour samples, while levels of TFIIIC90 were seen to decrease in the 
tumour sample. Although an exact correlation between TFIIIC2 and pol III transcript 
levels was not found in these samples, it is possible that this transcription factor may 
be a limiting factor in some breast tumours. There is a fairly good correlation between 
TFIIIC2 mRNA and pol III transcript levels in four of the cases. However, both sets 
of transcripts behave inconsistently in patient #4, whereas in patient #5 there is a 
uniform decrease in TFIIIC2 mRNA that is not reflected by pol III transcript levels.
4,2.4 The Brfl Subunit of TFIIIB is Upregulated in Breast Tumour 
Biopsy Samples.
To assess whether TFIIIB is deregulated in breast cancer, the three subunits of this 
transcription factor were examined by RT-PCR. It was found that the levels of Bdpl 
mRNA remained relatively constant apart from an increase in patient #1 (Figure 4.4). 
TBP was found to be elevated in half of the tumour samples, in comparison with the 
matched normal breast tissue (patients # 1 ,4 , 6). Again, this transcription factor did 
not correlate with the expression pattern of the pol III transcripts. Brfl mRNA was 
found to be elevated in all except one (#2) of the tumour samples.
4.2.5 Increasing the Concentration of TFIIIB and TFIIIC2 in Breast
Cells Stimulates Transcription of tRNA
To further examine the RT-PCR observations, it was investigated whether raising the 
level of TFIIIB or TFIIIC2 is sufficient to stimulate pol III transcription in extracts of
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Figure 4.3
Transcription of the TFIIIC2 subunits is co-regulated in breast biopsy samples.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour tissues. These cDNAs were PCR amplified using primers specific 
for TFIIIC220, TFIIICllO, TFIIIC102, TFIIIC90, TFIIIC63 and ARPP PO. N = 
normal, T = tumour.
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Figure 4.4
The Brfl subunit of TFIIIB is upregulated in breast tumour biopsy samples.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour tissues. These cDNAs were PCR amplified using primers specific 
for B rfl, B dpl, TBP and ARPP PO. N = normal, T = tumour.
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breast cells. MCF-7 whole cell extracts were incubated with increasing concentrations 
of TFIIIB or TFIIIC2 fractions. In initial experiments crude factions were used, 
prepared by phosphocellulose chromatogi'aphy. In vitro transcription assays revealed 
that incubating the extracts with PC-B or PC-C resulted in increased transcription of 
the pol III template tRNA^^" (Figme 4.5A). To reduce the possibility of 
uncharacterised contaminants, the experiments were repeated with purer fractions. 
TFIIIB was further purified from PC-B by gradient chromatography on MonoQ, to 
give fraction 2Q-56. TFIIIC2 was further purified from PC-C by step chiomatography 
on heparin, to give fraction Chepl-11, and on a B-block DNA affinity column to give 
fraction Oligo IIIC (White et a l,  1995a). Incubation of MCF-7 cell extracts with the 
TFIIIB fraction 2Q-56 or the TFIIIC2 fractions Oligo IIIC and Chepl-11 confirmed 
that transcription of tRNA was indeed upregulated upon increasing the 
concentration of these transcription factors (Figure 4.5B).
4.2.6 Increasing the Concentration of TFIIIB and TFIIIC2 in Breast
Cells Stimulates Transcription of VAI.
In vitro transcription assays were also carried out with the pol III template VAI to 
investigate whether the previously observed increase in transcription occurs at other 
class III genes upon the addition of TFIIIB and TFIIIC2 fractions. Again it was found 
that increasing the concentrations of these transcription factors by the addition of PC- 
B or PC-C fractions increased VAI transcription (Figure 4.6A). Increases in VAI 
transcription were also observed upon addition of the TFIIIC fraction Oligo IIIC or a
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Figure 4.5
Raising the concentration of TFIIIB and TFIIIC2 in breast cells stimulates pol 
III transcription of the gene encoding tRNA
MCF-7 whole cell extracts were prepared and incubated with (A) PC-B or PC-C 
fractions, or (B) the TFIIIB fraction 2Q-56 and the TFIIIC fractions Oligo IIIC and 
Chepl-11. In vitro transcription assays were carried out with the template tRNA
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TFIIIB TAF fraction, 5B1K, prepaied by affinity chromatography with immobilised 
TBP (White et ah, 1995a) (Figure 4.6B).
4.2.7 Raising the Concentration of TAFs, but not TBP, in Breast
Cells Stimulates Pol III Transcription.
MCF-7 whole cell extracts were prepared and incubated with either a PC-B fraction or 
a denatured PC-B fraction, which had been heated to 47 degrees for fifteen minutes, 
inactivating TBP, but leaving the TAFs unaffected (HTPC-B). In vitro transcription 
assays revealed that when TBP is inactivated, the PC-B fraction containing TAFs still 
stimulates pol III transcription at the VAI template, although slightly less than the 
untreated fraction (Figure 4.7A). Incubating 1.5-4.5 pg of recombinant TBP with the 
breast cell extracts depressed VAI transcription (Figure 4.7B). However, no effects 
were seen when in vitro transcription assays were repeated with recombinant TBP at 
lower concentrations (0.01-1 pg) (Figure 4.7C). This squelching effect seen with high 
concentrations of TBP has been previously observed by White et aL (1995b). Thus, 
TBP is not limiting for pol III transcription in breast cell extracts.
4.2.8 Pol I Transcripts are Overexpressed in Breast Tumour Biopsy 
Samples.
To investigate if pol I transcription is also deregulated in breast tumours, RT-PCRs 
were carried out using primers that detect the processed transcripts. 5.8S rRNA, 18S
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Figure 4.6
Raising the concentration of TFIIIB and TFIIIC2 in breast cells stimulates pol 
III transcription of the gene encoding VAI.
MCF-7 whole cell extracts were prepared and incubated with (A) PC-B or PC-C 
fractions, or (B) the TAF-containing fraction 5B1K and the TFIIIC fraction Oligo 
IIIC. In vitro transcription assays were carried out with the template VAT
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Figure 4.7
Raising the concentration of TAFs, but not TBP, in breast cells stimulates pol III 
transcription.
MCF-7 whole cell extracts were prepared and incubated with (A) 1.5-4.5 pg of PC-B 
fraction or 3-4.5 pg HTPC-B (PC-B fraction that has been heated to 47 degrees for 
fifteen minutes inactivating TBP, but leaving the TAFs unaffected), or recombinant 
TBP (B) 1.5-4.5 pg, (C) 1-0.01 pg. In vitro transcription assays were carried out 
with the pol III template VAI.
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rRNA and 28S rRNA each showed overexpression in five of the six tumour samples 
examined, when compared to the matched normal tissue (Figure 4.8). The exception 
to this was the tumour' sample from patient #3, which showed a decrease in 
transcription at these genes. This is the same tumour sample that consistently 
displayed down regulation of the genes transcribed by pol III. Upon investigation of 
the pol I-specific transcription factors Rrn3 and UBF, it was found that differences 
between the levels of these transcripts in normal and tumour samples fluctuated 
dramatically between patients, and did not correlate with pol I transcription (Figure
4.9). Availability of other factors (e.g. TAFs) may therefore be limiting for pol I 
transcription in breast epithelium.
4.2.9 c-Myc is Overexpressed in Breast Tumour Biopsy Samples.
Expression of the oncogene c-myc was also examined by RT-PCR in the breast biopsy 
samples. It was found that levels were elevated in four out of the six tumours 
examined in comparison with normal breast tissue from the same patient (Figure
4.10). The exceptions were tumour biopsy #3, which is the same sample that was 
consistently down regulated when the genes transcribed by pols I and III were 
examined, and #5.
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Figure 4.8
Pol I transcripts are overexpressed in breast tumour biopsy samples.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour tissues. These cDNAs were PCR amplified using primers specific 
for 28S rRNA, IBS rRNA, 5.8S rRNA and ARPP PO. N = normal, T = tumour.
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Figure 4.9
Rrn3 and UBF are only upregulated in two out of the six breast tumour biopsy 
samples examined.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour breast tissues. These cDNAs were PCR amplified using primers 
specific for Rm3, UBF and ARPP PO. N = normal, T = tumour.
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Figure 4.10
c-Myc mRNA is overexpressed in breast tumour biopsy samples.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour breast tissues. These cDNAs were PCR amplified using primers 
specific for c-Myc and ARPP PO. N = normal, T = tumour.
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4.3 Discussion.
As breast cells undergo the numerous genetic changes that occur in the development 
of cancer, transcription by pols I and III is deregulated. These changes in gene 
expression are complicated by the fact that breast tumours consist of many different 
cell types, including carcinoma cells, but also additional epithelial cell types, stromal 
cells, adipose cells, endothelial cells, and infiltrating lymphocytes. In addition to this, 
breast carcinoma cells themselves are morphologically and genetically diverse (Pérou 
et al., 1999).
Examination of tRNA, 5S rRNA and 7SL transcripts by RT-PCR revealed that 
transcription of these genes was elevated in 50% of the tumour biopsy samples 
examined when compared to the matched normal tissue. 5S rRNA genes have a type I 
promoter aiTangement, while tRNA has a type II stmcture. When the genes MRP and 
7SK, which have a type III promoter structure, were examined, it was found that 
transcription was elevated at a higher frequency in these breast tumours, with five out 
of the six patients showing an increase in transcription when the tumour sample was 
compared to the matched normal breast tissue (Table 4.1).
When the transcription factors utilized by pol III were examined, it was found that all 
of the five subunits of TFIIIC2 were upregulated in two tumour samples (#1, 6). This 
correlated with an upregulation of type I and II genes transcribed by pol III. However, 
the tumour biopsy from patient #5, which displayed elevated levels of pol III 
transcription, did not have elevated levels of the TFIIIC2 subunits. To assess the role 
of this transcription factor further, whole breast cell extracts were made from MCF-7 
cells, which were incubated with a PC-C fraction emiched with TFIIIC2. It was seen
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that the addition of this crude fraction increased transcription at the pol III templates 
tRNA and VAl. This was confirmed using the purer fractions Oligo IIIC and 
Chepl-11,
When the subunits of TFIIIB were investigated, it was found that Brfl was 
upregulated in all except for one of the breast tumour biopsy samples, and that TBP 
was upregulated in half of them, while Bdpl remained relatively constant. In vitro 
transcription assays revealed that addition of a PC-B fraction enriched with TFIIIB 
increased transcription at tRNA and VAl templates. Incubation of breast cells with 
the TAF fraction 5B1K or heat treated PC-B, in which TBP was denatured, also 
stimulated pol III transcription. The slight reduction in transcriptional stimulation 
observed when HTPC-B was added in comparison to untreated PC-B may be due to 
some dénaturation of the TAFs, since addition of recombinant TBP had no 
stimulatory effect on pol III transcription in the breast cell extracts. Therefore, it is 
possible that TBP is in relative excess in breast epithelium and that TAFs are limiting 
along with TFIIIC2. However, although upregulation of Brfl in most of the tumour 
samples was seen to correlate with upregulated transcription of MRP and 7SK, the 
con-elation is unlikely to be causal, because these genes do not utilise Brfl. Given 
more time, it would have been interesting to investigate whether the level of Brf2 
increases in parallel with Brfl, as this might be the limiting TAF for MRP and 7SK. 
Since these genes also require PTF, it would also be interesting to deteimine the 
expression level of this factor in the biopsy samples.
When RT-PCRs were carried out to examine pol I transcription, it was seen that the 
breast tumour biopsy samples were upregulated in five of the six patients. The
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exception was a tumour from patient #3, which was also the only tumour that 
displayed a decrease in transcription with the MRP and 7SK genes. Examining 
mRNAs for two of the transcription factors utilized by pol I, UBF and Ri'n3, did not 
reveal any correlation between these factors and expression of the processed pol I 
transcripts (Table 4.1). During the development of cancer, it is likely that the variety 
of transcription factors utilized by both pol I and III precludes a simplistic assigmnent 
of direct stimulatoiy capability to only one of them.
Analysis of c-myc transcription revealed that this gene was upregulated in four of the 
six tumour samples in comparison with the matched normal tissue. Apart from patient 
#5, this deregulation showed some correlation with the increased levels of pol I 
transcripts, as well as MRP and 7SK transcripts (Table 4.1). Since increased levels of 
c-Myc ai'e thought to be involved in the induction and progression of human breast 
cancer (Leder et al., 1986; Roux-Dosseto et al., 1992; Sierra et al., 1999; Watson et 
al., 1993, 1996) it may be that c-Myc ensures that the components required for 
increased growth are available by increasing transcription of pols I and III. Indeed, in 
c-Myc null cells there is a marked decrease in net RNA synthesis (Mateyak et al.,
1997). It has also recently been demonstrated that TFIIIB is a target for c-Myc, 
enabling it to directly activate pol III transcription (Gomez-Roman et al., 2003). It is 
unclear why the tumour sample from patient #3 displayed down regulation of most of 
the transcripts examined. However, it may be that a lot of necrotic material was 
present in this sample.
It is unsurprising, therefore, that pol I and III transcripts are frequently found to be 
upregulated in breast tumour cells, since these products are required for increased
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protein synthesis, which is necessaiy to sustain the higher rates of proliferation of 
tumour cells. These data suggest that alterations in the transcription of c-Myc, pol I 
transcripts, and pol III transcripts with a type III promoter, are common changes 
found in breast carcinomas. However, since such a small number of samples were 
available for analysis in this study, a larger scale investigation would need to be 
carried out in order to confirm these results.
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Table 4.1
Summary of changes in expression observed in breast tumour biopsy samples 
examined by RT-PCR.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour breast tissues. Arrows denote up or down regulation of a particular 
transcript. N = normal, T = tumour.
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5.1 Introduction.
Colorectal cancer is the second commonest cancer in developed countries, but is much 
rarer in developing countries. In the UK, in the year 1999, there were approximately 
36,000 new cases and 16,000 deaths from this cancer (Cancer Research UK, 2003a, 
b). The development of colorectal cancer results from an interplay of dietary, lifestyle 
and environmental factors on the genetic background of the individual (Fearon, 1997). 
Colorectal tumours progress through a series of clinical and histopathological stages, 
ranging from single ciypt lesions (abenant ciypt foci), through small benign tumours 
(adenomatous polyps), to malignant cancers (carcinomas) (reviewed by Vogelstein & 
Kinzler, 2002). As the tumour progresses thi'ough these events (Fearon, 1992) it 
invades underlying layers of tissue, and can be staged according to how far it has 
penetrated the bowel wall and nodal status of the tumour. One of the most commonly 
used staging systems is the Astler-Coller modification of the original Dukes’ system 
(Astler & Coller, 1954). "Dukes' A" is a cancer that is confined to the innermost lining 
of the bowel; "Dukes' B" means the cancer has invaded the muscle layer of the bowel; 
"Dukes' C" means the cancer has metastasised to at least one lymph node in the area, 
and "Dukes' D" means the cancer has metastasised to a distant site in the body, such 
as the liver or lungs.
A small proportion of cases of colorectal cancer are due to the inheritance of 
mutations in certain genes. Two of the best-characterized and most pronounced 
inherited predispositions are hereditary nonpolyposis colorectal cancer (HNPCC) 
(Ponz de Leon et al., 1993) and familial adenomatous polyposis (TAP) (Bussey el ah, 
1978). Unlike FAP patients, individuals with HNPCC do not have a maiked increase 
in the number of adenomas; instead they inherit defective DNA mismatch repair
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genes (Lynch et ah, 1995, 1996). However, the majority of cases of coloreetal cancer 
aie sporadic. Studies of cells from sporadic colorectal cancers have shown that the 
progression thr ough the adenoma-carcinoma sequence of events is a multistep process 
in which genetic alterations accumulate to bring about the neoplastic phenotype 
(Fearon & Vogelstein, 1990) (Figure 5.1).
Mutations which inactivate the AFC tumour suppressor gene on cliromosome 5q 
appear to be the earliest genetic event in colorectal tumourigenesis (Vogelstein et a i, 
1988). The frequency of APC mutations is just as high in adenomatous polyps as in 
carcinomas (Jen et al., 1994; Miyoshi et al., 1992; Powell et al., 1992). In addition to 
causing FAP through germ-line transmission, mutations in the APC gene occur 
somatically in over 80% of sporadic colorectal tumours, whether benign or malignant 
(Miyoshi ei al., 1992; Powell et al., 1992; Smith et al., 1994). These mutations cause 
truncation of the APC protein (Nagase & Nakamura, 1993), and are largely the result 
of splice-site mutations, or nonsense mutations, or insertions/deletions that lead to 
frameshifts (Miyoshi et al., 1992; Powell et al., 1992). The truncated APC protein is 
unable to regulate h-catenin/Tcf-mediated transcription and, therefore, transcription of 
downstream growth promoting genes is increased (Morin et al., 1997; Sparks et al.,
1998).
In cancer cells, a generalised hypomethylation of the genome occurs relatively early 
during colorectal tumourigenesis, and can be observed even in small adenomas (el- 
Deiry et al., 1991; Feinberg et al., 1988; Goelz et al., 1985). Although colorectal 
tumours are globally hypomethylated, a few specific regions of the chr omosome may 
be hypermethylated (Silverman et al., 1989). The cause of these changes in
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Figure 5.1
A model for the molecular progression of colorectal tumourigenesis.
A series of genetic changes are necessary to convert the normal epithelial cell to a 
metastatic cancer.
136
Norm al
epithelium
• ;Hyperproliferatiyé ; 
epithelium  !• ! .•
i
adiêhbmâ'
i
i
i *
Loss o f  5q 
APC
Activation o f  12p 
K-ras
Loss o f  18q 
D C C /SM A D 2/SM A D 4
Loss o f 17p 
p 5 3
Other
changes
Chapter 5_________________________________________________ Colorectal Cancer
méthylation is not yet understood. The loss of DNA méthylation can inhibit 
chromosome condensation (Schmid et a l,  1984), which, in turn, could result in 
abnormal chromosome segregation and in particular chromosome loss. This is one of 
the most common mechanisms for inactivating tumour suppressor genes (Vogelstein 
& Kinzler, 2002).
Activating mutations of ras oncogenes come a little later, occurring rarely in small 
polyps but quite commonly (about 50%) in colorectal cancers and in adenomas larger 
than 1.0cm in diameter (Bos et al., 1987; Forrester et al., 1987; Vogelstein et al., 
1988). The majority of the mutations identified (85%) are in codons 12 and 13 of K- 
ras, with the rest affecting codon 61 of K-ra.y or N-ra.s' (Pretlow et al., 1993; Shibata 
et al., 1993). The lack of mutations in smaller adenomas suggests that ras mutations 
are acquired during adenoma progression. Microdissection studies have provided 
direct evidence for this by demonstrating subpopulations of adenoma cells that have 
acquired ras mutations (Shibata et ah, 1993). When malignant colorectal cells 
containing such ras mutations are grown in culture, they show typical features of 
transformed cells, such as the ability to proliferate without anchorage to a substratum; 
the cells revert to a nontransformed character and reduce their rate of proliferation if 
their activated ras gene is eliminated (Shirasawa et al., 1993).
Tluee candidate tumour suppressor genes, DCC, SMAD2 and SMAD4 have been 
isolated from chromosome 18q (Eppert et ah, 1996; Fearon et ah, 1990; Hahn et al., 
1996). At least one copy of these genes is lost in 70% of colorectal carcinomas, and in 
almost 50% of late adenomas (Vogelstein et al., 1988). Somatic alterations, including 
homozygous deletions, point mutations, or insertions, have been detected in all three
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candidate genes, with mutations in SMAD4 being most frequent (Vogelstein & 
Kinzler, 20002).
Mutations in the p53 gene on chromosome 17p come later still. This tumour- 
suppressor gene is inactivated in at least 75% of colorectal cancers, but rarely in 
benign adenomatous polyps (Vogelstein et a l, 1988). Loss of p53 seems to relieve 
mutant cells of their last inhibitions, and if normal p53 is transfected back into 
colorectal carcinoma cells, their proliferation is suppressed (Baker et al., 1990). p53 
has been demonstrated to arrest cell growth in response to DNA damage. Cells with 
mutant p53 are only partially blocked and continue to divide (Kastan et al., 1991, 
1992; Kuerbitz et al., 1992). Therefore, it has been suggested that p53 protects the 
integrity of the genome by preventing propagation of cells with DNA damage (Lane, 
1992). Although mutations in p53, DCC, SMAD2, SMAD4, ras and APC may be 
critical rate-limiting steps in a large proportion of colorectal cancers, these mutations 
do not always occur in the same sequence, nor aie they the only route to disease.
The increase in the rate of growth required during the adenoma-carcinoma sequence 
of events suggests the possibility that transcription would need to increase in order to 
sustain increased protein synthesis. Therefore, the aim of this chapter was to examine 
whether pols I and III are deregulated in colorectal tumours.
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5.2 Results.
5.2.1 Pol III Activity in Colorectal Tumours.
Total RNA, extracted from colorectal tumours and matched normal mucosa samples 
from eleven patients, was used to generate cDNAs by reverse transcription. 
Frequently used normalization controls, such as the housekeeping gene ARPP PO, 
have been shown to be upregulated during colorectal cancer; therefore, primers 
against another more suitable gene had to be designed. This proved problematic, as 
many of the potential control genes that were tested displayed elevated levels of 
mRNA in the colorectal tumour samples. RT-PCRs carried out with primers against 
TFIIB showed far less variation between normal and tumour colorectal samples; thus 
these primers were used as a control for subsequent PCR analyses.
To investigate the levels of pol III activity in colorectal tumour biopsy samples, RT- 
PCRs were carried out using primers specific for the pol III transcripts 5S rRNA, 
tRNA tRNA tRNA 7SK, and MRP. Out of the eleven colorectal tumour 
biopsies, it was found that four samples consistently overexpressed pol III transcripts 
in comparison with the matched normal tissue from the same individual (samples #1, 
6, 9 & 10, Figure 5.2). This effect was specific, as no change was detected in the 
levels of mRNA encoding TFIIB, which is synthesized by pol II. In the other tumours 
examined, three of the samples displayed decreased levels of transcription at these 
class III genes, one remained relatively constant, and thiee showed a combination of 
equal and decreased levels, depending on the transcript.
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Figure 5.2
Pol III transcripts are overexpressed in four out of the eleven colorectal tumour 
biopsy samples examined.
cD N A s were generated by reverse transcription o f  total R N A  extracted from matched  
normal and tumour colorectal tissues. These cD N A s were PCR am plified using  
primers specific for 5S rRNA, tRN A tR N A  tR N A  7SK , M RP and TFIIB. 
Ad =  adenoma, N  =  normal, T =  tumour.
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5.2.2 Activity of Pol III Transcription Factors.
As deregulation is observed for a range of class III genes with distinct promoter 
sequences and structures, the general pol III transcription machineiy that is utilised by 
each of these templates was investigated. First, the levels of the three subunits of 
TFIIIB were examined by RT-PCR to assess whether the upregulation of pol III 
activity in four of the colorectal tumours (samples #1, 6, 9 & 10) was due to an 
increase in the availability of transcription factors (Figure 5.3). Although upregulation 
of all tliree subunits occuned in the later stage Dukes’ B and Dukes’ B/C tumours 
(samples #6, 9 & 10), this was not the case with the earlier stage Dukes’ A sample 
(#1). This tumour sample did, however, display elevated levels of the TFIIIB subunit 
Bdpl. Despite the fact that the colorectal tumour sample #2 displayed elevated levels 
of all of the TFIIIB subunits, overexpression of pol III templates examined was not 
observed. Tumour samples that displayed decreased levels of transcription at two or 
more of the pol III templates were also observed to have decreased levels of TBP and 
Brfl RNA, and in some cases Bdpl.
Next, transcription of the TFIIIC2 subunits was investigated. Again, RT-PCRs 
showed that these subunits were expressed in a similar manner to TFIIIB. 
Upregulation of all five subunits occurred in the later stage colorectal tumours 
(Dukes’ B and Dukes’ B/C) that overexpressed pol III transcripts (samples #6, 9 & 
10). This correlated upregulation of the five TFIIIC2 subunits was not observed in 
adenoma sample #1. Furthermore, sample #2 displayed elevated levels of the subunits 
TFIIICllO and TFIIIC90 in comparison with the matched normal mucosa from the 
same individual (Figure 5.4). It was also observed that expression of at least one of
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the TFIIIC2 subunits and, in sample #5 all of the subunits, were down regulated in the 
other tumour samples.
5.2.3 Pol I Activity in Coloreetal Tumours.
As pols I and III are frequently regulated together, RT-PCRs were carried out using 
primers specific for the processed ribosomal RNAs 28S, 18S and 5.8S. These pol I 
transcripts were found to be overexpressed in over 50% of the colorectal tumour 
biopsy samples examined, in comparison with matched normal tissue from the same 
individual. Four of the samples that showed upregulation of pol I activity were the 
same samples that displayed upregulation of pol III transcripts (samples #1, 6, 9 & 10, 
Figure 5.5). The other two colorectal samples were a late stage Dukes’ D tumour 
(sample #11) and another Dukes’ B/C tumour (sample #8). Tumour samples #2 and 3 
showed a decrease in the levels of the transcripts.
Upon investigation of the pol I-specific transcription factors Rin3 and UBF, it was 
found that the levels of these transcripts are only upregulated in two out of the eleven 
colorectal tumour biopsy samples examined in compai'ison with matched normal 
tissue from the same individual (samples #6 & 10). These are two of the tumours that 
display elevated levels of pol I transcripts, but no evidence of coordinated 
overexpression was seen in the other four tumours that displayed increased levels of 
pol I activity (Figure 5.6). In the other tumour samples (excluding sample #9, which 
remained constant), decreased levels of one or both of these factors were observed.
142
Chapter 5_____________________________________________________ Colon Cancer
Figure 5.3
The subunits of TFIIIB are upregulated in four out of the eleven colorectal 
tumour biopsy samples examined.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour colorectal tissues. These cDNAs were PCR amplified using 
primers specific for Brfl, Bdpl, TBP and TFIIB. Ad = adenoma, N = normal, T = 
tumour.
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Figure 5.4
Transcription of the TFIIIC2 subunits is upregulated in three out of the eleven 
colorectal tumour biopsy samples examined.
cDNAs were generated by reverse transcription of total RNA extracted from matehed 
normal and tumour colorectal tissues. These cDNAs were PCR amplified using 
primers specific for TFIIIC220, TFIIICllO, TFIIIC102, TFmC90, TFIIIC63 and 
TFIIB. Ad = adenoma, N = normal, T = tumour.
144
A B B/C D iDukes *stage
4  X ----------
2 3 4  5
X  ►
6 7 8 9  10 W '.Patient#
N A d N A d N T N T N T N T N T N T N T N T N T :  Sample
y» A4W
am Mf,:
'dAdr
arigMfti
JCJ/.3
."z»' #
,C^ •
:^ ?^ %KK&auGkar
TFI1IC220
TFIIICllO
TFI1C102
TFIIIC90
TFI1IC63
TFIIB
Chapter 5_____________________________________________________ Colon Cancer
Figure 5.5
Pol I transcripts are overexpressed in over half of the colorectal tumour biopsy 
samples examined.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour colorectal tissues. These cDNAs were PCR amplified using 
primers specific for 28S rRNA, 18S rRNA, 5.8SrRNA and TFIIB. Ad = adenoma, N 
= normal, T = tumour.
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Figure 5.6
Rrn3 and UBF are only upregulated in two out of the eleven colorectal tumour 
biopsy samples examined.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour colorectal tissues. These cDNAs were PCR amplified using 
primers specific for Rrn3, UBF and TFIIB. Ad = adenoma, N = normal, T = tumour.
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5.2.4 rRNA Levels are Elevated in Colorectal Tumours.
The overexpression of pol I transcripts observed in colorectal tumours was also 
confirmed in another two Dukes’ B matched normal and tumour colorectal samples 
(Figure 5.7). RNA from these two sets of samples was also assessed using an Agilent 
2100 Bioanlayzer. This piece of equipment assesses the purity and integrity of the 
RNA and allows concentration to be measured very accurately. 250 ng of each of the 
colorectal RNA samples was loaded onto a RNA 6000 Nano microchip. When an 
electrical voltage is applied to the microchip, the sample migrates through 
microchannels etched in the chip surface. As the sample moves, ribosomal RNA and 
ribosomal transcripts of different sizes separate according to their mass. Intercalating 
dye within the sieving matrix allows the migrating RNA to be detected. The Agilent 
2100 Bioanalyzer uses a laser for excitation of intercalating fluorescent dyes. The 
electropherograms for each matched normal/tumour pair were then overlaid (Figure 
5.8). Levels of the two dominant ribosomal peaks representing 18S and 28S rRNA are 
a lot higher in the colorectal tumour samples in comparison with the matched normal 
mucosa from the same individual. The levels of the RNA apart from these two peaks 
are relatively constant between the normal and tumour samples. This confirms that the 
majority of transcripts present in these samples do not show the specific increase in 
expression observed in the tumour for rRNA.
5.2.5 c-Myc is Overexpressed in Colorectal Tumour Biopsy Samples.
As the ARC gene is mutated early in colorectal tumourigenesis, downstream targets of 
B-catenin were investigated. One B-catenin target is the c-myc gene, which was found
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Figure 5.7
Pol I transcripts are overexpressed in additional colon tumour biopsy samples.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour colorectal tissues. These cDNAs were PCR amplified using 
primers specific for 28S rRNA, 18S rRNA, 5.8S rRNA and TFIIB. N = normal, T = 
tumour.
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Figure 5.8
The levels of rRNA are specifically elevated in colorectal tumour biopsy samples 
compared to normal tissue from the same individuals.
RNA levels from matched normal and tumour colorectal tissues were assessed using 
an Agilent 2100 Bioanlayzer. 250 ng of each of the RNA samples were loaded onto a 
RNA 6000 Nano microchip. The electropherograms for each normal/tumour pair were 
then overlaid. The first peak is the marker. The next peak is a combination of the 5S 
rRNA, 5.8S rRNA and tRNA, and the following two peaks represent 18S and 28S 
rRNA.
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to be overexpressed in all except one (sample #1) of the colorectal biopsy samples 
examined in comparison with matched normal tissue from the same individuals 
(Figure 5.9). B-catenin also targets cyclin D1.
5.2.6 Levels of Cyclin D1 and D2 in Colorectal Tumours.
Various cyclins accumulate in a cell cycle-regulated manner and complex with cyclin- 
dependent kinases. Binding of a cyclin-dependent kinase to a specific cyclin partner 
activates the kinase, which in turn phosphorylates and activates downstream target 
proteins that are necessary to propel the cell into the next phase of the cell cycle 
(Buckley et ah, 1993). Oveiproduction of cyclins and cyclin-dependent kinases, or 
their presence at an inappropriate time, would be expected to cause umegulated cell 
division. Therefore, RT-PCRs were carried out to investigate the levels of cyclin D1 
and cyclin D2 transcripts. Figure 5.10 shows that cyclin D1 is overexpressed in seven 
(samples #1, 5, 6, 7, 8, 9 & 10) of the eleven colorectal tumours in comparison with 
surrounding normal mucosa. In contrast, cyclin D2, which is a direct target of Myc, is 
overexpressed in four of these samples (#1, 6, 9 & 10). It is interesting to note that 
overexpression of cyclin D2 occurs in the same colorectal tumours that overexpress 
pol III transcripts.
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Figure 5.9
c-Myc mRNA is overexpressed in colorectal tumour biopsy samples.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour colorectal tissues. These cDNAs were PCR amplified using 
primers specific for c-Myc and TFIIB. Ad = adenoma, N = normal, T = tumour.
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Figure 5.10
Cyclin D-dependent kinase mRNAs are overexpressed in many of the colorectal 
tumour biopsy samples examined.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour colorectal tissues. These cDNAs were PCR amplified using 
primers specific for cyclin D l, cyclin D2, and TFIIB. Ad = adenoma, N = normal, T = 
tumour.
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5.3 Discussion.
It has been observed that relatively few changes in transcript expression are associated 
with colon cancer (Notterman et al, 2001; Zhang et al, 1997). Expression profiles 
obtained by oligonucleotide arrays from colorectal samples revealed that only 
nineteen transcripts out of the 4000 examined had elevated mRNA expression in 
colorectal tumours compared with paired normal samples, whereas 47 transcripts 
displayed lower expression in the tumour tissue compared with the normal samples 
(Notterman e/a/., 2001).
The results from this study found that genes transcribed by pol 111 were elevated in 
over a third of the colorectal tumours examined. This upregulation o f transcripts such 
as 5S rRNA and tRNAs agrees with previous tumour investigations carried out by 
Winter et ah (2000), who found that each of the four ovarian tumours examined 
displayed elevated levels of the aforementioned genes. In addition to upregulation 
observed in pol 111 transcription, pol 1 activity was found to be elevated in half of the 
colorectal tumour samples tested. Transcriptional down regulation by pols 1 and 111 
was also observed in some tumour samples. These changes in transcript levels are 
summarised in table 5.1.
The variability in gene expression across different tumour and normal samples could 
be due to a number of factors. It is conceivable that the histopathologically normal 
appearing mucosa adjacent to a tumour is not normal at the molecular level. It is 
possible, therefore, that elevated transcription in these adjacent areas may be higher 
than normal tissue in mucosa distant from the tumour. Alternatively, tumour cells may 
secrete a factor(s) that affects gene regulation in the adjacent normal cells in a
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paracrine fashion (Wang et a i,  2002). Differences could also be due to imbalances of 
cell types. This has been observed previously by groups working with colorectal 
tissue samples (Notterman et al., 2001). Both normal and tumour tissues contain 
variable amounts of non-epithelial cells in which the normal expression of the 
investigated genes may outweigh the tumour associated alterations. Furthermore, the 
alterations in gene expression may not be homogeneous within a tumour. For 
example, overexpression of the gene encoding p21 is detected in mucinous carcinoma 
cell lines and can also be confirmed after analysis of tissue on a single cell level. 
However, this change is not detectable in tissue RNA, due to the inliomogeneity of 
p21 expression in the tumour (Backert et al., 1999). The best way to overcome such 
problems might be to cany out in situ hybridisation of tissue sections.
With such a limited survey of tissue samples, the clinical stage of disease was not 
seen to be related to a specific pattern of gene expression. However, it was observed 
that elevation of transcription by pols 1 and 111 appeared to occur frequently in the 
later stages of tumour development (table 5.1). This is to be expected, as increases in 
the biosynthetic machineiy are required to sustain rapidly increasing growth rates that 
occur in tumour progression. Indeed, oligonucleotide arrays have shown that a cluster 
of ribosomal protein genes is expressed at higher levels in colon tumour tissues than 
in normal colon tissues (Alon et al, 1999).
Transcription by pols 1 and 111 was also seen to be upregulated in one of the adenoma 
samples. Since adenomas are considered to be the pathological precursors to 
colorectal carcinogenesis (Kinzler & Vogelstein, 1996), it may be that upregulation of 
pol I and 111 transcription occurs as an early event in tumour development. In
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agreement with this, several ribosomal proteins (S6, S8, S12, L5 and ARPP PO) have 
been shown to be overexpressed in adenomas (Pogue-Geile et aL, 1991). With the 
furthest progressed Dukes’ D tumour, there is seen to be no increase in the rate of 
transcription by either pol 1 or pol 111. At this late stage, this lack of upregulation may 
be due to decreased growth rates in some regions of the tumour that are poorly 
vascularised and have become hypoxic. Indeed, it is well known that different areas of 
tumours express different genes according to the available oxygen supply. Therefore, 
tissue removed from the centre of a carcinogenic lesion may not reflect the active 
transcription at the perimeter of a tumour. Unfortunately, data regarding the precise 
location of tissue samples obtained was not available for analysis.
Analysis of some of the transcription factors utilized by pols 1 and 111 revealed that 
UBF and Rjtn3 were not upregulated in all the tumour samples that displayed elevated 
pol 1 activity. In fact, they were only elevated in two of these samples and down 
regulation of these factors was more frequently observed. Therefore, pol 1 
upregulation does not seem to require upregulation of these initiation factors, at least 
at the RNA level. This is in agreement with results from Huang et al. (2002) who 
previously observed that although upregulation of UBF was seen in eleven out of 
sixteen hepatocellular carcinomas tested, this is specifrc to this particular cancer and 
was not observed in lung, esophageous, breast and ovarian cancers. In fact, some of 
these tumour samples displayed lower levels of UBF in comparison with matched 
normal tissue. There appealed to be more correlation between TBP upregulation and 
increased transcription in both the pol 1 and 111 systems. However, in the colorectal 
adenoma sample #2, although TBP mRNA is elevated, there is no increase in the rate 
of transcription by pols 1 or 111. The remaining TFIIIB subunits as well as TBP, and
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all five of the TF111C2 subunits were found to be coordinately upregulated in samples 
#6, 9, and 10. The colorectal tumour sample #2 displayed elevated levels of TFlllB 
and two of the subunits of TFÏ11C2 (TFIIICIIO & TF111C90). However, transcription 
of pol 111 templates remained unchanged. The adenoma sample which displayed 
elevated levels of pol 111 transcripts (sample #1) also displayed upregulated Bdpl 
transcription. Unfortunately, due to the limited amount of biopsy tissue available, 
protein could not be isolated to further analyse levels of these transcription factors. It 
therefore remains possible that some samples overexpress transcription factors 
without any change in their mRNA levels through translational control. Conversely, a 
change in mRNA level might not result in changed protein levels.
As no clear correlation was established between the level of expression of 
transcription factors utilized by pols 1 and 111, and their activity, other regulators that 
are known to affect transcriptional activity were investigated. It has been shown that 
mutations in the tumour suppressor gene APC lead to aberrant nuclear accumulation 
of the p-catenin/Tcf transcription complex. This, in turn, leads to increased 
expression of target genes, such as c-myc (He et al., 1998). In this study, c-Myc 
mRNA levels were found to be elevated in ten of the eleven colorectal tumours tested, 
in comparison with the adjacent normal mucosa. The high percentage of tumours in 
which c-Myc was upregulated is in agreement with results from other groups (Nesbit 
etal., 1999; Rothberg, 1987; Wang et a l,  2002).
Cyclin Dl is another gene targeted by the p-cateniiVTcf transcription complex 
(Shtutman et al., 1999; Tetsu & McCormick, 1999; Wang et al., 2002). Cyclin Dl 
overexpression has been observed in a subset of neoplastic conditions, including
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human colorectal cancers (Arber et al., 1996, 1997; Sutter et al., 1997). Arber et al. 
(1996) demonstrated that nuclear expression of cyclin Dl occurs in one third of the 
samples of colonic tumours, but this was not found to correlate with Dukes’ staging. 
In addition, this group showed that inhibition of cyclin D l expression causes growth 
arrest in colon carcinoma cell lines (Arber et ah, 1997). The constitutive activation of 
Ras further stimulates transcription of the cyclin Dl gene (Albanese et al., 1995; 
Tetsu & McCormick, 1999). In keeping with these findings, many of the colorectal 
tumour samples examined displayed upregulated levels of cyclin D l mRNA (seven 
out of the eleven tested). This oceurred frequently in the later stage tumours (Table 
5.1), presumably after activation of K-m^. Cyclin D2, which is controlled by different 
signalling pathways, was not seen to be upregulated as frequently. Although cyclin 
D l is upregulated in many of the colorectal tumours, it is only when cyclin D2 is also 
elevated that increased pol 111 activity is observed. Overexpression of these products 
is expected to have a stimulating effect on transcription, as it would enable the 
phosphoiylation of RB. Thus, in a hyperphosphoiylated state RB would no longer be 
able to bind to UBF and TFlllB, and therefore the transcriptional repression mediated 
by this tumour suppressor protein would be alleviated. Cyclin D2 is a well- 
characterized direct target for c-Myc. Elevated expression of cyclin D2 mRNA may 
therefore be taken as an indicator that c-Myc activity is raised. It is veiy striking that 
there is a perfect correlation between the induction of cyclin D2 mRNA and the 
induction of pol 111 transcripts. This suggests that Myc activity may be rate-limiting 
for pol 111 transcription in colorectal cells.
The results of this study suggest that activity of pol 1 and 111 is upregulated in a 
number of colorectal carcinomas, in one case occurring at an early stage in the
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development of adenomas, with continued deregulation throughout the progression of 
the neoplastic disease. Further samples would need to be tested to gather more 
information regarding the frequencies of these overexpression events, but it appears 
that in colorectal carcinoma pol 1 is deregulated with a higher frequency than pol 111.
A straightforward correlation is not apparent between the products of pols 1 and 111 
and the mRNAs encoding any of the transcription factors that were investigated. This 
might be because regulation is occurring at a different level, such as phosphorylation 
of TFlllB by Erk or CK2. Alternatively, individual tumours might use different 
mechanisms to achieve the same molecular end. For example, upregulation of Bdpl 
might drive the activation of pol 111 transcription that is seen in adenoma #1, whereas 
the increase in tumours #6, 9 and 10 might be caused by increases in TF111C2 
expression. However, one event that correlates perfectly with pol 111 activation is the 
induction of cyclin D2 mRNA. This might indicate that cyclin D2 has a direct effect 
on the pol 111 machineiy, but it might also indicate a dependence on c-Myc activity. 
Although nearly all of the tumours express elevated c-Myc mRNA, only four of the 
samples show increased c-Myc function, as assessed by expression of its target cyclin 
D2. Perhaps c-Myc activation in these four samples is responsible for the induction of 
pol 111 transcription.
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Table 5.1
Summary of changes in expression observed in colorectal tumour biopsy samples 
examined by RT-PCR.
cDNAs were generated by reverse transcription of total RNA extracted from matched 
normal and tumour colorectal tissues. Arrows denote up or down regulation o f a 
particular transcript in the tumour relative to the matched healthy sample. Ad = 
adenoma, N = normal, T = tumour.
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6.1 Introduction.
Gene expression is under the control of enzymes that regulate transcription by 
modifying the acétylation state of histones. Deregulation of the activity of these 
histone acetyltransferases (HATs) and histone deacetylases (HDACs) has been 
implicated as having a causative role in the generation of cancer (Wang et al., 2001).
HATs transfer the acetyl moiety from acetyl coenzyme A to the groups of
internal lysine residues (Kuo & Allis, 1998). Introduction of the acetyl group 
neutralizes the positive charge and increases the hydrophobicity. This acétylation of 
the histone H3 and H4 lysines is associated with destabilization of nucleosomes, as 
the DNA wi'apped around the core histone becomes loosened (Grunstein, 1997). This 
DNA conformation enables transcription factors, regulatory complexes and RNA 
polymerases to gain access to the DNA. Therefore, expression of the corresponding 
genes is promoted (Bannister & Miska 2000; Bronwell & Allis, 1996; Tse et al., 
1998; Ura era/., 1997).
Histone acétylation is a reversible process (Figure 6.1) and, in the opposing reaction, 
HDACs remove the acetyl groups, re-establishing the positive charge in the histone 
tails and enabling condensation of the nucleosome structure (Kuo & Allis, 1998). This 
causes a tighter association between DNA and nucleosomes, which inhibits 
transcription by impairing the access of the transcription apparatus (Knoepfler & 
Eisenman, 1999).
In addition to modifying the acétylation state of histones, HATs and HDACs can 
regulate gene expression through their actions on transcription factors (Gu & Roeder,
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Figure 6.1
Model depicting the regulation of gene expression by histone acétylation and 
deactetylation.
Recruitment of histone acetyltransferases (HATs) to silent regions of DNA causes the 
transfer of acetyl groups to the N-terminal tails of histones, thereby reducing the 
ability of nucleosomes to occlude the promoter region. The transcription machinery 
can then gain access to this area and transcription initiation can commence. 
Recruitment of histone deacetylases (HDACs) to active regions of DNA reverses this 
process. The box illustrates the molecular structure of trichostatin A (TSA), a specific 
inhibitor of HDACs.
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1997; Imhof et aL, 1997; Muth et al., 2001; Smirnov et al., 2000; Zhang & Bieker, 
1998). In addition, some transcription factors have intrinsic acctyltransferasc activity, 
such as TFIIIC2, which displays HAT activity that is intrinsic to the TFIIIC90 
subunit, and probably also to the TFIIIC220 and TFIICllO subunits (Hsieh et al, 
1999a; Kundu et al, 1999).
HATs and HDACs also paiticipate in cell cycle regulation. It has been demonstrated 
in the pol II system that transcriptional repression by the tumour suppressors p53 and 
RB, involves the recruitment of HDAC complexes (Brehm et al., 1998; Luo & 
Postigo, 1998; Magnaghi-Jaulin et a l, 1998; Murphy et al., 1999). RB binding to the 
transcription factor E2F involves recruitment of HDACs (Brehm et al., 1998; Luo & 
Postigo, 1998; Magnaghi-Jaulin et a l, 1998). The importance of the binding of 
HDAC to RB is suggested by the fact that many tumour-specific mutations found in 
RB disrupt its association with the deacetylase (Brehm et al., 1998). In addition, viral 
oncoproteins such as the HPV16 E7 protein or the SV40 T-antigen are able to 
displace deacetylase activity from RB (Brehm et al., 1998; Magnahi-Jaulin et al., 
1998). These observations suggest a key role for HDACs in G1 arrest. Repression by 
RB of E2F can also occur because RB masks the activation domain of E2F (Ross et 
a l, 1999). These two distinct mechanisms used in the control of pol II transcription 
are selective, since many E2F-dependent promoters can be repressed by RB in the 
absence of HDAC activity (Luo & Postigo, 1998).
As deregulation of these enzymes would cause changes in the expression of a broad 
range of genes, it is unsuiprising that mutations in HATs or aberrant recruitment of 
HDACs are associated with increased risks for cancer (Wang et a l,  2001).
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Amplification and overexpression of the acetylase AIBl has been demonstrated to be 
clearly associated with breast cancer (Anzick et al., 1997). The p300/CBP family of 
acetylases is also implicated in cancer. It is found translocated in acute myelocytic 
leukaemia (Borrow et al., 1996; Ida et al., 1997; Sobulo et al., 1997), and is found 
mutated in colorectal and gastric carcinomas (Muraoka et al., 1996). Furthermore, 
interaction of p300/CBP with E l A is necessaiy for immortalisation by El A (Moran, 
1993). Aberrant recruitment of histone deacetylases has been found in cell lines 
derived from patients with acute promyelocytic leukaemia, acute myelogenous 
leukaemia, involving acute myelogenous leukaemia 1 and ETO genes, and non- 
Hodgkin lymphoma, with inappropriate expression of repressor BCL-6 (Marks et al., 
2000).
The use of drugs that inhibit the activity of HDACs has attracted considerable interest 
as a new therapeutic approach for cancer therapy. Low molecular weight molecules 
such as trichostatin A (TSA), suberoylaniUde hydroxamic acid, and oxamflatin are 
potent HDAC inhibitors that block the growth of tumour cells (Marks ei al., 2001). 
The microbial metabolite TSA induces cell differentiation and cell-cycle arrest, at 
both G1 and G2 phases, and inhibits morphological transformation (Futamura et al., 
1995; Yoshida gr a/., 1990, 1995).
TSA consists of a dimethylamino-phenyl group linked to hydroxamic acid (Yoshida et 
al., 2001). Ciystallographic studies have shown that this inhibitor mimics the 
substrate and is able to chelate the zinc in the catalytic pocket of HDACs through the 
actions of its functional hydroxamic acid group (Finnin et al., 1999). Several studies 
have shown that the inhibition of HDACs with TSA induces the hyperacetylation of
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histones (Van Lint et ah, 1996; Yoshida et a l, 1990, 1995) and regulates transcription 
of several genes (Chen ei al., 1997b; Chireux et al., 1996; Van Lint et al., 1996; 
Yoshida a/., 1995).
Previously it has been demonstrated that histone acétylation can facilitate pol III 
transcription from a chromatin template in vitro (Lee et al., 1993; Tse et al., 1998; 
Ura et al., 1997). Furthermore, acétylation can influence pol III activity in vivo. Pol III 
transcription of SINEs is heavily repressed by histones in chromatin from murine 
fibroblasts (Carey & Singh 1988; Russanova et al, 1995). Treatment with TSA 
overcomes this repression, resulting in a strong induction of B2 transcripts in these 
untransformed cells (Sutcliffe et al., 2000). Nevertheless, TSA does not block the 
ability of RB to regulate pol III genes in vitro or in vivo. This indicates that RB 
represses pol III transcription by an HD AC-independent method.
The aim of this chapter was to examine the effects of TSA on the expression of pol 
Ill-transcribed genes in matched transformed and untransformed cells in order to 
assess whether elevated transcription after transformation results from abnormal 
acétylation.
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6,2 Results.
6.2.1 TSA may Interfere with Ribosomal Processing in Transformed 
Cells.
Previously it has been shown that TSA can upregulate expression of B2 genes, 
presumably by inhibiting HDACs (Sutcliffe et al., 2000), To examine the effects of 
this drug on transformed cells in comparison with untransformed cells, the parental 
Balb/c 3T3 A31 and SV40-transfbrmed C149 cell lines were cultured either without 
TSA, or in the presence of 100, 200 or 300 nM TSA. It was observed that culturing 
the transformed murine fibroblasts in the presence of TSA over a period of 48 hours 
caused significant apoptosis. This occurred in a dose dependent manner. Another 
SV40-transformed cell line, C138, was also initially examined in preliminary 
experiments. However, levels of apoptosis were extremely high, even at the lower 
concentrations of TSA; therefore this cell line was not used in further experiments. In 
the untransformed cells, TSA had no effect on cell viability.
RNA extracted from these cell lines was loaded onto a MOPS gel and stained with 
ethidium bromide. Upon analysis of this gel it was apparent that an additional band 
was present, which migrated in between 28S and 18S rRNA in the C149 samples that 
had been treated with TSA (Figure 6.2A). This additional band was also extremely 
prominent in the RNA extracted from C138 cells that had been treated with the HDAC 
inhibitor (Figure 6.2B). It was also observed that as the levels o f this unidentified 
band increased with increasing TSA concentration, the intensity of 28S rRNA, and to 
a lesser extent 18S rRNA, decreased. In the untransformed cells, TSA had no such
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effect on the RNA. This raises the possibility that TSA may be interfering with 
ribosomal processing in the transformed cells.
6.2,2 TSA Induces B2 Gene Expression in Untransformed and 
Transformed Cells.
Northern blot analysis was carried out with the same A31 and C149 RNA samples 
used in Figure 6.2A. The blot was first probed with a B2 gene, and then was stripped 
and reprobed with the control ARPP PO gene. It was found that both the 
untransformed and SV40-transformed fibroblasts displayed increases in the 
expression of B2 with the HDAC inhibitor TSA. This occurred in a dose dependent 
manner (Figure 6.3). This response was seen to be specific, since the gene encoding 
ARPP PO was unaffected by the presence of TSA. As previously observed by White et 
al. (1990), it was found that the transformed C149 fibroblasts expressed B2 at a higher 
rate than the untransfoimed A31 cells. Quantification of these RNA levels revealed 
that addition of TSA caused less of an increase in the transformed cells 
(approximately 1.5 fold) than in the untransformed cells (approximately 5 fold).
6.2.3 TSA Stimulates the Expression of other Pol III Templates.
To assess whether TSA causes increases in the expression of other pol III templates, 
RT-PCRs were carried out on RNA extracted from A31 and C149 fibroblasts cultured 
either without TSA or in the presence of 200 nM TSA. It was found that this drug 
caused increases in the expression of 5S rRNA, tRNA and as well as B2 in
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Figure 6.2
TSA may interfere with ribosomal processing in transformed cells.
Total RNA extracted from A31 and (A) C149, or (B) C138 fibroblasts cultured either 
without TSA, or in the presence of 100, 200 or 300 nM TSA was loaded onto a 
MOPS gel and stained with ethidium bromide.
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Figure 6.3
TSA induces B2 gene expression in untransformed and transformed cells.
Northern blot analysis of total RNA extracted from A31 and C149 fibroblasts cultured 
either without TSA, or in the presence o f 100, 200 or 300 nM TSA. The blot was first 
probed with a B2 gene, and then was stripped and reprobed with the ARPP PO gene. 
Levels of RNA were quantified using a phosphoimager. Values shown represent the 
means from two experiments.
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both A31 and C149 fibroblasts (Figine 6.4). However, levels of expression of the pol 
III transcript 7SK, which has a type III promoter structure, did not appear to be 
affected by the presence of TSA in the transformed cells, and the levels of this 
transcript decreased in the untransformed A31 cells. When the subunits of TF111C2 
were examined, it was found that TSA caused a decrease in expression in C149 cells, 
whereas it appeared to have no effect in A31 cells (data not shown).
6.2.4 Inhibition of HDACs Increases the Occupancy of Pol III 
Transcription Machinery at Class III Gene Promoters in 
Untransformed and Transformed Murine Fibroblasts.
To examine whether TSA could affect the occupancy of transcriptional machineiy on 
a pol Ill-transcribed gene, chromatin immunopreciptiation (ChlP) assays were carried 
out. Formaldehyde cross-linked soluble chromatin was prepared from A31 and C149 
fibroblasts cultured either without TSA or in the presence of 200 nM TSA for a period 
of 48 hours. This was immunoprecipitated with antibodies against acetylated histone 
H4, the RPC155 subunit of pol III, the Brfl subunit of TFlllB, and the 110 kDa 
subunit of TF1I1C2. Various concentrations o f DNA were used to ensure that the PCR 
reactions were in the linear range for each antibody used for the ChlP assays. 
Acetylated histone H4 was used as a positive control, and negative control ChlPs 
were carried out in the absence of antibody. In both the untransformed and 
transformed cells it was found that addition of TSA increased pol III, Brfl and 
TFllICl 10 promoter occupancy at the promoters of B2, 5S rRNA and tRNA genes 
(Figures 6.5 & 6.6).
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Figure 6.4
TSA stimulates the expression of multiple pol III templates.
cDNAs were generated by reverse transcription of total RNA extracted from A31 and 
C149 fibroblasts cultured either without TSA or in the presence of 200 nM TSA. 
These cDNAs were PCR amplified using primers specific for B2, tRNA tRNA 
tRNA 5S rRNA, 7SK and ARPP PO.
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Immunoblot analysis demonstrated that the observed changes in pol III, Brfl, and 
TFIIICllO occupancy did not result from altered protein levels (Figure 6.7). The 
levels of these proteins were comparable in the TSA treated and untreated extracts 
from both the transformed and untransformed cell lines. However, as expected, 
increases were observed in the acetylated histone H4. Thus, the significantly increased 
presence of these proteins on the chromatin-assembled genes that were investigated 
reflects changes in their recruitment to the promoter, and not the protein availability.
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Figure 6.5
Repression of HDACs increases the occupancy of pol III transcription machinery 
at class III gene promoters in untransformed murine fibroblasts.
A31 fibroblasts were cultured either without TSA or in the presence o f 200 nM TSA. 
Association of acetylated histone H4, pol III, Brfl, and TFIIICllO with B2, tRNA 
and 5S rRNA genes was determined by ChlPs, and quantitative PCR was performed 
on undiluted, 1:5 diluted, and 1:25 diluted input chromatin. Control ChlPs were 
carried out in the absence of antibody.
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Figure 6.6
Repression of HDACs increases the occupancy of pol HI transcription machinery 
at class HI gene promoters in transformed murine fibroblasts.
C149 fibroblasts were cultured either without TSA or in the presence of 200 nM TSA. 
Association of acetylated histone H4, pol 111, Brfl, and TFllICl 10 with B2, tRNA 
and 5S rRNA genes was determined by ChlPs, and quantitative PCR was performed 
on undiluted, 1:5 diluted, and 1:25 diluted input chromatin. Control ChlPs were 
carried out in the absence of antibody.
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Figure 6.7
TSA treatment does not change the levels of pol III, Brfl and TFIIICllO protein 
in transformed and untransformed murine fibroblasts.
Whole cell extracts were made from A31 and C149 fibroblasts cultured either without 
TSA or in the presence of 200 nM TSA. 50 pg of each protein sample was resolved 
on an SDS polyacrylamide gel and then analysed by Western blotting with antibodies 
directed against acetylated histone H4, pol 111 (RPC155 subunit), Brfl, TFllCllO and 
TFllB.
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6.3 Discussion.
Transcription can be directly regulated through acétylation and deacetylation of 
chromatin. In many cases, recruitment of HATs to histones is associated with 
increased transcriptional activity, whereas recruitment of HDACs correlates with 
transcriptional repression. Pol III transcription may be regulated by such clu'omatin 
remodelling effects. In this study it was found that pol 111 transcription was increased 
in the presence of the HDAC inhibitor TSA. This occurred in both untransformed and 
transformed murine fibroblasts. As previously observed by White et al. (1990), 
transcription was seen to be higher in the SV40-transformed fibroblasts C149s than in 
the untransformed parental cell line A31, suggesting that expression is especially 
restrained in the untransformed cells. This is likely to be due, at least in part, to 
restraint by repressive chromatin structure, since TSA treatment has less effect on 
transcription in the transformed cells (approximately 1.5 fold, Figure 6.3) than in the 
untransformed cells (approximately 4 fold, Figure 6.3), suggesting that untransformed 
cells have less acétylation at their histones.
Addition of TSA to transformed cells was observed to cause significant apoptosis. 
TSA has been previously reported to cause apoptosis in human hepatoma, Jurkat 
lymphoid and colorectal carcinoma cells (Chen et al., 2002; Medina et al., 1997; 
Yamishita et al., 2003). Examination of RNA from these samples revealed an 
unidentified band that migrated between 28S and 18S rRNA. This may be an 
indication that TSA is interfering with ribosomal processing in the transformed cells. 
It would be interesting in future work to develop primers that recognise such 
transcripts in the mui'ine cells, such as MRP which is involved in rRNA splicing.
176
Chapter 6_____________________________________________________ Trichostatin A
TSA was seen to inhibit HDACs at nanomolar concentrations, resulting in increased 
histone acétylation and modulation of gene expression at a selection of different pol 
III templates including B2, tRNA and 5S rRNA. However, 7SK, which has
a type III promoter structure, was not seen to be affected by the presence of this drug. 
Boyd et al. (2000) have suggested that at 7SK genes a nucleosome positioned over the 
promoter region brings the DSE and PSE into juxtaposition. This facilitates 
interaction between the factors binding to these elements. This arrangement is very 
different from the type 1 and 11 promoters of the other genes investigated. Relaxation 
of the nucleosome structure upon addition of TSA, therefore could account for the 
observed decrease in transcription of 7SK seen in the untransformed A31 fibroblasts. 
Furthermore, the presence of binding sites for ZID, a transcription factor known to 
interact with a HDAC, have been identified upstream of the DSE (Boyd et al., 2000), 
suggesting that deacetylation of histones may play a role in the regulation of the 7SK 
gene, perhaps by ensuring that a positioned nucleosome is stabilised. In the cell line 
C149, it is possible that transformation has caused aben'ant acétylation of histones, 
which could account for the lack of effectiveness of TSA.
ChlPs and immunoblotting confirmed that the increases in expression of the pol 111 
genes B2, tRNA and 5S rRNA upon addition of TSA, reflected increased 
promoter occupancy of the pol III transcriptional machineiy. This was observed with 
the RPC 155 subunit of pol 111, Brfl, and TFIIICllO. At most of these genes this 
correlated with an increased presence of acetylated histone H4, and also elevated 
levels of acetylated H4 protein, upon the addition of TSA. However, at B2 genes it 
was surprising to observe that histone H4 is hyperacetylated without TSA, yet 
transcription still increases upon addition of the HDAC inhibitor. It is therefore
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possible that TSA is affecting histone H3, or perhaps the increased transcription 
occurs as a result of histone-independent acétylation involving some other protein, for 
example B rfl.
These data, which suggest that tRNA and 5S rRNA are repressed by their 
chromatin structures, are not unprecedented. Previous studies have shown that B2 
elements are sequestered by histone HI in untransformed and SV40-transformed 
murine cells (Carey & Singh, 1988). It has also been shown that changes in both the 
chromatin structure and TFIIIA concentration regulate differential expression of 
Xenopus 5S rRNA genes during development (Brown & Schlissel., 1985; Schlissel & 
Brown, 1984). In addition, Lee et al. (1993) showed that acétylation of core histones 
improves the accessibility of the 5S rRNA gene to TFIIIA. tRNA genes are also 
thought to be repressed by nucleosome foiTnation. TFIIIC, which has intrinsic HAT 
activity, has been found to relieve chiomatin-mediated repression of this gene (Hsieh 
et al., 1999a; Kundu et al., 1999). However, it may be acétylation of a pol III factor 
that is crucial, rather than histone acétylation. Like phosphoiylation, acétylation of 
transcription factors has been shown to regulate protein-DNA and protein-protein 
interactions (Boyes et al., 1998; Gu & Roeder, 1997; Martinez-Bàlbas et al., 2000; 
Waltzer & Bienz, 1998; Zhang & Bierker, 1998), and it may also increase protein 
stability (Martinez-Bàlbas et al., 2000).
These results suggest that acétylation provides a link between chromatin structure and 
pol III transcriptional output. Class III genes with type I and II promoters may be 
repressed by their chromatin structure. This can be overcome by inhibition of 
HDACs, thus allowing the acétylation of histones, which in turn results in unfolding
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of the nucleosome structure so that transcription factors and pol III can gain access. 
Alternatively, it may be that pol III transcription factors become acetylated. Since 
numerous studies (reviewed in Kouzarides, 1999) have implicated the involvement of 
acetylases in the control of cell proliferation, it may well be that acétylation provides 
an additional method for controlling pol III transcription. It would, therefore, be 
interesting to examine if tumours containing mutations in HATs and HDACs show 
deregulated pol III transcription.
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Over the past 50 years much research has been devoted to unraveling the 
abnormalities that occur during the development of cancer. Despite this, many of the 
specific cellular and molecular processes of these complex events still remain to be 
elucidated. The genesis of malignancy requires the sequential accumulation of a 
number of genetic alterations (Fearon, 1992; Weinberg, 1991). These changes disrupt 
the regulatory mechanisms that limit growth potential and as a result, tumour cells are 
able to escape from senescence and display elevated proliferative activity. This would 
not be possible if the levels of transcription were limiting.
The main aim of this study was to investigate transcription by pols I and III in 
different tumours, to examine if deregulation occurs, and to identify transcription 
factors that may contribute to this. Expression studies of genes transcribed by these 
polymerases demonstrated that most of the tumour biopsies examined displayed 
deregulated transcriptional activity in comparison with matched normal tissue. 
However, the relationship between carcinogenesis and transcription was not found to 
be clear-cut and therefore, would not be suitable for diagnostic purposes.
Transcription by pol III in the cervical biopsy samples correlated with the presence of 
high risk HPV16, which caused a specific increase in the transcription of genes 
encoding tRNA and 5S rRNA, and was irrespective of the degree of
transformation. The presence of lower risk HPVs appeared to have little effect on pol 
III transcription. In addition, the physical status of the virus may also affect 
transcription by pol III, with integration correlating with an increase in the levels of 
pol III transcripts in comparison with cells where the virus remained episomal. In the 
breast and colon samples, where viral entities played no part in the development of
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cancer, expression patterns of pol Ill-transcribed genes were more complex. However, 
examination of tRNA 5S rRNA and 7SL transcripts by RT-PCR revealed that
transcription of these genes was elevated in 50% of the breast tumour biopsy samples 
examined, when compared to the matched normal tissue. It was found that genes 
transcribed by pol III were elevated in over a third of the colorectal tumours 
examined.
In addition to the tumoui’ biopsy samples examined, it was observed that pol III 
transcription in a SV40-transformed cell line was higher than in the untransformed 
parental cell line. This suggests that expression in the untransformed cells is 
restrained. This is likely to be due, at least in part, to restraint by repressive chromatin 
structure, since treatment of transformed cells with the HD AC inhibitor TSA had less 
effect on transcription at a selection of different pol III templates than the observed 
effect of this drug on the untransformed cells. This suggests that histones associated 
with pol Ill-transcribed genes are less highly acetylated in untransformed cells. 
Differential acétylation of non-histone targets is also a possibility.
Transcription of MRP and 7SK genes was observed to behave very differently from 
the other pol Ill-transcribed genes examined. For example, in the breast biopsy 
samples it was found that transcriptional upregulation of these genes occurred more 
frequently in the tumour samples (five out of the six) when compared to the other pol 
Ill-transcribed genes that were examined. In the HPV16 infected ceiwical biopsy 
samples, 7SK and MRP RNA levels did not correlate with viral status, unlike tRNA 
and 5S rRNA. In the W12 system, the cells containing integrated HPV16 compared to 
cells that maintain HPV16 episomally did not display the large increase in
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transcription of MRP and 7SK that was observed in the other pol III transcripts 
examined. The distinct response of 7SK and MRP might reflect their very different 
promoter arrangements from those of 5S rRNA and tRNA genes. Unlike tRNA and 
5S rRNA genes, which have internal promoters, 7SK and MRP genes do not utilize 
TFIIIC2 or Brfl (Schi'amm & Hernandez, 2002). Indeed, it was observed that raising 
the concentration of Brfl in cervical epithelial cells had no effect on transcription of 
7SK, in contrast to tRNA and 5S rRNA.
In the untransformed and transfoimed fibroblasts it was also observed that genes with 
a type III promoter behaved differently than the other genes investigated. 7SK was not 
affected by the presence of the HD AC inhibitor TSA in transformed fibroblasts. 
However, upon addition of TSA to untransformed A31 fibroblasts, a decrease in 
transcription of 7SK was observed. This may be due to relaxation of the nucleosome 
structure, since it has been suggested that at 7SK genes a nucleosome brings the DSE 
and PSE into juxtaposition, which facilitates interaction between the factors binding 
to these elements (Boyd et al., 2000). Indeed, the presence of binding sites for ZID, a 
transcription factor known to interact with a HDAC, have been identified upstream of 
the DSE (Boyd et al., 2000), suggesting that deacetylation of histones may play a role 
in the regulation of the 7SK gene, perhaps by ensuring that a positioned nucleosome is 
stabilised.
Recruitment of pol III to particular DNA sequences requires the presence of 
transcription factors to position the enzyme over the promoter regions of specific 
genes. Investigation of these factors revealed a correlation between transcriptional 
output and the TFIIIB subunit B rfl. The increase in the levels of tRNA and
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5S rRNA transcripts in HPV16 infected cervical biopsy samples were concomitant 
with an elevation of Brfl mRNA. Furthermore, it was found that raising the 
concentration of Brfl in cervical epithelial cells increased transcription of tRNA 
and 5S rRNA genes. In addition, upon integration of HPV16, the cervical cell line 
W12 displayed upregulated levels of Brfl, alongside an increase in pol III transcripts. 
In the breast biopsy samples, Brfl was upregulated in all except for one of the breast 
tumours, and in the colorectal samples deregulation of Brfl appeared to conelate with 
most of the changes in the levels of pol III transcripts.
Analysis of the expression of the other two subunits of TFIIIB in the colorectal 
samples did not reveal any straightforward correlations between the levels of Bdpl 
and TBP mRNAs and the products transcribed by pol III. In the breast samples, Bdpl 
remained relatively constant, while TBP was upregulated in half of the tumours. 
Previously, it has been reported that the HBV X oncoprotein stimulates pol III 
transcription by increasing TBP expression (Wang et ah, 1997), but this was not 
evident in the HPV infected cervical biopsies. Although the levels of TBP mRNA 
fluctuated dramatically in these samples, they did not correlate with any of the pol III 
transcripts examined. It has also been demonstrated that SV40 and polyomavirus 
transformed fibroblasts display increased levels of Bdpl (Felton-Edkins & White, 
2002), but in the cervical biopsy samples, like TBP, the levels of Bdpl mRNA varied 
markedly, showing little correlation with expression of pol III templates. This 
suggests that TBP and Bdpl may be in relative excess in the cervix. In one of the 
eervical tumour biopsy samples a dramatic overexpression of Bdpl mRNA was 
found, which correlated with high levels of transcription at 7SK and MRP genes. This
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raises the possibility that transcription of MRP and 7SK genes might be activated by 
very high levels of Bdpl, even if it is not normally limiting.
To further examine the effects of increased levels of TFIIIB, in vitro transcription 
assays were carried out with cervical and breast cell lines. It was found that raising the 
levels of TFIIIB increased transcription at tRNA and YAl templates. Furthermore, 
incubation of breast cells with a TFIIIB TAF-containing fraction and a TFIIIB 
fraction in which TBP was denatured, also stimulated pol III transcription. However, 
addition of recombinant TBP had no stimulatory effect. Therefore, it may be that in 
breast epithelium, TBP is in relative excess, and that TFIIIB TAFs aie limiting. It 
would be interesting to investigate if this is also the case in colorectal cells. It is not 
unprecedented to suggest that subunits of the same transcription factor may be present 
in cells at different levels, since this has been demonstrated in virally transformed 
cells (Felton-Edkins & White, 2002; Wang et al., 1997). By increasing the levels of 
TAFs, in particular Brfl, it may be that transcriptional repression by RB and p53 is 
overcome. These tumoui' suppressors exert their repressional effects on pol III 
transcription by disrupting key interactions between TFIIIB and the other components 
of the basal transcription apparatus (Crighton et al., 2003; Sutcliffe et al., 2000). It has 
been shown that binding of TFIIIB to TFIIIC2 can be blocked by RB. In addition, RB 
dismpts the interaction between TFIIIB and pol III (Sutcliffe et al., 2000). In contrast, 
repression by p53 is mediated through direct contacts with the TBP subunit (Crighton 
et al., 2003). p53 does not disrupt the direct interaction between TBP and Brfl, but 
prevents the association of Brfl complexes with TFIIIC2 and pol III, thereby 
impeding the formation of functional transcription complexes (Crighton et al., 2003). 
Therefore, by increasing the levels of Brfl it may be that cancer cells are able to
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overcome repression by promoting assembly of functional transcription complexes by 
mass action.
When the levels of TFIIIC2 were examined in the cervical biopsy samples, it was 
found that unlike SV40, polyomavirus and adenovirus (Felton-Edkins & White, 2002; 
Larminie et al., 1999; Sinn et al., 1995), the presence of HPV did not deregulate 
expression of the mRNAs encoding the TFIIIC2 subunits. The five subuits of this 
transcription factor have also been shown to be upregulated in ovarian cancer (Winter 
et al., 2000). However, as observed in the cervical biopsy samples, it was found that 
in the colon and breast tumour biopsies deregulation of pol III was not always found 
to correlate with a conesponding change in the levels of TFIIIC2. But in whole cell 
breast extracts increasing the level of TFIIIC2 was found to elevate transcription of 
tRNA and VAl. It is therefore possible that in some of the tumours TFIIIC2 may 
have been a limiting factor. Unfortunately, due to the limited amount of biopsy tissue 
available, protein could not be isolated to further analyse levels of these transcription 
factors. Therefore, in interpreting the RT-PCR results, the assumption is made that 
transcription factor levels in these tissue samples reflect the expression of their 
corresponding mRNAs. However, this might not be the case, as posttranscriptional 
controls may have a significant influence.
Investigations into the increased levels of pol III transcription observed in both 
untransformed and transformed fibroblasts that had been treated with TSA revealed 
increased promoter occupancy of pol III transcriptional machinery. This was observed 
by Chip assays with the RPC 155 subunit of pol III, Brfl and TFIIIC 110, and 
conelated with an increased presence of acetylated histone H4, and also elevated
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levels of acetylated H4 protein. Since inhibition of HDACs is able to cause these 
changes, it may well be that the increases observed in the levels of pol III transcripts 
in some of the biopsy samples could be attributable to aberrant recruitment of 
HDACs. Indeed, such effects have been demonstrated in cell lines derived from 
patients with acute promyelocytic leukaemia, acute myelogenous leukaemia involving 
acute myelogenous leukaemia 1 and ETO genes, and non-Hodgkin lymphoma, with 
inappropriate expression of repressor BCL-6 (Marks et aL, 2000).
Investigation of pol I transcription revealed that it was deregulated with a higher 
frequency than pol III transcription. Indeed, in the breast biopsies upregulation of pol 
I was found in five out of the six tumours examined. In the cervical biopsy samples, 
deregulation of pol I transcription was seen to occur at the same frequency as pol III. 
Infection of cervical epithelium with HPV 16 elevated the activity of pol I, but this 
was not the case in samples infected with HPV33 or H PV ll. In the colorectal 
biopsies, pol I activity was found to be elevated in over half of the tumour samples 
examined. It is unlikely that the increased levels of transcripts involved in protein 
synthesis are simply due to the presence of a higher percentage of dividing cells in the 
tumour, since it has been shown that in colorectal carcinomas the proliferative index 
is not significantly different fr om that of normal colonic mucosa (Bleiberg & Galand, 
1976; Hoffman & Post; 1967). Furthermore, the regulation of ribosomal protein levels 
does not generally involve increased mRNA stability (Pogue-Geile et aL, 1991). 
Instead, several investigations have demonstrated that growing cells more efficiently 
translate ribosomal protein mRNAs than do resting cells (Geyer et aL, 1982; 
Hammond & Bowman, 1988; Ignotz et aL, 1981).
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Examination of the levels of the pol I transcription factors UBF and Rrn3 in breast 
and colorectal biopsy samples did not reveal any correlation with pol I deregulation. 
Therefore, pol I activation does not seem to be occurring as a result o f upregulation of 
these iniatiation factors that it utilizes during transcriptional assembly. In fact, both 
factors were frequently seen to be down-regulated in the tumour samples in 
comparison with the matched normal tissue. In the case of UBF, this has previously 
been observed by Huang et al. (2002), who demonstrated that some lung, 
oesophageal, breast and ovarian tumour samples displayed lower levels of UBF than 
matched normal tissue. In addition to these pol I-specific transcription factors, TBP 
was also assessed to find out if expression patterns correlated with pol I activity. 
Previously it has been shown that promoter activation of TBP by the X oncoprotein of 
HBV stimulates pol I transcription (Wang et al., 1998). However, in each of the three 
different types of biopsy samples analysed little correlation was observed between 
TBP mRNA and rRNA expression. During the development of cancer it is likely that 
that the great complexity and variety of transcription factors utilized by both pols I 
and III precludes a simplistic assignment of direct stimulatoiy capability to only one 
of them. Just as individual tumours show considerable heterogeneity, so there seem to 
be variable strategies that are used to increase transcriptional output.
The increase in pol I and III activity that was obseiwed in some of the tumours 
examined is unsurprising since the products made by these polymerases are required 
for increased levels of the biosynthetic machinery. This is necessary to sustain the 
rapid growth rates which occur in tumour progression. What is surprising, however, 
are the decreases in the levels of transcripts that were observed in some tumours. The 
variability observed in expression of pol I and Ill-transeribed genes and their
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transcription factors in different normal and tumour biopsy samples could be due to a 
number of factors. Changes in gene expression are complicated by the fact that 
tumours consist of many different cell types (Notterman et al., 2001, Pérou et al., 
1999). In addition to this, carcinoma cells themselves are morphologically and 
genetically diverse (Pérou et al., 1999). Furthermore, it may be that 
histopathologically normal appearing tissue surrounding a tumour is not normal at the 
molecular level. It is possible, therefore, that elevated transcription in these adjacent 
areas may be higher than in tissue distant from the tumour. Moreover, alterations in 
gene expression may be inliomogenous within a tumour (Backert et al., 1999).
The biopsy samples were also investigated for changes in the levels of other 
regulators that are known to affect transcriptional activity. Analysis of the cellular 
oncogene e-myc in biopsy samples revealed that this gene was upregulated in five of 
the six breast tumour samples, and ten of the eleven colorectal tumours, in comparison 
with the surrounding normal tissue. This could be due to a number of alterations to c- 
myc, including gene amplification, chromosomal translocation, insertional mutations, 
altered transcriptional elongation rates, and prolonged mRNA half-life (Dang, 1999). 
In the breast samples, the upregulation of c-Myc was seen to closely correlate with the 
increased levels of pol I transcripts, as well as MRP and 7SK transcripts. Since 
increased levels of c-Myc are thought to be involved in the induction and progression 
of cancer (Leder et al., 1986; Roux-Dosseto et al., 1992; Sierra et al., 1999; Watson et 
al., 1993, 1996), it may be that e-Myc ensures that the components required for 
increased growth are available by increasing transcription by pols I and III. Indeed, in 
c~myc null cells there is a marked decrease in net RNA synthesis (Mateyak et al.,
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1997). It has also recently been demonstrated that TFIIIB is a target for c-Myc, 
enabling it to directly activate pol III transcription (Gomez-Roman et aL, 2003).
In the colorectal samples, the high percentage of tumours in which c-Myc was 
upregulated is in agreement with results from other groups (Nesbit et aL, 1999; 
Rothberg, 1987; Wang et aL, 2002). This probably occurs as a consequence of 
mutations in the tumour suppressor gene APC that lead to aberrant nuclear 
accumulation of the p-catenin/Tcf transcription complex, which, in turn, leads to 
increased expression of target genes, such as c-myc (He et aL, 1998). Cyclin D1 is 
another gene targeted by the p-catenin/Tcf transcription complex (Shtutman et aL, 
1999; Tetsu & McCormick, 1999; Wang et aL, 2002). Cyclin D1 overexpression has 
been observed in a subset of neoplastic conditions, including human colorectal 
cancers (Arber et aL, 1996, 1997; Sutter et aL, 1997). The constitutive activation of 
Ras further stimulates transcription of the cyclin D1 gene (Albanese et aL, 1995; 
Tetsu & McCormick, 1999). In keeping with these findings, many of the colorectal 
tumour samples examined displayed upregulated levels of cyclin D1 mRNA (seven 
out of the eleven tested). This occurred frequently in the later stage tumours, 
presumably after activation of ¥^-ras. Cyclin D2, which is controlled by different 
signalling pathways, was not seen to be upregulated as frequently. Although cyclin 
D1 is upregulated in many of the colorectal tumours, it is only when cyclin D2 is also 
elevated that increased pol III activity is observed. Overexpression of cyclins D1 and 
D2 would be expected to have a stimulating effect on transcription, as it would enable 
the phosphorylation of RB. Thus, in a hyperphosphoiylated state RB would no longer 
be able to bind to UBF and TFIIIB, and therefore the transcriptional repression 
mediated by this tumour suppressor protein would be alleviated. Cyclin D2 is a well-
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characterized direct target for c-Myc. Elevated expression of cyclin D2 mRNA may 
therefore be taken as an indicator that c-Myc activity is raised. It is very striking that 
there is a perfect coiTelation between the induction of cyclin D2 mRNA and the 
induction of pol III transcripts. This suggests that Myc activity may be rate-limiting 
for pol III transcription in colorectal cells.
Numerous studies have found that in the majority of tumours the functions of p53 
and/or RB are compromised. In the cervical biopsies examined in this study, 
inactivation of these tumour suppressor proteins would have occurred in some of the 
samples. Alterations in the levels of pol I and pol III transcription in HPV16 infected 
cervical samples may be explained by the fact that this high risk virus expresses the 
oncoproteins E6 and E7, which can inactivate tumour suppressors (Larminie et al., 
1999; Stein et aL, 2002a; Sutcliffe et aL, 1999). E6 is able to inactivate p53, which 
causes the pol III transcription factor TFIIIB and the pol I transcription factor SLl to 
be released from repression. E7 inactivates RB, which also causes the release of 
TFIIIB and the pol I transcription factor, UBF. Both these oncoproteins from high risk 
HPV 16 bind to these tumour suppressors with a higher affinity than the proteins from 
lower risk HPVs, perhaps explaining why HPV33 and HPVl 1 do not elevate pol I or 
III transcription. Had protein samples been available for analysis from the biopsy 
samples it would have been interesting to investigate the levels of these tumour 
suppressors and their interaction with UBF, SLl and TFIIIB, not only in the cervical 
tissue but also in the breast and colorectal biopsies, to examine if the samples 
displaying increased levels of pol I and III transcripts displayed decreased binding of 
tumour suppressor proteins to pol I and III factors.
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The deregulation of pols I and III was seen to occur in a number of tumours in the 
three different types of carcinomas. In the colorectal samples the clinical stage of 
disease could not be directly correlated to a specific pattern of gene expression, 
perhaps due to a limited number of tissue samples. However, it was observed that 
elevated transcription by pols I and III appeared to occur frequently in the later stages 
of tumour development. Despite this, the furthest progressed colorectal tumour 
sample did not display increased rates of transcription by either pol I or pol III. At this 
late stage, the lack of upregulation may be due to decreased growth rates in some 
regions of the tumour that are poorly vascularised and have become hypoxic. Indeed, 
it is well known that different areas of tumours express different genes according to 
the available oxygen supply. Therefore, tissue removed from the centre of a 
carcinogenic lesion may not reflect the active transcription at the perimeter of a 
tumoui'. Transcription by pols I and III was also seen to be upregulated in one of the 
adenoma samples. Since adenomas are considered to be the pathological precursors to 
colorectal carcinogenesis (Kinzler & Vogelstein, 1996), it may be that upregulation of 
pol I and III transcription occurs as an early event in tumour development. In 
agreement with this, several ribosomal proteins (S6, 88, 812, L5 and ARPP PO) have 
been shown to be overexpressed in adenomas (Pogue-Geile el aL, 1991). Similarly, in 
the cervical samples infected with HPV 16 it was observed that activation of pols I and 
III occurred as an early response preceding transformation, since transcriptional 
upregulation was observed in premalignant cervical biopsy samples, relative to 
uninfected normal tissue. Unfortunately, data regarding the staging of the breast 
samples was not available for analysis.
192
Chapter 7__________________________________________________ Final Discussion
The data gathered dui'ing the course of this study was limited by numerous factors that 
would need to be addressed before commencing further studies. These include the 
unavailability of large numbers of biopsy samples, which would have allowed protein 
studies to be caiTied out; and the lack of clinical data regarding the disease state of the 
tumour, such as the staging. In addition, it would have been of interest to obtain 
follow-up information on the patients from which the biopsy samples were taken, so 
that any trends with regard to receptiveness to treatment and certain expression 
patterns of the genes investigated could have been examined.
From this study, it is apparent that the genetic changes which arise in tumours are 
dependent not only on the specific tissue type, but also on the individual tumour. 
Analysis of the biopsy samples provides clear evidence that deregulation of pols I and 
III is a frequent event during carcinogenesis. This appears to be a veiy complicated 
process, involving the co-operative interaction of many transcription factors. 
Understanding these changes that occur in transcription, and the mechanisms 
underlying this deregulation, may well provide opportunities for the design and 
construction of more effective therapeutics against cancer.
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